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Preface 
 
 
 
 
 
 
 
 
 
 
 
 
Private- and public-sector investment in health care is immense, and 
wide agreement exists in both sectors that the U.S. health care system 
needs to be improved in many ways in order to reduce costs and provide 
equitable access to high-quality care. The availability of cutting-edge 
technologies and new preventive and therapeutic interventions is a result 
of the United States’ historic investment in biomedical and health re-
search. New efforts in clinical and translational research hold great 
promise for even more effective and efficient ways to improve the health 
of our population. Investments in research support tools, informatics, 
infrastructure, and training and education are essential to facilitate new 
discoveries and to move promising discoveries in basic science and clini-
cal research into use in clinics, hospitals, and homes. 
In 2006, the National Institutes of Health (NIH) began an investment 
in the Clinical and Translational Science Awards (CTSA) Program, a 
bold initiative aimed at facilitating and accelerating clinical and transla-
tional research—lofty and challenging goals. Simultaneously building on 
a legacy program (NIH’s General Clinical Research Center Program) and 
pioneering a new initiative is never easy.  
Our Institute of Medicine (IOM) committee was given the task of as-
sessing progress and recommending a path forward to help improve the 
efficiency and effectiveness of one of the nation’s most important re-
sources for clinical and translational science. As we assessed the CTSA 
Program, we were fully cognizant of both the importance of our task and 
the opportunity it presented. Among our conclusions was that the CTSA 
Program has had many initial successes in creating academic homes for 
clinical and translational research, providing education and training, and 
beginning to build the tools and partnerships needed to advance clinical 
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and translational science. As requested by the sponsor, we identified 
ways the program can be strengthened. 
The future of the CTSA Program is exciting, as well as daunting. 
Although there is great potential for the creation of new preventive and 
treatment approaches, there remain numerous institutional, logistical, and 
methodological barriers to doing so. Moving clinical and translational 
research forward will greatly benefit from the strong leadership, creative 
partnerships, and institutional commitments that the CTSA Program can 
bring to this effort. 
It was our pleasure and privilege to lead the efforts of this IOM 
committee—superb committee members and outstanding staff who have 
worked diligently to learn about this complex program and contemplate 
the potential for its future. The expertise and grace of these generous in-
dividuals combined to create deep discourse and solid consensus. 
We thank everyone who provided testimony, gave presentations, and 
participated in discussions with the committee. We are grateful to the 
staff of the National Center for Advancing Translational Sciences 
(NCATS) who responded thoroughly to our numerous inquiries. The 
committee is truly appreciative of the many individuals who provided the 
diversity and breadth of knowledge and opinion needed to complete this 
study. 
The CTSA Program has made some remarkable progress to date and 
has great potential to further advance clinical and translational science 
and improve human health. We look forward to seeing this potential fully 
realized in the coming years. 
 
Alan I. Leshner, Chair 
Sharon F. Terry, Vice-Chair 
Committee to Review the Clinical and 
Translational Science Awards Program at the 
National Center for Advancing Translational Sciences 
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Summary 
 
 
 
 
 
 
 
 
 
 
During the past half century, biomedical research has expanded 
exponentially, yielding many discoveries that offer the promise of im-
proved human health. Translating basic and clinical research findings 
into clinical and community practice has been slow and cumbersome, 
however, and many years may pass before the benefits of research reach 
individual patients and communities. Recognizing the need for a new 
impetus to spur clinical and translational research, the National Institutes 
of Health (NIH) established the Clinical and Translational Science 
Awards (CTSA) Program in 2006.  
The CTSA Program was designed to “provide integrated intellectual 
and physical resources for the conduct of original clinical and transla-
tional science,”1 and individual CTSA sites were intended to serve as 
“catalysts and test beds for policies and practices that can benefit clinical 
and translational research organizations throughout the country.”2 In its 
first 7 years, the CTSA Program grew from 12 initial sites to the current 
61, which are housed at academic health centers and other institutions 
across the United States. During this time, the program has made notable 
strides in accomplishing its initial goal of reshaping clinical and transla-
tional research at these institutions and has begun to build a national 
network that has the potential to catalyze further progress.  
                                                        
1Zerhouni, E. A. 2005. Translational and clinical science—time for a new vision. New 
England Journal of Medicine 353(15):1621–1623. 
2Zerhouni, E. A. 2006. Clinical and Translational Science Awards: A framework for a 
national research agenda. Translational Research 148(1):4–5. 
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In 2012 the NIH contracted with the Institute of Medicine (IOM) to 
conduct a consensus study to assess and provide recommendations on the 
appropriateness of the CTSA Program’s mission and strategic goals and 
whether changes were needed. The committee was also tasked with 
providing an independent appraisal of and advice on the implementation 
of the program by the National Center for Advancing Translational Sci-
ences (NCATS), while exploring the contributions of CTSAs in acceler-
ating the development of new therapeutics, facilitating disease-specific 
and child health research, and enhancing the integration of research 
funded by NIH institutes and centers. To conduct this study, the IOM con-
vened a 13-member committee with expertise in community outreach and 
engagement, public health and health policy, bioethics, education and 
training, pharmaceutical research and development, program evaluation, 
clinical and biomedical research, and child health research, along the full 
continuum of clinical and translation research. The committee’s overarch-
ing conclusion is that the CTSA Program is contributing significantly to 
the advancement of clinical and translational research and is therefore a 
worthwhile investment that would benefit from a variety of revisions to 
make it more efficient and effective.  
 
 
THE CTSA PROGRAM 
 
The CTSA Program is a direct outgrowth of the NIH’s General Clin-
ical Research Center Program, which for more than 40 years provided 
clinical research infrastructure funding. Development of the CTSA Pro-
gram was an integral part of the implementation of the 2004 NIH 
Roadmap for Medical Research. From 2006 to 2011, the program was 
administered through the NIH’s National Center for Research Resources. 
In fiscal year (FY) 2012, NIH established NCATS, and the CTSA Pro-
gram became the largest component of that center.  
Individual CTSAs are funded through 5-year cooperative agree-
ments, and site budgets range from $4 million to $23 million annually, 
with a total CTSA Program budget of $461 million in FY2012. Building 
an active and productive CTSA at an institution often involves not only 
the funds from the CTSA cooperative agreement but also substantial fi-
nancial and staff commitments from the institution; although institutional 
cost sharing is not required. The committee could not identify any data to 
quantify these institutional contributions but heard testimony from many 
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individuals about the depth of efforts and the commitment to the CTSA 
Program from top leaders at health research institutions across the nation.  
Currently the 61 CTSAs provide a wide array of training and re-
search support to help researchers identify promising therapeutics and 
interventions and move them forward as rapidly as possible. Research 
support is provided in areas that include core facilities; biomedical in-
formatics; pilot funding; regulatory knowledge and support; biostatistics, 
epidemiology, research design, and ethics; participant and clinical inter-
action resources; and community engagement efforts and resources.  
From the outset of the program, the NIH charged the CTSAs with 
developing a national consortium to promote the identification and use of 
best research practices. This effort has developed into the primarily self-
governing CTSA Consortium, which oversees numerous collaborative 
committees. The CTSA Consortium’s efforts are guided by three leader-
ship committees: an Executive Committee, a Steering Committee, and a 
Child Health Oversight Committee. In addition, CTSA principal investi-
gators, researchers, and staff work on 5 strategic goal committees and 14 
key function committees (plus a number of interest groups, task forces, 
and work groups) that were established over time to discuss crosscutting 
issues, promote collaboration, and identify and implement best practices. 
In November 2011, the CTSA Consortium Coordinating Center was 
established at Vanderbilt University through a competitive application 
process. The coordinating center has taken many steps to standardize and 
coordinate consortium activities and is working to ensure the availability 
of best practices, facilitate the uptake of available tools and resources, 
and promote collaboration, in part through its website, CTSACentral.org.  
 
 
CONTEXT AND VISION FOR THE CTSA PROGRAM 
 
The CTSA Program does not exist in isolation; it is part of a larger 
clinical and translational research ecosystem that plays a vital role in an 
increasingly complex and dynamic U.S. health care system. Decades of 
innovation and technological advances have led to progress in biomedi-
cal sciences, medicine, and public health, contributing to increased life 
expectancy and improved individual and population health. At the same 
time, however, the accelerating pace of scientific discoveries has also 
been one cause of the increasing complexity of the U.S. health care sys-
tem, contributing to inconsistent health care quality and escalating costs.  
Copyright © National Academy of Sciences. All rights reserved.
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Across the United States, momentum is growing in support of a 
learning health care system in which researchers and health care provid-
ers design and implement care, evaluations, or research based on needs 
of specific communities and populations. The findings are disseminated 
to inform clinical practice and research models to improve health. A 
learning health care system is founded on the concept of continuous im-
provement and the imperative to translate “what we know” into “what 
we do.” Such a system fuels greater value in health care by harnessing 
the promise of new technological capabilities, market opportunities, and 
policies. Thus, clinical and translational research is integral to a learning 
health care system. 
The CTSA Program has been successful in establishing CTSAs as 
academic focal points for clinical and translational research. The chal-
lenge for the next phase of the program—which NCATS has described 
as CTSA 2.0—will be to set the goals and create incentives for its 61 
sites to function as the core of a national network that initiates and sus-
tains collaborations both inside and outside their home institutions; 
across NIH institutes and centers; and with community, industry, and 
research network partners. The IOM committee envisions a transfor-
mation of the CTSA Program from its current, loosely organized struc-
ture into a more tightly integrated network that works collectively to 
enhance the transit of therapeutics, diagnostics, and preventive interven-
tions along the developmental pipeline; disseminate innovative transla-
tional research methods and best practices; and provide leadership in 
informatics standards and policy development to promote shared resources. 
The committee identified four key opportunities for action:  
 
 Adopt and sustain active program leadership—NCATS should 
increase its leadership presence in the overall program, con-
sistent with the cooperative agreement model under which the 
CTSAs are funded. A centralized leadership model that includes 
participation by NCATS, leaders of individual CTSAs, communi-
ty partners, and other stakeholders will increase overall program 
efficiency, enable mechanisms for maximizing accountability, and 
provide the direction needed to develop and nurture substantive 
partnerships.  
 Engage in substantive and productive collaborations—The 
CTSA Program needs to capitalize on the collaborations devel-
oped within and among individual CTSAs and continue to initi-
ate and forge true partnerships with other NIH institutes and 
Copyright © National Academy of Sciences. All rights reserved.
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centers and with entities external to the program, including pa-
tient groups, communities, health care providers, industry, and 
regulatory organizations.  
 Develop and widely disseminate innovative research resources—
Fully developing the role of the CTSA Program as a facilitator and 
accelerator of clinical and translational research will require en-
hanced efforts to engage and support researchers and other stake-
holders as they develop, refine, widely disseminate, and 
implement novel research and health informatics tools, methodol-
ogies, policies, and other resources.  
 Build on initial successes in training and education, community 
engagement, and child health research—The CTSA Program 
needs to continue its strong efforts in each of these areas. A ro-
bust and diverse workforce that is well trained in team science is 
critically important. Ensuring an emphasis on community in-
volvement across the research spectrum will bring a range of 
much-needed perspectives and innovations along with increased 
public support for research. Program efforts can also help over-
come the paucity of research specific to child health. 
 
 
LEADERSHIP 
 
 Today’s CTSA Program has a complex, multilevel structure of or-
ganization and oversight involving NCATS; individual CTSAs; the 
CTSA Consortium with multiple levels and type of committees and 
working groups; and the CTSA Coordinating Center. An initiative with 
the scope and structure of the CTSA Program inherently faces challenges 
in balancing grass-roots and top-down leadership approaches. To date, 
the program has, for the most part, relied on the energy and efforts of 
individual CTSAs and their principal investigators. As the program moves 
forward, the IOM committee sees the need for a more centralized approach 
to leadership, one in which NCATS plays a much more active role.  
The IOM committee envisions the primary governance of the pro-
gram residing within a new NCATS-CTSA Steering Committee that 
would be responsible for program oversight and direction; trans-CTSA 
activities; collaborative efforts with external partners; promotion of col-
laborative opportunities within and outside of NIH; identification, dis-
semination, and implementation of best practices; and implementation of 
Copyright © National Academy of Sciences. All rights reserved.
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a proposed new innovations fund to promote collaboration with other 
NIH institutes and centers and external partners.  
 A strategic planning process is needed as NCATS leads the program 
into its next phase. The program’s mission statement should be updated 
to clarify its overall purpose and to align it with the mission of NCATS. 
Identifying and disseminating a set of clearly defined, measurable strate-
gic goals is the starting point for shaping the program’s future. These 
measurable goals should serve as a foundation for developing high-level 
common metrics and measures that could be applied and publicly report-
ed on consistently to demonstrate progress. At this point, NCATS’s plans 
for evaluating individual CTSA sites and the CTSA Program as a whole 
are unclear. Progress is being made at the individual CTSA level in terms 
of self-evaluation, but the current lack of transparency in reporting and 
lack of high-level common metrics are barriers to overall program ac-
countability. 
Streamlining the current consortium structure is an urgent need. 
However, the structure and governance should evolve during the next 
year or two as a component of the recommended strategic planning pro-
cess. Only those consortium committees that are most relevant to the 
program’s revised goals and priorities should be retained.  
 
Recommendation 1: Strengthen NCATS Leadership of the CTSA 
Program 
 
NCATS should strengthen its leadership of the CTSA Program 
to advance innovative and transformative efforts in clinical and 
translational research. As it implements CTSA 2.0, NCATS 
should 
 
 increase active involvement in the CTSA cooperative agree-
ments and the CTSA Consortium;  
 conduct a strategic planning process to set measurable goals 
and objectives for the program that address the full spec-
trum of clinical and translational research;  
 ensure that the CTSA Program as a whole actively supports 
the full spectrum of clinical and translational research while 
encouraging flexibility for each institution to build on its 
unique strengths; 
 form strategic partnerships with NIH institutes and centers 
and with other research networks and industry;  
Copyright © National Academy of Sciences. All rights reserved.
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 establish an innovations fund through a set-aside mechanism 
that would be used for collaborative pilot studies and other 
initiatives involving CTSA institutions, other NIH institutes, 
and/or other public and private entities (e.g., industry, other 
government agencies, private foundations, community advo-
cates and organizations); 
 evaluate the program as a whole to identify gaps, weakness-
es, and opportunities and create mechanisms to address 
them; and 
 distill and widely disseminate best practices and lessons 
learned by the CTSA Program and work to communicate its 
value and accomplishments and seek opportunities for fur-
ther efforts and collaborations.  
 
Recommendation 2: Reconfigure and Streamline the CTSA 
Consortium 
 
NCATS should reconfigure and streamline the structure of the 
CTSA Program by establishing a new multi-stakeholder NCATS-
CTSA Steering Committee that would 
 
 be chaired by a member of NCATS leadership team and 
have a CTSA principal investigator as vice-chair, and 
 provide direction to the CTSA Coordinating Center in devel-
oping and promoting the use of available shared resources. 
 
Recommendation 3: Build on the Strengths of Individual CTSAs 
Across the Spectrum of Clinical and Translational Research  
 
Individual CTSAs, with the leadership of NCATS, should em-
phasize their particular strengths in advancing the program’s 
broad mission and goals. In doing so, CTSAs should 
 
 drive innovation and collaboration in methodologies, pro-
cesses, tools, and resources across the spectrum of clinical 
and translational research;  
 emphasize interdisciplinary team-based approaches in train-
ing, education, and research; 
Copyright © National Academy of Sciences. All rights reserved.
The CTSA Program at NIH:  Opportunities for Advancing Clinical and Translational Research
8 THE CTSA PROGRAM AT NIH 
 
PREPUBLICATION COPY: UNCORRECTED PROOFS 
 involve patients, family members, health care providers, and 
other community partners in all phases of the work of the 
CTSA;  
 strengthen collaborations across the schools and disciplines 
in their home institutions;  
 build partnerships with industry, other research networks, 
community groups, and other stakeholders; and 
 communicate the resources available through the CTSA 
Program. 
 
Recommendation 4: Formalize and Standardize Evaluation 
Processes for Individual CTSAs and the CTSA Program 
 
NCATS should formalize and standardize its evaluation process-
es for individual CTSAs and the CTSA Program. The evalua-
tions should use clear, consistent, and innovative metrics that 
align with the program’s mission and goals and that go beyond 
standard academic benchmarks of publications and number of 
grant awards to assess the CTSA Program and the individual 
CTSAs.  
 
 
CROSSCUTTING TOPICS  
 
 The CTSA Program has demonstrated progress in three crosscutting 
domains that the IOM committee believes are integral to advancing clini-
cal and translational science effectively: training and education, commu-
nity engagement, and child health research. These efforts, along with the 
program’s contributions in building infrastructure and providing a range 
of research resources, make the CTSA Program a unique national re-
source within the clinical and translational research landscape. Each of 
these functions can be strengthened, as discussed below.  
 
 
Training and Education 
 
 Sustaining a vibrant clinical and translational research enterprise in 
the future depends on building and retaining a diverse research work-
force. Education and training in clinical and translational research are 
priorities for the CTSA Program. All CTSA institutions are expected to 
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provide robust postgraduate training, and many have extensive training 
programs that include undergraduate and predoctoral student training as 
well as training for research staff and community collaborators. The KL2 
and TL1 training awards3 have been an integral part of CTSA training 
programs. In FY2011, 501 scholars participated in the KL2 program, and 
469 trainees participated in the TL1 program through the CTSA Pro-
gram. Moving forward, the committee urges increased flexibility in train-
ing and education programs with options available to personalize the 
training experience to meet the needs and goals of individual partici-
pants.  
This flexibility will be valuable in attracting and retaining scholars 
and trainees and may be particularly pertinent to the clinician-scientists 
who are essential in clinical and translational research. NCATS and indi-
vidual CTSAs have the opportunity to lead changes in the following: 
emphasizing the team-based skills that are required in clinical and trans-
lational research, developing metrics to assess clinical and translational 
training and education programs, and instituting incentives for recogni-
tion and promotion of those involved. New benchmarks that value team-
based efforts and collaborative approaches are needed to complement the 
traditional benchmarks for academic success that focus on individual 
accomplishments and products (e.g., publications, new grants). 
 
Recommendation 5: Advance Innovation in Education and 
Training Programs 
 
The CTSA Program should provide training, mentoring, and 
education as essential core elements. To better prepare the next 
generation of a diverse clinical and translational science work-
force, the CTSA Program should 
 
 emphasize innovative education and training models and 
methodologies, which include a focus on team science, lead-
ership, community engagement, and entrepreneurship;  
                                                        
3The KL2 Mentored Clinical Research Scholar Program is a career development award 
that provides individuals who have a doctoral degree with formal research experience and 
funding support to help them become independent investigators in clinical and transla-
tional research. The TL1 Clinical Research Training Program provides an introduction to 
clinical and translational research to pre- and postdoctoral candidates or others who want 
to learn more about these types of research. 
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 disseminate high-quality online offerings for essential core 
courses for use in CTSA and other institutions; 
 champion the reshaping of career development pathways for 
researchers involved in the conduct of clinical and transla-
tional science; and  
 ensure flexible and personalized training experiences that of-
fer optional advanced degrees.  
 
 
Community Engagement  
 
The ultimate goal of translational research—to improve human 
health—requires meaningful community engagement across the entire 
spectrum of research from basic science to community and population 
health research. Communities can contribute to the full range of clinical 
and translational research in important ways that are not always recog-
nized. For example, partnerships with community representatives can 
identify community health needs and priorities, provide critical input and 
data on clinically relevant questions, develop culturally appropriate clini-
cal research protocols, promote successful enrollment and retention of 
research participants, and, ultimately, disseminate and implement re-
search results more effectively.  
The initial commitment to community engagement within the CTSA 
Program should be commended. However, NCATS’s vision for how 
community engagement will be a part of the CTSA Program moving 
forward remains unclear. Although indications point to community en-
gagement remaining an important feature of the program, there are seri-
ous concerns that if it is not an explicit requirement for all CTSAs, it 
may fade in importance. The IOM committee fully supports community 
engagement and involvement throughout the entire research process and 
believes that this program component is essential and needs to be pre-
served, nurtured, and expanded. 
Because involving the community in the continuum of research is a 
new experience for many researchers, the CTSA Program and NCATS 
must provide clear guidance and leadership that effectively define and 
communicate goals and expectations. 
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Recommendation 6: Ensure Community Engagement in All Phases 
of Research 
 
NCATS and the CTSA Program should ensure that patients, 
family members, health care providers, clinical researchers, and 
other community stakeholders are involved across the continu-
um of clinical and translational research. NCATS and the CTSA 
Program should 
 
 define community engagement broadly and use this defini-
tion consistently in requests for applications and communica-
tions about the CTSA Program; 
 ensure active and substantive community stakeholder partic-
ipation in priority setting and decision making across all 
phases of clinical and translational research and in the lead-
ership and governance of the CTSA Program;  
 define and clearly communicate goals and expectations for 
community engagement at the individual CTSA level and 
across the program and ensure the broad dissemination of 
best practices in community engagement; and 
 explore opportunities and incentives to engage a more di-
verse community.  
 
 
Child Health Research 
 
For too long, research examining the safety and efficacy of medica-
tions and other health interventions has focused on adults, and little has 
been known about health- and development-related impacts of medica-
tions, devices, and preventive measures on children. Thus, clinical and 
translational research is urgently needed in the area of child health. The 
IOM committee believes that the CTSA Program has placed an appropri-
ate emphasis on accelerating clinical and translational research to im-
prove child health, and the CTSA Program, through the CTSA 
Consortium Child Health Oversight Committee (CC-CHOC), has made 
important steps toward streamlining and accelerating this type of research.  
To strengthen these efforts, the IOM committee believes that the 
NCATS-CTSA Steering Committee should identify a relatively small 
number of CTSAs with established expertise that provide outstanding 
efforts in child health research as leaders in this arena. This would not 
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preclude other CTSAs from being involved in child health research. In-
stead, the IOM committee hopes that such focused efforts would encour-
age and promote collaborations among CTSAs for multisite studies and 
other efforts. The committee also believes that CTSAs should be en-
gaged in a life-span approach that includes research on the transition 
from adolescence into adulthood.  
As part of a learning health care system, those involved in child 
health research need to be sure that this area of investigation is well posi-
tioned to fully embrace the use of electronic health records for research 
purposes and to actively partner with practice-based research networks. 
Implementing these types of strategies will allow researchers to under-
stand what is occurring in clinical practice and will allow pediatric health 
care providers, patients, and families to learn about new medications, 
therapeutics, and preventive measures.  
 
Recommendation 7: Strengthen Clinical and Translational 
Research Relevant to Child Health 
 
NCATS should collaborate with the CTSA Consortium Child 
Health Oversight Committee to strengthen clinical and transla-
tional research relevant to child health through efforts to 
 
 identify and designate CTSAs with expertise in child health 
research as leaders in advancing clinical and translational 
research relevant to child health and as coordinators for 
CTSA programwide efforts and other collaborative efforts in 
this research; and  
 promote and increase community engagement specific to 
child health by 
 
o raising awareness of the opportunities for children and 
families to participate in research efforts with clear in-
formation conveyed on the risks and potential benefits; 
and  
o involving parents, patients, and family members more 
fully at all stages of the research process, including iden-
tifying priorities and setting research agendas.  
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CONCLUSION: OPPORTUNITIES FOR ACTION 
 
With the ultimate goal of improving human health, the CTSA Pro-
gram now has the opportunity to propel clinical and translational re-
search efforts forward rapidly. To move to CTSA 2.0, the CTSA 
Program can build on its foundation; draw on the creativity and dedica-
tion of CTSA principal investigators, researchers, and staff; use the ever-
expanding capabilities of informatics and other technologies; share data 
and research support tools as openly and freely as possible; and fully en-
gage new cadres of researchers focused on team-based science.  
The IOM committee believes that the CTSA Program should be the 
national leader for advancing innovative and transformative clinical and 
translational research to improve human health. To achieve this, the 
CTSA Program should reshape its goals to reflect its new location within 
NCATS; build on the work of individual CTSAs to provide institutional 
leadership; focus on team-based education and training; and establish a 
national network that will accelerate the development of new diagnostics, 
therapeutics, and preventive interventions and, at the same time, will 
drive innovation in clinical and translational research methods, process-
es, tools, and resources. The committee’s recommendations are summa-
rized in Box S-1.  
Because the CTSA Program is not disease specific in its orientation, 
strong collaborations must be forged across disciplinary units within in-
dividual CTSA institutions and with other NIH institutes and centers, as 
well as with other government funders, industry, philanthropies, and 
community organizations. The CTSA Program should continue to lead 
efforts in expanding and diversifying the research workforce and to co-
ordinate and advance child health research by streamlining and building 
on the expertise of individual CTSAs. In all these efforts, community 
engagement is essential.  
In short, the contributions of the individual CTSAs and the CTSA 
Program are vital to the clinical and translational research enterprise, and 
the nation’s health can benefit greatly from strengthening their efforts.  
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BOX S-1 
Overview of Recommendationsa 
 
The next steps for the Clinical and Translational Science Awards 
(CTSA) Program and opportunities for advancing clinical and translational 
research are as follows: 
 
 Strengthen leadership of the CTSA Program by the National Center 
for Advancing Translational Sciences (NCATS). 
 Reconfigure and streamline the CTSA Consortium. 
 Build on the strengths of individual CTSAs across the spectrum of 
clinical and translational research. 
 Formalize and standardize evaluation processes for individual 
CTSAs and the CTSA Program. 
 Advance innovation in education and training programs.  
 Ensure community engagement in all phases of research. 
 Strengthen clinical and translational research relevant to child 
health. 
___________________________ 
aThe full text of the recommendations appears throughout the summary 
and in Chapters 3 and 4 of the report. 
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Introduction 
 
 
 
 
 
 
 
 
 
 
During the past-half century, biomedical research has expanded ex-
ponentially, becoming increasingly complex (IOM, 2013). As a result of 
improved scientific knowledge, the biomedical research enterprise in the 
United States has witnessed many successes that offer the promise of 
improved human health. For example, advances in the fields of genomics 
and proteomics have led to new targeted diagnostic tools and therapies 
for diseases as diverse as lung cancer, schizophrenia, and cystic fibrosis 
(IOM, 2012).  
Despite the production of new data and numerous publications dis-
seminating these research findings, translating the results of basic and 
clinical research into clinical and community practice has been slow and 
cumbersome, and many years may pass before the benefits of basic sci-
ence discoveries and clinical investigations reach individual patients and 
communities. Barriers to translation include long research timelines; the 
large number of clinical trials that must be abandoned because of limited 
enrollment; data-sharing challenges; a lack of available resources (in-
cluding investigators, study participants, and financial support for clini-
cal trials); and increasing costs, complexity, and regulatory burdens 
(Collins, 2011; Kitterman et al., 2011; NCATS, 2013d; Zerhouni, 2005). 
These persistent challenges required a new approach to accelerating the 
translation of research to clinical applications and maximizing improve-
ments in individual and public health. 
Recognizing the need for a new research paradigm, the National In-
stitutes of Health (NIH) developed a Roadmap for Medical Research in 
2004 to focus efforts on the challenges facing medical research (NIH, 
2006, 2011, 2013a; Zerhouni, 2005). The NIH Roadmap sought to facili-
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tate new pathways to discovery; promote interdisciplinary and collabora-
tive research teams; and “re-engineer the clinical research enterprise” by 
harmonizing regulatory policies, encouraging multidisciplinary training, 
and facilitating the establishment of academic homes for clinical and 
translational research (NIH, 2006; Zerhouni, 2003).  
As part of its effort to implement its Roadmap and spur clinical and 
translational research, the NIH established the Clinical and Translational 
Science Awards (CTSA) Program. The CTSA Program was designed to 
“provide integrated intellectual and physical resources for the conduct of 
original clinical and translational science” (Zerhouni, 2005, p. 1622), and 
individual CTSA sites were intended to serve as “catalysts and test beds 
for policies and practices that can benefit clinical and translational re-
search organizations throughout the country” (Zerhouni, 2006, p. 4). The 
CTSA Program originally focused on “re-engineering existing capabili-
ties at medical research institutions and developing new resources in the 
areas of clinical and translational research training, community outreach 
and informatics” (NCATS, 2013a). Although the CTSA Program does 
not directly fund or conduct large-scale clinical and translational re-
search, it supports the development and application of shared resources 
and innovative technologies for clinical and translational studies across 
the full spectrum of research (NIH, 2012b). Consistent with NIH’s 
Roadmap, the CTSA Program’s initial goals were to 
 
 “create academic homes for clinical and translational research;  
 provide investigators and research teams with research cores, 
tools and a local environment that encourages and facilitates the 
conduct of clinical and translational research, including with 
community and industry partners; and 
 train the scientific workforce needed for the translational sciences” 
(NCATS, 2013a). 
 
Diverse groups of stakeholders (researchers, funders, the public, and 
congressional representatives) increasingly seek evidence that the enor-
mous U.S. investment in biomedical research, including the CTSA Pro-
gram, is bearing tangible fruit in the form of new and better preventive 
and treatment options. A 2011 congressional conference report high-
lighted the success and additional promise of the CTSA Program and 
“urge[d] NIH to support a study by the Institute of Medicine to evaluate 
the CTSA program and to recommend whether changes to the current 
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mission are needed” (U.S. Congress, 2011). The report specified the 
charge as follows: 
 
CTSAs now represent an investment of half a decade of 
innovation in translational research. To ensure the bene-
fits of this investment are maintained, the conferees urge 
NIH to support a study by the IOM that would evaluate 
the CTSA program and recommend whether changes to 
the current mission are needed. The review should in-
clude stakeholders’ input and be available no later than 
18 months after the enactment of this bill (U.S. 
Congress, 2011, p. 1137). 
 
 
SCOPE OF WORK AND STUDY PROCESS 
 
In 2012 the NIH contracted with the Institute of Medicine (IOM) to 
conduct a consensus study to review the CTSA Program. The IOM con-
vened a 13-member committee with expertise in community outreach 
and engagement, public health and health policy, bioethics, education 
and training, pharmaceutical research and development, program evalua-
tion, clinical and biomedical research, and child health research, along 
the continuum of clinical and translation research (Appendix B). 
The committee’s statement of task (see Box 1-1) directed it to assess 
the CTSA Program and its mission and strategic goals and to offer advice 
on the implementation of the program by the National Center for Ad-
vancing Translational Sciences (NCATS), while exploring the contribu-
tions of CTSAs in accelerating the development of new therapeutics, 
facilitating disease-specific research and child health research, and en-
hancing the integration of research funded by NIH institutes and centers. 
When presenting the charge to the committee at its first meeting in Octo-
ber 2012, NCATS leaders offered the following questions to help clarify 
the statement of task: 
 
 “Is the breadth of the program supporting T1 through T4 re-
search appropriate?  
 Should the goal of creating an academic home for clinical and 
translational sciences continue to be a major focus of the CTSA 
program? 
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 Are CTSAs effectively providing innovative education, training, 
and career development support to meet the needs of the biomed-
ical research workforce? How could this aspect of the program 
be strengthened? 
 Are the CTSAs configured effectively to accelerate new thera-
peutics, and if not, what changes should be implemented?” 
(Briggs and Austin, 2012). 
 
Throughout this study, the committee considered these questions and 
used a forward-looking approach to respond to its statement of task. This 
report builds on previous program evaluations and assessments, although 
it was not designed to provide a comprehensive and in-depth evaluation 
of the operations, administration, or achievements of individual CTSA 
sites or the program as a whole. The committee’s advice and recommen-
dations are intended to help NCATS implement the program effectively 
and enable the full realization of its potential.  
 
 
BOX 1-1 
Committee to Review the Clinical and Translational 
Science Awards Program at the National Center 
for Advancing Translation Sciences 
Statement of Task 
In response to a request from the National Institutes of Health (NIH), the 
Institute of Medicine (IOM) will assemble an ad hoc expert committee to 
provide an independent appraisal of and advice on the NIH Clinical and 
Translational Science Awards (CTSA) Program as it will be implemented by 
the newly formed National Center for Advancing Translational Sciences 
(NCATS). The current mission of the CTSA program includes services and 
infrastructure support for the full continuum of clinical and translational re-
search. The services provided by CTSAs have supported T1 through T4 
research, with primary emphasis on support for human subjects research 
extending from first-in-man and proof-of-concept studies through efficacy 
and effectiveness studies, and including research on how to achieve com-
munity and patient engagement, implementation and dissemination scienc-
es, and behavioral research. 
The IOM committee will review existing evaluations and available stake-
holder input on the program, and will seek additional stakeholder input as 
needed. Based on this assessment, the committee will provide recommen-
dations on the appropriateness of the program’s current mission and over-
arching goals and whether changes are needed. This study will explore the 
contributions of the CTSAs in accelerating the development of new thera-
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peutics with consideration given to the role of the CTSA program in facilitat-
ing disease-specific research and pediatric research and in enhancing the 
integration of programs funded by the categorical NIH Institutes and Centers. 
 
 
During the course of its work, the committee held four meetings, two 
public workshops, and four open-session conference calls to solicit input 
about the successes, challenges, and future directions of the CTSA Pro-
gram (Appendix A). Throughout the study, the committee heard from a 
number of CTSA principal investigators (PIs) and researchers, members 
of the NIH and NCATS leadership, community and patient advocacy 
organizations, industry partners and representatives, and thought leaders 
and researchers in the clinical and translational sciences arena who were 
not connected to the CTSA Program. As part of its assessment, the com-
mittee reviewed the scientific literature, previous CTSA Program evalua-
tions, available progress reports, responses to formal NIH requests for 
information (RFIs) related to the CTSA Program, information submitted 
by a range of CTSA Consortium committees and stakeholder groups, and 
data and recommendations from other relevant working groups and 
stakeholder meetings. The committee’s work was also informed by re-
sponses to a series of public input questions that focused on the CTSA 
Program’s mission and strategic goals and its role in advancing research 
along the continuum of clinical and translational science.1 
 
 
CLINICAL AND TRANSLATIONAL RESEARCH 
 
Translational research means different things to different people 
 but it seems important to almost everyone. 
    —Steven Woolf (Woolf, 2008) 
 
The CTSA Program’s focus, by definition, is on clinical and transla-
tional research. Clinical research involves human participants and in-
cludes epidemiological and behavioral studies; outcome and health 
services research; and patient-oriented research, such as the study of dis-
ease pathology and mechanisms, development and testing of therapeutic 
interventions or technologies, and clinical trials (NIH, 2013b). The 
NIH’s definition of translational research includes two broad areas: the 
                                                            
1Public testimony and other materials submitted to the committee are available by re-
quest through the National Academies’ Public Access Records Office.  
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translation of basic science and preclinical discoveries into human sub-
ject research and the subsequent translation of clinical trial results, re-
search findings, and knowledge into practice in clinical and community 
settings (NIH, 2013b). For the purposes of this report, however, the 
committee has adopted a conceptual model of translational research that 
exists along a dynamic continuum that connects basic research findings 
to decisions made within clinical settings and interventions that are applied 
in community and public health settings to improve health broadly. Figure 
1-1 defines and illustrates the conceptual progression across the five 
phases of translational research, from the initial stages of research (such 
as preclinical and animal models) to large-scale research in communities 
and populations. The translational phases along this continuum are some-
times referred to as “bench-to-bedside” and “bedside-to-community” 
(Blumberg et al., 2012; ITHS, 2013; Khoury et al., 2007).  
Despite efforts to raise the profile and improve the accessibility of 
translational research, misconceptions persist about its scope, and many 
people conflate the concepts of clinical and translational research. As 
illustrated above, the continuum of translational research ((T0–T4) is 
broader than clinical research (T1–T3). Although the depiction of the 
separate phases of translational research above suggests a linear model 
 
 
 
 
FIGURE 1-1 Operational phases of translational research (T0–T4). 
SOURCE. Adapted with permission from Macmillan Publishers Ltd.: Nature 
Medicine (Blumberg et al., 2012), copyright (2012). 
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with a finite beginning and end, in reality the operational phases of trans-
lational research include many feedback loops. Its process is more circu-
lar and interdependent across research phases, requiring continuous data 
gathering, analysis, dissemination, and interaction (see Figure 1-2). In-
formation sharing at each stage ensures that researchers are meeting pa-
tient and community health needs and that progress in the clinic and 
community, in turn, informs the work in the laboratory. As a result, the 
impact of translational research on health improvements hinges on an 
integrated and responsive research infrastructure, similar to models of a 
“learning health care system” (discussed in Chapter 2). 
The value of continuous feedback from communities to researchers 
is illustrated by three of the many advances in clinical and translational 
research the CTSA Program has achieved (see Box 1-2), which are being 
used by individuals and communities to improve health and quality of 
life.  
 
 
 
FIGURE 1-2 An integrated model of clinical and translational research.  
SOURCE: Adapted from Austin, 2013. 
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BOX 1-2 
Examples of Advances Accomplished Through Successful  
Clinical and Translational Research 
 
Cystic Fibrosis. On January 31, 2012, the Food and Drug Administration (FDA) 
approved the drug Kalydeco for people with a rare form of cystic fibrosis. 
Kalydeco is the first drug to target the underlying cause of this type of cystic 
fibrosis and is the result of a unique collaboration between the Cystic Fibrosis 
Foundation, Vertex Pharmaceuticals, and 10 CTSA institutions. This collabora-
tion facilitated clinical trials that garnered FDA approval (FDA, 2012; NCATS, 
2012, 2013b).  
 
Paralysis. A multidisciplinary team of researchers at the University of Pitts-
burgh, including neurosurgeons, neurologists, neurobiologists, and bioengi-
neers, are conducting brain-computer interface research that has translated 
brain-mapping studies into an animal model study. During the last 2 years, re-
searchers have initiated the first human studies, implanting devices into the 
brains of two paralyzed individuals. The implants allow research participants to 
use the brain’s electrical impulses to control a robotic arm designed by the 
Johns Hopkins University’s Applied Physics Lab. These studies offer great po-
tential for individuals with paralysis and are the result of collaborative funding 
efforts by the Department of Defense, the Department of Veterans Affairs, the 
FDA, and the National Institutes of Health (NIH) (Collinger et al., 2012; NCATS, 
2012, 2013c; University of Pittsburgh Medical Center, 2011, 2012). 
 
Diabetes. To improve the health of individuals with diabetes or those who are 
at risk of developing diabetes, investigators at CTSAs in California, Connecti-
cut, and South Carolina are working with local communities to explore models 
of diabetes prevention and interventions tailored to the needs of those commu-
nities. For example, researchers at Yale University are currently testing and 
implementing a 12-week intervention at a local community health center that 
features intensive lifestyle changes for women with pre-diabetes (NIH, 2012b; 
Tamborlane, 2009; Yale School of Medicine, 2012a,b). 
 
 
OVERVIEW OF THE CTSA PROGRAM 
 
History 
 
The CTSA Program is a direct outgrowth of the NIH’s General Clini-
cal Research Center (GCRC) Program, which for more than 40 years pro-
vided clinical research infrastructure funding.2 The GCRCs provided 
                                                            
2The GCRCs began in the early 1960s and focused on metabolic and nutritional studies 
(Briggs and Austin, 2012; Robertson and Tung, 2001). Researchers applied to the GCRC 
in a specific institution to use its clinical research units for their institutional review board 
(IRB)-approved research. In 2005 there were 78 GCRC sites with a total budget of ap-
proximately $288 million (Briggs and Austin, 2012).  
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clinical researchers with dedicated inpatient beds, outpatient units, core 
laboratory support, and staffing support (e.g., research nurses, laboratory 
technicians, biostatisticians) (Robertson and Tung, 2001). Beginning in 
2005, with the implementation of the NIH Roadmap and NIH’s efforts to 
revitalize its work in clinical and translational research, the GCRC Pro-
gram was phased out. Funding from that program was redirected and 
consolidated with other existing resources (e.g., T- and K-training and 
career development awards), along with additional support from the NIH 
Common Fund, to launch the CTSA Program (NIH, 2005; Shurin, 2008).  
In 2006, 12 CTSA sites were funded through 5-year cooperative 
agreements as a first step toward establishing academic homes for clini-
cal and translational research (Briggs and Austin, 2012; NIH, 2005; OIG, 
2011). Institutional CTSA funding levels were based on the applicant’s 
previous GCRC funding and other NIH training awards (Briggs and 
Austin, 2012). A number of GCRC institutions applied for and received 
CTSA Program funding, and their GCRC clinical research units and as-
sociated resources were folded into the new program (NIH, 2012a). Fol-
lowing the first round of awards, the NIH added 5 to 14 new CTSA sites 
annually until, by the end of 2012, the program reached capacity at 61 
sites nationwide (see Figure 1-3) (Briggs and Austin, 2012; Reis et al., 
2010). The annual budgets for these sites range from $4 million to $23 
million (Briggs and Austin, 2012; CTSA Central, 2013a), and the total 
annual budget for the program for fiscal year (FY) 2012 was $461 million. 
The CTSA Program was administered by the National Center for Re-
search Resources (NCRR) through 2011, when the Consolidated Appro-
priations Act of 2012 (Public Law 112-74) established NCATS and 
dissolved the NCRR (Collins, 2011; Reed et al., 2012). The NCATS 
mission focuses on catalyzing innovative methods and technologies re-
lated to the development of diagnostics and therapeutics, and it became 
home to the CTSA Program and several smaller, related NIH programs. 
The CTSA Program accounted for approximately 80 percent of the 
NCATS budget in FY2012 (Briggs and Austin, 2012).  
During the initial transition period and under interim leadership, 
NCATS sought input from a wide range of stakeholders through a varie-
ty of mechanisms (e.g., RFIs, internal NIH working groups) on the im-
plementation of the CTSA Program and strategies for enhancing it. As 
NCATS begins to lead the program forward, it is taking incremental 
steps to reshape its work. For example, its first request for applications 
(RFA) signaled more flexibility in focus for individual CTSAs (Chapter 3) 
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FIGURE 1-3 CTSA-funded institutions and participating states. 
SOURCE: CTSA Central, 2013a. Reprinted with permission from the National 
Institutes of Health, U.S. Department of Health and Human Services. 
 
and a new funding structure in which support for individual CTSAs will 
be based on their institution’s total NIH research funding base (NIH, 
2012c).  
 
 
Structure of the CTSA Program 
 
Today’s CTSA Program facilitates the training and education of in-
vestigators and fosters a collaborative environment to promote improve-
ments in the quality, safety, efficiency, and cost-effectiveness of clinical 
and translational research. It does not focus on any one disease or disor-
der, although individual CTSA sites and projects may do so (NIH, 
2012c). The program has a complex, multilevel organizational and over-
sight structure involving individual institutions, the CTSA Consortium, 
the CTSA Coordinating Center, and NCATS. NCATS’s Division of 
Clinical Innovation oversees the CTSA Program and provides funding 
and other resource support for individual CTSA sites.  
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Individual CTSAs 
 
At the heart of the CTSA Program are the 61 individual CTSAs es-
tablished in academic health centers and other institutions across the 
United States and the commitment and ingenuity of the researchers and 
partners who work with them. These institutions have some flexibility in 
how to structure their individual programs. Many CTSAs are housed in 
medical schools and collaborate with other departments and schools in 
their universities, as well as with other universities, hospitals, and health 
care systems (CTSA Central, 2013h). Each CTSA must set up an exter-
nal advisory committee that meets annually to provide advice on struc-
ture, progress, and challenges of the program (NIH, 2012c). Many 
CTSAs also have established internal advisory committees and other ad-
visory and governance committees (e.g., executive committees, commu-
nity advisory boards). 
Because CTSA funding levels vary widely across sites, the scope of 
their activities also varies (see also Chapter 3). In general, CTSA sites 
provide an array of training and research resources and support tools de-
signed to help investigators conduct promising research, including 
 
 core facilities (e.g., translational technologies, core laboratory 
services, and novel methodologies, such as specific embryonic 
stem cell lines, nanotechnology, and epigenomics);  
 biomedical informatics (e.g., behavioral data analysis, geograph-
ic coding, proteomics, registration for trials through tools such as 
ResearchMatch [see Chapter 3], customized software); 
 pilot funding (e.g., through CTSA pilots, institutional pilots, 
trainee and scholar pilot programs, and partnerships with indus-
try and not-for-profit organizations); 
 regulatory knowledge and support (e.g., auditing and compliance 
measures, HIPAA compliance, conflicts-of-interest management, 
protocol development and preparation, and IRB agreements); 
 biostatistics, epidemiology, research design, and ethics (e.g., 
ethics consultations, adaptive trial design, randomization and 
blinding, statistical modeling and analysis, multicenter coordina-
tion, grant application support); 
 participant and clinical interaction resources (e.g., cost recovery 
planning, case report form development and reporting compli-
ance, research nurse support, research subject advocacy); and  
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 community engagement efforts and resources (e.g., adult literacy 
assessment, cultural competency training, public databases, pro-
motion of research participation) (Rosenblum, 2012).  
 
CTSA Consortium Committees and Coordinating Center 
 
CTSA Consortium committees From the outset of the program, the 
NIH charged the CTSAs with developing a national consortium to pro-
mote the identification and use of best research practices (Berglund and 
Tarantal, 2009). The original funding announcement called for a consor-
tium steering committee comprised of CTSA PIs. In addition, it directed 
that subcommittees be formed around NIH-identified key functions (e.g., 
education, informatics, regulation) (NIH, 2005). Further details on the 
governance and structure of the CTSA Consortium and its committees 
were formalized in 2008 as part of the PI-directed strategic planning pro-
cess. At that time, the CTSA Program consisted of two dozen individual 
CTSAs (Reis et al., 2010). The initial NIH guidance and the strategic 
planning effort formed the basis for the complex, multi-tiered CTSA 
Consortium committee structure that exists today, which includes hun-
dreds of participants. 
The CTSAs’ collaborative efforts are overseen by three leadership 
committees:  
 
 The Consortium Executive Committee is the main governing 
body and has 31 members (more than 20 of whom are voting 
members), including leadership of the Consortium Steering 
Committee (described below), 5 CTSA PIs, NCATS staff, and 
other members who serve 1-year terms. Its purpose, in part, is to 
facilitate interactions among the PIs, NCATS staff, and the vari-
ous consortium committees (CTSA Central, 2013e).  
 The Consortium Steering Committee has more than 175 mem-
bers (more than 85 of whom at voting members), including PIs 
from each CTSA institution and representatives from NCATS 
and a number of other NIH institutes and centers. It provides 
leadership and management of the consortium and is responsible 
for setting strategic goals and priorities (CTSA Central, 2013g).  
 The CTSA Consortium Child Health Oversight Committee fo-
cuses on overcoming barriers and promoting opportunities for 
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child health research and has more than 230 members, almost 60 
of whom are voting members (also discussed in Chapter 4). 
 
In addition to the leadership committees, CTSA PIs, researchers, and 
staff coordinate collaborative efforts and work to improve program func-
tioning through numerous CTSA Consortium committees, interest 
groups, working groups, and task forces that have evolved with the 
growth of the program (see Box 1-3). Five strategic goal committees 
consist of 20 to 30 members each. These committees identify and priori-
tize efforts related to achieving the strategic goals defined in 2008 
(CTSA Central, 2013b; Reis et al., 2010).  
Fourteen key function committees discuss crosscutting issues, pro-
mote collaboration, and identify and implement best practices. The key 
function committees reflect areas deemed essential to the program’s mis-
sion, and some of them have been required in NIH funding announce-
ments. The number and focus of the key function committees have 
fluctuated over the life of the CTSA program as priorities shifted 
(Evanoff, 2012). Many of these committees include more than 100 mem-
bers and have subcommittees, working groups, and task forces (CTSA 
Central, 2013c). In addition, numerous informal groups of CTSA re-
searchers have developed around topics of mutual interest.  
 
 
BOX 1-3 
CTSA Consortium Committees and Working Groups 
 
 
 
Consortium Leadership Committee 
 
 Consortium Executive Committee 
 Consortium Steering Committee 
 CTSA Consortium Child Health Oversight Committee 
 
Consortium Strategic Goal Committees 
 
 Strategic Goal Committee 1—National Clinical and Translational Re-
search Capability 
 Strategic Goal Committee 2—Training and Career Development of 
Clinical/Translational Scientists 
 Strategic Goal Committee 3—Enhancing Consortium-Wide Collabora-
tions 
 Strategic Goal Committee 4—Enhancing the Health of Our Communi-
ties and the Nation 
 Strategic Goal Committee 5—T1 Translational Research 
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Key Function Committees 
 
 Administration Key Function Committee 
 Biostatistics/Epidemiology/Research Design Key Function Committee 
 Clinical Research Ethics Key Function Committee 
 Clinical Research Management Key Function Committee 
 Clinical Services Core Key Function Committee 
 Communications Key Function Committee 
 Community Engagement Key Function Committee 
 Comparative Effectiveness Research Key Function Committee 
 Education and Career Development Key Function Committee 
 Evaluation Key Function Committee 
 Informatics Key Function Committee 
 Public–Private Partnerships Key Function Committee 
 Regulatory Knowledge Key Function Committee 
 Translational Key Function Committee 
 
CTSA Thematic Special Interest Groups 
 
 CTSA Nurse Scientist 
 CTSA Pain Research Interest Group 
 CTSA TEAM (TElemed, teleheAlth, Mhealth) 
 CTSA-USCIITG Critical Care Interest Group 
 Dentistry and Oral Health 
 Emergency Care Researchers 
 Neuroscience Researchers 
 Sleep Research Network 
 VA Research Collaboration 
 Women in Clinical and Translational Research Interest Group 
 
SOURCES: CTSA Central, 2013c,f,i. 
 
 
After the development of the strategic goals in 2008, an effort was made 
to map the key functions to correspond to one or more of program strate-
gic goals (Reis et al., 2010). Table 1-1 indicates that, although related, 
strategic goals and key function groups do not consistently align. A 
commitment to participate in CTSA Consortium efforts, including the 
committees, has been a condition of receiving a CTSA award (NIH, 
2010). All the committees described above convene regular conference 
calls to discuss progress and share best practices. The committees com-
prise PIs and researchers who take on these extra responsibilities in addi-
tion to their work at their institution’s CTSA.  
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TABLE 1-1 Alignment of the CTSA Key Function Committees and Strategic 
Goal Committees  
Strategic Goal Committees 1 2 3 4 5 
Key Function Committees That 
Support Strategic Goal Committees 
     
Clinical Research Management  X     
Clinical Services Core  X     
Regulatory Knowledge  X     
Education and Career Development   X    
Community Engagement     X  
Comparative Effectiveness Research     X  
Public–Private Partnerships       X 
Translational      X 
Communications    X    
Cross Cutting Key Function Committees 
Informatics      
Evaluation      
Biostatistics/Epidemiology/Design      
Clinical Research Ethics      
General Grant/Consortium Operations 
Administration      
NOTE: X = alignment for reporting purposes and on-going management of 
deliverables. 
 = alignment for related agenda topics and deliverable support. 
SOURCE: https://www.ctsacentral.org/committees. 
 
 
CTSA Consortium Coordinating Center In November 2011, the 
CTSA Consortium Coordinating Center was established through a com-
petitive application process, which awarded Vanderbilt University a 
budget of $20 million over 5 years to: 
 
 establish a high visibility and accessible “national home” for the 
CTSA Program; 
 manage meetings, projects, and communications of the CTSA 
Consortium;  
 compile and organize the CTSA Consortium’s networking re-
sources; and 
 develop and disseminate research tools and resources that sup-
port translational research (CTSA Central, 2013d; Snyder, 2011). 
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Since its inception, the coordinating center has taken many steps to 
standardize and coordinate consortium activities (e.g., project and meet-
ing support, listservs). In its efforts, the coordinating center also attempts 
to ensure the dissemination of best practices, facilitate the uptake of 
available tools and resources, and promote collaboration, in part, through 
its website, CTSACentral.org. The coordinating center facilitated PI ef-
forts to produce a joint publication on the program’s transition to 
NCATS and a joint response to an NCATS RFI regarding opportunities 
to enhance the CTSA Program (Bernard, 2012; CTSA PIs, 2012; Pulley, 
2013). The coordinating center is also striving to improve connections 
between the CTSA Program and NIH institutes and centers through a 
new liaison effort. Under that initiative, 40 CTSA PIs are working with 
18 NIH institutes and centers to increase communication, awareness of 
available CTSA resources, and the integration of trans-NIH resources 
(Bernard, 2012). 
 
 
ORGANIZATION OF THE REPORT 
 
This report provides the IOM committee’s findings and recommen-
dations regarding the progress and potential of NIH’s CTSA Program. 
The report covers the breadth of the statement of task and highlights op-
portunities to bolster the program and ensure its continued success and 
sustainability in supporting clinical and translational researchers and 
serving the needs of the communities CTSAs are linked to and in which 
they reside. Chapter 2 discusses the ecosystem in which NCATS and the 
CTSA Program operate and provides the committee’s vision for the next 
phase of the CTSA Program. Chapter 3 emphasizes the need for strong 
and active leadership by NCATS in establishing a clear vision and mis-
sion for the program along with measurable goals; supporting individual 
CTSAs; partnering and collaborating within the NIH and with external 
partners; and evaluating and communicating the program’s value. Chap-
ter 4 highlights specific opportunities and priorities in the areas of train-
ing and education, community engagement, and research related to child 
health. On the basis of discussions, conclusions, and recommendations 
outlined in the preceding chapters, in Chapter 5 the report concludes with 
next steps and potential future directions. 
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A Vision for the CTSA Program 
in a Changing Landscape 
 
 
 
 
 
 
 
 
The Clinical and Translational Science Awards (CTSA) Program 
does not exist in isolation; it is part of a larger clinical and translational 
research ecosystem that plays a vital role in an increasingly complex and 
dynamic U.S. health care system. The individual CTSAs were originally 
designed as a set of academic focal points (or academic “homes”) for 
facilitating clinical and translational research. To better determine 
whether the CTSA Program’s mission and goals remain appropriate, as 
requested in its statement of task, the IOM committee examined how the 
changing U.S. health care landscape affects the relationship between the 
CTSA Program and the larger clinical and translational research ecosystem.  
This chapter begins by exploring some of these large-scale changes 
and their impact on clinical and translational research and concludes by 
describing a new vision for the CTSA Program and opportunities for the 
National Center for Advancing Translational Sciences (NCATS) to fulfill 
this vision. 
 
 
THE CURRENT U.S. HEALTH CARE 
RESEARCH LANDSCAPE 
 
Decades of innovation and technological advances have led to pro-
gress in biomedical sciences, medicine, and public health, contributing to 
increased life expectancy and improved individual and population health. 
National initiatives and an emphasis on public reporting of quality 
measures have improved some specific health outcomes and the man-
agement of chronic diseases (Commonwealth Fund, 2011). For example, 
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in recent decades there have been strides in controlling high blood 
pressure and in improving factors associated with diabetes control (i.e., 
A1C, blood pressure, and cholesterol) (Casagrande et al., 2013; 
Commonwealth Fund, 2011). Another significant change is that medical 
screening and diagnostics continue to move to less expensive settings—from 
hospitals, to physician offices, to retail clinics, to homes. For example, 
rapid advances in screening tools led the Food and Drug Administration 
(FDA) to approve the first in-home testing kit for HIV in 2012 (Chappel 
et al., 2009; FDA, 2012). At the same time, sophisticated laboratory 
techniques, combined with a growing data infrastructure and new analyt-
ic tools, are reshaping research. For example, researchers and entrepre-
neurs now have online access to an ever-expanding library of human 
genome sequence data generated by the 1000 Genomes Project, provided 
at no cost through the Amazon Web Services cloud (EMBL-EBI, 2013; 
NIH, 2012a). 
The accelerating pace of scientific discoveries has a downside as 
well. The complexity of the U.S. health care system has increased,  
contributing to inconsistent health care quality, escalating costs, inequi-
ties in access, and shortcomings in improvement in population health 
outcomes (IOM, 2013a). The IOM has reported that systematic underuse, 
misuse, and overuse of medical treatments significantly and negatively 
affect the overall quality and safety of health care and put individual  
patients at risk (IOM, 1998, 2001, 2013a). In response to these persistent 
challenges, diverse stakeholders (e.g., policy makers, payers, health care 
professionals, researchers, industry representatives, community advocacy 
groups, and individual patients) have called for dramatic changes in 
health care research and delivery. Efforts are under way to increase  
accountability for the effectiveness and efficiency of the U.S. health care 
system by aligning stakeholder interests around the concept of value 
(Public Law 111-148) (Porter, 2010; Porter and Teisberg, 2006). Across 
the United States, momentum is growing in support of a learning health 
care system that promote novel partnerships and collaborations around 
research networks and clinical and delivery system innovations to  
continually improve health care value. 
A learning health care system is founded on the concept of continu-
ous improvement and the imperative to translate “what we know” into 
“what we do.” Such a system fuels greater value in health care by  
harnessing the promise of new technological capabilities, market oppor-
tunities, and policies across the health care landscape (IOM, 2013a). 
Leaders in the public and private sectors are “generating and using real-
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time knowledge through science and informatics to improve outcomes”  
(p. S-13); engaging patients, families, and communities in decisions  
related to health and health care; and promoting a new culture of care 
committed to sustained improvement in human health and health care 
efficiency (IOM, 2013a).  
Clinical and translational research are integral to a learning health 
care system, which relies on an “iterative innovation process designed to  
generate and apply the best evidence for the collaborative health care 
choices of each patient and provider; to drive the process of discovery as 
a natural outgrowth of patient care; and to ensure innovation, quality, 
safety, and value in health care” (Kemp, 2012, p. 1).  
As Figure 2-1 illustrates, the interconnected forces of clinical  
research and practice fuel a learning health care system. Researchers and 
health care providers design and implement care, evaluations, or research 
based on needs of specific communities and populations, which are  
identified through needs assessments (external scans) or on the basis of 
observations of researchers and health care providers (internal scans). 
The resulting data and analyses measure the effectiveness of particular 
health care goods, services, and processes. These findings are dissemi-
nated to inform clinical practice and research models to improve health. 
This cyclical relationship allows a learning health care system to stay 
relevant in an ever-changing health care landscape.  
The concepts of a learning health care system and translational  
research both rely on successful integration of clinical research and  
practice, which has significant implications for conventional notions of 
bioethics. The traditional paradigm draws a “sharp distinction between 
clinical research and practice” (Faden et al., 2013, p. s16). Human  
subject research, unlike clinical practice, is subject to strict federal  
regulations that protect research participants,1 and overall health care 
system improvement activities must act accordingly (Faden et al., 2013). 
Regulatory oversight burdens can threaten the health of patients and 
populations by delaying or obstructing potentially beneficial changes to 
clinical practice (Millum and Menikoff, 2010), especially if concerns 
about research oversight limit research utility, analytic rigor, or dissemi-
nation of quality improvement data (Faden et al., 2013).  
CTSAs can play a crucial role in recalibrating the longtime ethical 
divide between research and clinical care. The Ethics Consultation 
 
                                                            
1See, for example, 45 C.F.R. 46. 
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FIGURE 2-1 The learning health care system.  
SOURCE: Larson et al., 2013. Reprinted with permission from Radcliffe 
Publishing.  
 
Working Group, which includes members from 40 CTSAs, “creat[es]  
a professional community to share strategies, policies, practices,  
approaches, and information” on this topic (NCATS, 2012, p. 20). By 
serving as best-practices laboratories in this new ethics environment  
and by disseminating lessons learned, CTSAs have the potential to  
advance a new regulatory framework in which the interests in improving 
health care for patients and protecting individual research participants 
converge. In addition to the CTSAs’ efforts in advancing this new  
regulatory framework, ongoing collaboration with key research and regu-
latory agencies, such as the FDA, the National Institutes of Health (NIH), 
and the Department of Health and Human Services’ (HHS’s) Office for 
Human Research Protections, will be necessary. 
 
 
AN EVOLVING CLINICAL AND TRANSLATIONAL 
RESEARCH ECOSYSTEM 
 
The clinical and translational research ecosystem currently involves 
researchers, funders, health care systems, research networks, health  
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professionals, regulators, industry, community stakeholders, and individ-
uals working in varied settings—laboratories, hospitals, academic health 
centers, community clinics, private practices, and other places patients 
receive care. The CTSA Program facilitates interactions between stake-
holders within the ecosystem and across settings to accelerate progress in 
clinical and translational research.  
The diversity of stakeholders’ interests makes the research  
ecosystem susceptible to a wide range of transformative forces. In the 
1970s, for example, clinical and basic research began to diverge; basic 
biomedical research developed as a distinct discipline, with a separate 
training and career trajectory (Butler, 2008), a divide that translational 
research is now trying to address. 
Other broader social concerns also affect researchers. With the  
proliferation of health information systems and technologies, including 
the use of electronic health records and databases, concerns about  
individual privacy and the security of health information have intensi-
fied, especially around data not directly relevant to health care goods and 
services (IOM, 2010). Major shifts toward enhanced patient confidential-
ity (e.g., the Health Insurance Portability and Accountability Act of 
1996) have led to greater protection of personal information, but also 
present challenges in the conduct of efficient and clinical and trans-
lational research by “restrict[ing] the manner in which health care  
providers may use and disclose health information for health research” 
(Pritts, 2008). These challenges will likely increase as research expands 
within the context of the learning health care system, with traditional 
distinctions between clinical care and research blurring and with the role 
of research participant protections requiring new analysis, clarification, 
or even revision. 
Although advances in biomedical sciences and informatics have 
vastly expanded opportunities for research, a number of persistent data 
challenges will need to be overcome in order to realize the full potential 
of clinical and translational science. For example, interoperability and 
connectivity issues among data sources, along with privacy concerns, 
cultural barriers, and lack of incentives, impede data sharing among  
researchers and across sectors (e.g., academia, industry). Nevertheless, a 
recent Institute of Medicine (IOM) workshop report noted that “research 
advances derived from data pooling and analysis could improve public 
health, enhance patient safety, and spur drug development” (IOM, 2013c, 
p. 1). Fragmentation, lack of standardization/heterogeneity, and the une-
Copyright © National Academy of Sciences. All rights reserved.
The CTSA Program at NIH:  Opportunities for Advancing Clinical and Translational Research
40 THE CTSA PROGRAM AT NIH 
 
PREPUBLICATION COPY: UNCORRECTED PROOF 
ven accuracy and quality of available health data are additional challeng-
es for researchers (IOM, 2010, 2013c). 
Finally, funding limits are forcing stakeholders to set priorities, share 
resources, and target their investments. Today, industry’s focus has  
shifted away from the full range of bench-to-bedside discoveries toward 
investments in potential products that have already completed the early 
phases of research (Butler, 2008; Reed et al., 2012). Resource scarcity 
has focused attention on research value, and increasingly stakeholders, 
including research funders, the public, and Congress, are demanding  
evidence of returns on investments and greater accountability (Austin, 
2013; Reed et al., 2012; Shuster, 2012).  
Although “measuring the outcomes of translational research is  
notoriously difficult” (Butler, 2008, p. 842) for many reasons (e.g.,  
significant time lapses between original clinical trials and measurable 
impacts on population health or clinical practice), tracking research out-
comes is necessary in order to improve accountability and efficiency of 
translational research, as well as overall health care system performance.  
 
 
Responding to a Changing Ecosystem 
 
In response to this shifting health care landscape, the clinical and 
translational research ecosystem has begun to reinvent and realign itself. 
These adaptations include enhanced collaboration, emerging data and 
technology, streamlined institutional review board (IRB) processes and 
enhanced patient protections, broader research participant recruitment 
efforts, and development of a dynamic research workforce. 
 
Enhanced Collaboration 
 
A growing number of private and public institutions are collabo-
rating to share limited resources for clinical and translational research 
activities. The resulting coordination is creating broader research net-
works, enhancing facilitation of investigator-initiated projects, and  
improving the validity of patient-centered research outcomes.2 It also has 
                                                            
2For example, the NIH initiative PROMIS (Patient Reported Outcomes Measurement 
Information System) was designed to provide flexible yet valid, precise, and responsive 
assessment tools to measure self-reported health status (Fries et al., 2011; NIH PROMIS, 
2013).  
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the potential to accelerate the translation of research findings into clinical 
practice (Lieu et al., 2011; Main et al., 2012; Marantz et al., 2011; 
Melese et al., 2009). These partnerships build on the strength of the 
stakeholders, expand the stakeholders’ reach and capacity, and push 
boundaries on roles in translational science.  
Diverse collaborations and novel roles and partnerships among  
academic, industry, and nonprofit organizations are emerging. Pfizer’s 
Centers for Therapeutic Innovations are partnering with academic institu-
tions through jointly staffed laboratories and shared access to compound 
libraries and screening technologies (Pfizer, 2013). Disease advocacy 
organizations have spun off drug discovery and development entities 
(e.g., Cystic Fibrosis Foundation Therapeutics, Inc.) (CFF, 2013). 
Academic health centers, which once served as the exclusive “home” 
for clinical investigation, now share the field with other types of research 
organizations. Health maintenance organizations (HMOs), hospital  
networks, health care systems, community health centers, and practice-
based research networks (PBRNs) have established their own research 
networks to conduct and facilitate clinical studies (Calmbach et al., 2012; 
Lieu et al., 2011). The conduct of translational research in primary care 
settings can lead to improvements in patient care by directly evaluating 
the feasibility of an intervention or protocol (Calmbach et al., 2012; 
Fulda et al., 2011). For example, the North Texas Primary Care Practice-
Based Research Network (NorTex), housed within the Primary Care Re-
search Center at the University of North Texas Health Science Center, is 
engaged in a range of studies involving more than 300 physicians at 135 
clinics (Fulda et al., 2011). CTSAs provide an opportunity to further 
strengthen collaborative programs with HMOs and PBRNs in order to 
accelerate patient-focused research initiatives (also see Chapter 3). The 
NIH has established the Common Fund’s Health Care Systems (HCS) 
Research Collaboratory, which encourages partnerships between health 
care delivery systems rather than relying on single research centers 
(Matthews, 2012; NIH, 2012b). The Collaboratory enhances “the  
national capacity to implement cost-effective large-scale research stud-
ies” (NIH, 2012b). In 2010 the Patient-Centered Outcomes Research  
Institute was established to provide the best available evidence to help  
patients and their health care providers make more informed decisions 
(Burns, 2012; PCORI, 2013). These new entities and collaborations are 
bridging gaps between research and practice in ways that could expedite 
the translational process. 
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Community engagement is becoming an established principle in  
facilitating and strengthening clinical research (Task Force on  
the Principles of Community Engagement, 2011; Zerhouni, 2005).  
Government, patients, families, and advocacy groups are increasingly 
recognizing the value of community engagement. As a result, patient 
advocacy groups, health care providers, and community organizations 
are assuming more active roles in processes related to peer review,  
research protocol design, recruitment and retention of participants in 
clinical research, and translation of findings back to the community. 
Studies of broader community involvement could strengthen evidence of 
the value of community participation and provide best practices of  
community engagement across all phases of clinical and translational 
research.  
 
Emerging Data and Technology  
 
The public- and private-sectors are further increasing access to new 
sources of health-related data and forging new partnerships to  
revolutionize the way this information is disseminated and used. For  
example, the Health Data Initiative, launched in 2010 by HHS and the 
IOM, “is a public-private collaboration that encourages innovators to 
utilize health data to develop applications to raise awareness of health 
and health system performance and spark community action to improve 
health” (IOM, 2013b). 
Advances in computational abilities and connectivity, as well as  
implementation of electronic health records (EHRs), are facilitating 
many clinical and translational research projects. Each year, the capacity 
to share information rises by approximately 30 percent (Hilbert and 
López, 2011; IOM, 2011). New developments in bioinformatics allow 
researchers to store, retrieve, organize, protect, and analyze vast amounts 
of data, resulting in larger and more efficient clinical research and trials 
(CTSA PIs, 2012). This capacity is enhanced by developing techno-
logies, such as “mobile and social computing with advanced analytics to 
enable fact-based decision-making” (Cognizant, 2012b, p. 5). These  
rapidly changing technologies hold great promise for drug development 
and first-in-human studies (Melese et al., 2009; Waldman and Terzic, 
2010). 
Data and computational capabilities are “expanding the reach of 
knowledge, increasing access to clinical information when and where 
needed, and assisting patients and providers in managing chronic  
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disease” (IOM, 2013a, p. S-9). Health information technology also has 
the potential to improve the quality and efficiency of the care that pa-
tients receive, through improved diagnostic practices and personalized 
medicine (Friedman et al., 2010). For example, in Arkansas, Blue Health  
Intelligence is applying predictive analytics to claims databases in order 
to reduce costs by improving the care of patients with diabetes 
(Rosenbush, 2012). EHRs, now used by more than half of all physicians 
in the United States (Jamoom et al., 2012), enable HMOs, PBRNs, and 
other research networks to serve as venues and partners for patient-
oriented research (e.g., comparative effectiveness research) (Elliott, 
2012; Miriovsky et al., 2012). In addition, studies are currently  
investigating the potential usefulness of EHRs in improving patient  
participation in their care and overall outcomes (University of Illinois at 
Urbana-Champaign, 2011).  
 
Streamlined IRB Review Processes and Enhanced Patient Protections 
 
Increased coordination between a growing number of private and 
public institutions has led to streamlined research oversight while  
enhancing patient protections. In compliance with federal regulations 
governing human subject research,3 a number of multisite studies are 
choosing to use single IRBs to coordinate joint, multi-institution IRB 
review of research protocols. For example, the Central Institutional  
Review Board Initiative performs a single review of some National  
Cancer Institute–sponsored multicenter protocols, allowing the local IRB 
to focus solely on ethical issues unique to local conditions (Millum and 
Menikoff, 2010). The CTSA Consortium’s IRBshare system facilitates 
multisite studies by using shared review documents that are supported by 
a centralized secure Web portal and an IRBshare Master Agreement 
(Vanderbilt University, 2013).  
New approaches to clinical trial monitoring also strengthen research 
participant protections. In response to increasingly variable investigator 
experience, ethical oversight, site infrastructure, health care standards, 
treatment choices, and the globalization of clinical research (Glickman et 
al., 2009), many study sponsors are capitalizing on new technologies and 
strategies to enhance the efficiency and effectiveness of monitoring  
activities. For example, centralized monitoring allows sponsor organiza-
tions to assess data trends and access data remotely to identify deviations 
                                                            
345 C.F.R. 46. 
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or problems more efficiently (Bhatt, 2011; Cognizant, 2012a; FDA, 
2011). Moreover, risk-based monitoring verifies completion of critical 
study parameters that protect human research participants while  
maintaining study integrity (FDA, 2011). 
 
Broader Research Participant Recruitment 
 
Research participant recruitment efforts have increased and diversi-
fied in response to persistent barriers to enrollment and retention of  
research participants. Research participants now include individuals in 
randomized trials, patients and their records within health care networks, 
and collaborating institutions and community organizations. As noted by 
Harris and colleagues (2012), however, the general public has little 
knowledge about clinical research or how to participate, despite an inter-
est in clinical trials. ResearchMatch, a CTSA-developed tool, was  
created to overcome recruitment challenges by connecting volunteers and 
researchers. In its first 19 months, approximately half of the studies that 
used ResearchMatch were clinical trials. Other types of research using 
ResearchMatch include behavioral and psychosocial studies, observa-
tional studies, and community-based research (Harris et al., 2012).  
Collaborations between CTSAs and organizations such as PBRNs, are 
also working to engage a wide range of community members across the 
entire clinical research process, including clinical research participant 
recruitment (NCATS, 2012). 
 
Development of a Dynamic Research Workforce  
The continued success of clinical and translational research depends 
on an adaptable, well-trained, and diverse workforce. As the field of 
translational science continues to evolve, so too must programs continue 
to update the skills of the existing workforce as well as prepare the next 
generation of scientists and clinicians. Demographic shifts in the U.S. 
population require a strong commitment to achieving greater partici-
pation of underrepresented groups in clinical and translational research 
careers at both the investigator and patient care levels. Effective clinical 
and translational research requires teams of researchers that can traverse 
the divides between basic and clinical sciences and health care practice. 
Key members of these teams will be clinician-scientists. The proportion 
of physicians involved in research has declined steadily in recent  
decades, however, and innovative solutions and incentives are needed to 
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reverse this trend (Roberts et al., 2012). Investments in interdisciplinary 
training and mentoring programs continue to be a core function of the 
CTSA Program, offering opportunities to bolster the research workforce. 
Continuous innovations are necessary to encourage multidisciplinary, 
team-based science—a core CTSA principle (Kroenke et al., 2010; 
Pienta et al., 2011).  
 
 
A VISION FOR THE CTSA PROGRAM 
 
Despite the accelerating pace of scientific discovery, the current  
clinical research enterprise does not adequately tackle pressing clinical 
and methodological questions relevant to health and health care  
improvement. CTSAs can play a substantial role in facilitating efforts to 
remediate limitations in the clinical and translational research ecosystem 
such as the following: challenges associated with first-in-human studies; 
limited recruitment and retention in clinical trials; the identification and 
measurement of health outcomes to assess intervention effectiveness; 
barriers to increasing awareness about research resources and potential 
research partnerships at the investigator and community levels; lack of 
incentives for team-based science; policy and regulatory challenges in 
developing full and substantive collaborations with industry and other 
partners; and ethical concerns (including related regulatory requirements) 
associated with the interplay between clinical research and practice.  
The CTSA Program has been successful in establishing CTSAs as 
academic focal points for clinical and translational research. Its 61 
awardees can have a broad impact on research practices and informatics 
and, ultimately, on patient care and individual health outcomes. The 
CTSAs continue to provide funding and infrastructure to investigators in 
their local environments, facilitating the conduct of clinical and transla-
tional research and the training of the translational science workforce.  
In addition, the CTSA Program has begun to foster interactions with the 
community and outside partners, such as the pharmaceutical industry.  
Yet, more progress is needed in order to assure a proactive research 
environment responsive to the demands of a continually evolving health 
care landscape. As the new home for the CTSA Program, NCATS  
has described a commitment to building on the program’s initial  
accomplishments with further advances. NCATS has called the next 
phase of the program CTSA 2.0 (Briggs and Austin, 2012), a term the 
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IOM committee has adopted and uses in this report. The challenge for 
this next phase of the CTSA Program will be to set the goals and create 
the incentives for these 61 sites to function as the core of a national  
network that initiates and sustains collaborations both inside and outside 
their home institutions, across NIH institutes and centers,  
and with community, industry, and research network partners.  
The IOM committee envisions a transformation of the CTSA  
Program from its current, loosely organized structure into a more tightly 
integrated network, with all the sites, committees, and coordinating  
center working collectively to enhance the transit of therapeutics,  
diagnostics, and preventive interventions along the developmental  
pipeline; disseminate innovative translational research methods and best 
practices; and provide leadership in informatics standards and policy  
development to promote shared resources. By providing infrastructure 
and innovations to accelerate clinical and translational research, an  
increasingly networked CTSA Program will increase its benefit to  
research and researchers across diseases, health conditions, age ranges, 
and health care delivery systems.  
To reach its potential in an ever-changing environment, the CTSA 
Program must build on its core strengths and successes and transform 
CTSAs from academic research homes to active hubs in a fully  
integrated network of clinical and translational research. On the basis of 
its findings, the IOM committee identified four key opportunities for  
action to guide efforts to strengthen the CTSA Program and ensure future 
success:  
 
 Adopt and sustain active program leadership—NCATS should 
increase its leadership presence in the overall program, con-
sistent with the cooperative agreement model under which the 
CTSAs are funded. A centralized leadership model that includes 
participation by NCATS, leaders of individual CTSAs, commu-
nity partners, and other stakeholders will increase overall program 
efficiency, enable mechanisms for maximizing accountability, and 
provide the direction needed to develop and nurture substantive 
partnerships. 
 Engage in substantive and productive collaborations—The 
CTSA Program needs to capitalize on the collaborations  
developed within and among individual CTSAs and continue to 
initiate and forge true partnerships with other NIH institutes and 
centers and with entities external to the program, including  
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patient groups, communities, health care providers, industry, and 
regulatory organizations.  
 Develop and widely disseminate innovative research  
resources—Fully developing the role of the CTSA Program as  
a facilitator and accelerator of clinical and translational research 
will require enhanced efforts to engage and support researchers 
and other stakeholders as they develop, refine, widely dissemi-
nate, and implement novel research and health informatics tools, 
methodologies, policies, and other resources.  
 Build on initial successes in training and education, community 
engagement, and child health research—The CTSA Program 
needs to continue its strong efforts in each of these areas. A  
robust and diverse workforce that is well trained in team science 
is critically important. Ensuring an emphasis on community  
involvement across the research spectrum will bring a range of 
much-needed perspectives and innovations along with increased 
public support for research. Program efforts can also help  
overcome the paucity of research specific to child health.  
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Leadership 
 
 
 
 
 
 
 
 
 
As envisioned by the Institute of Medicine (IOM) committee, the 
Clinical and Translational Science Awards (CTSA) Program has the po-
tential to overcome many bottlenecks and pioneer new solutions that can 
be used to accelerate clinical and translational research. Accomplishing 
the tasks ahead, however, will require a revitalized approach to program 
leadership—one that builds on the academic homes that have been estab-
lished and moves toward an integrated network of CTSAs that increas-
ingly applies collaborative and systems-based approaches. Leadership 
opportunities and challenges facing the CTSA Program are outlined in 
this chapter with discussion and recommendations related to leadership 
strategies, organizational structure, collaborations and partnerships, lead-
ership for individual CTSAs, evaluation, and communications. Leading 
the CTSA Program into its next phase, CTSA 2.0, will involve building 
on the strengths of individual CTSAs; leveraging the dedication of indi-
viduals working in clinical and translational science; and expanding suc-
cessful collaborative endeavors, both within and outside of the National 
Institutes of Health (NIH). 
 
 
LEADERSHIP STRATEGIES 
 
Balancing the tensions and benefits of two seemingly contradictory 
approaches to leadership is one of the challenges inherent in an endeavor 
with the scope and structure of the CTSA Program. A variety of possible 
advantages and disadvantages exist for differing leadership approaches. 
For example, the grass-roots approach to leadership offers the potential 
for creativity and innovation. It harnesses the dedication and energy of 
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multiple researchers and stakeholders, all with an interest in moving clin-
ical and translational research forward, but all of whom also have ties 
and obligations to their home institutions. The top-down leadership ap-
proach offers the potential for a systems-level perspective, greater focus 
and direction, and a commitment to progress for the overall research en-
terprise. However, this approach usually means fewer people will have 
direct decision-making responsibilities, and it requires careful oversight 
and coordination to ensure that multiple people and projects are on track 
and working to meet the same goals. Finding the correct balance between 
these two approaches will be an important element for future CTSA suc-
cess. 
 As CTSA 2.0 moves forward, the IOM committee sees the need for a 
more centralized approach to leadership, one in which National Center 
for Advancing Translational Sciences (NCATS) plays a more active role. 
To date, the program has, for the most part, relied on the energy and ef-
forts of individual CTSAs and their principal investigators (PIs). This has 
created a largely ad hoc structure and process for identifying next steps 
and overall management. Direction from the NIH (first through the Na-
tional Center for Research Resources [NCRR] and more recently through 
NCATS) has been articulated primarily through the funding announce-
ments. With each cycle of applications for new CTSAs or renewals, the-
se announcements have emphasized specific key functions or priorities 
for the investigators to include in their applications.  
The mechanism by which the CTSA Program is funded gives 
NCATS the opportunity to lead awardees toward fulfilling the NIH’s 
vision for the program both in the performance of individual institutions 
and in the program’s overall achievements. The NIH has three funding 
mechanisms for making research awards—grants, contracts, and cooper-
ative agreements. The individual CTSAs and the coordinating center are 
funded through cooperative agreements. The salient feature of coopera-
tive agreements is that NIH staff members provide assistance to award-
ees “above and beyond the levels usually required for program 
stewardship of grants. This level of stewardship is known as substantial 
involvement” (OIG, 2011, p. i). Substantial involvement can be achieved 
through various means, including technical assistance, advice, and coor-
dination, and the most recent request for application (RFA) for the CTSA 
Program noted that “substantial involvement means that, after award, 
NIH staff will assist, guide, coordinate, or participate in project activi-
ties” (NIH, 2012c). 
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Cooperative agreements provide the structure and mechanisms with 
which NCATS can exert a stronger leadership role while also promoting 
collaboration and innovation by individual CTSAs and researchers and 
guiding the program forward. As described throughout this chapter, the 
IOM committee urges NCATS to take a more active role in the direction 
and oversight of the CTSA Program. A number of lessons can be learned 
from a report on the program’s early experience that was prepared by the 
Department of Health & Human Services’ (HHS’s) Office of the Inspec-
tor General (OIG) (discussed below), as well from insights gained from 
the management of other collectives of academic institutions working 
toward specific goals, such as the Human Genome Project (HGP). Alt-
hough there are several differences between the HGP and the CTSA Pro-
gram, they share many common elements, such as the following: 
 
 an emphasis on innovation, supported by the development of 
new technologies and databases;  
 the expectation of useful, actionable results and a need for ongo-
ing evaluation;  
 an emphasis on efficiency and timely outcomes;  
 the development of a parallel research effort in bioethics and, in 
the CTSA case, community involvement; and  
 a commitment to collaborative, team-based science and to wide-
ly sharing tools and results. 
 
An analysis of the management of HGP identified five key factors in 
the project’s success. HGP had (1) a clear goal; (2) a flexible organiza-
tional structure (the “bottom-up” approach); (3) political support; (4) 
competition; and (5) strong leadership (the “top-down” approach) 
(Lambright, 2002). The Lambright analysis of the program says that, of 
these factors, “the fifth was the most important because it pulled the oth-
er factors together and made the most of them when it counted” (2002, p. 
5). Leadership manifested in different ways over the life of the project 
and ultimately provided a balance between the top-down and bottom-up 
leadership approaches that not only promoted flexibility and innovation 
but also provided the direction and oversight needed to achieve out-
comes.  
Although the purpose and tasks of the two programs were widely dif-
ferent, a number of management and leadership lessons can be learned 
from the HGP that could be useful in the administration of the CTSA 
Program. For example, as with the HGP, a compelling vision, clearly 
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articulated goals, and a mission-oriented approach could be used to or-
ganize and align the work of the individual CTSAs. In addition, the com-
bination of flexibility and active leadership that was used in the HGP to 
promote innovation and excellence in a pool of talented, multidiscipli-
nary researchers collaborating across multiple research centers is also 
applicable to the CTSA Program.  
Although collaboration was a key element of the HGP, the types of 
collaboration and partnerships necessary to define and achieve success 
for the CTSA Program are very different (e.g., community partnerships, 
collaboration with industry) and will require new leadership strategies. 
In 2011, the HHS OIG conducted a review of the administration of 
the CTSA Program in which OIG reviewers assessed files for the 38 co-
operative agreements awarded from 2006 through 2008 (when the pro-
gram was administered by the NCRR). This assessment found numerous 
lapses in program oversight. In addition to the administrative critiques 
described in the report, the OIG found no evidence that NIH program 
staff provided the “substantial involvement” required by federal regula-
tions and NIH policy with respect to cooperative agreements. In fact, 
OIG reviewers found no documentation of technical assistance by project 
scientists for any of the cooperative agreements. Further, they found no 
evidence that project scientists assisted awardees in performing project 
activities; stopped activities that were not meeting performance require-
ments; reviewed or approved the various stages of projects; approved the 
selection of key personnel, subawardees, or external contractors; con-
ducted technical monitoring; or served on committees (OIG, 2011). The 
NCRR agreed that relevant information was not in the files in a meaning-
ful way and presented its view that the NCRR worked with awardees 
“jointly in a partner role but did not assume direction, prime responsibil-
ity, or a dominant role” (OIG, 2011, p. 27). Although more project moni-
toring and aid may have taken place than the files reflect, there is no way 
to know. The OIG made several recommendations to remedy these 
shortcomings, including the following: 
 
 “NIH must ensure that staff document awardee accomplishments 
toward meeting project goals; reasons for not meeting project 
goals, if applicable; and plans for activities during the coming 
year.” 
 “NIH should ensure that staff document correspondence with 
awardees as they act to obtain delinquent progress reports and fi-
nancial status reports.” 
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 “At a minimum, staff must clearly list the Project Scientists in-
volved and include the annual summary of involvement within 
the award files” (OIG, 2011, pp. ii–iii). 
 
In considering the next steps for the CTSA Program and the recom-
mendations that are made in this report, the IOM committee believes that 
NCATS should learn from previous experiences and lessons and take a 
more active role in the direction and oversight of the CTSA Program. 
The goal would be to ensure the highest achievable performance of indi-
vidual CTSAs and to provide stronger guidance toward the development 
of a national network of institutions engaged in accelerating clinical and 
translational science. As the program’s newly designated home, NCATS 
has the opportunity, mission, and purpose to provide leadership for 
CTSA 2.0 and subsequent program phases.  
 In addition to setting program direction through a revised mission 
and strategic goals for the CTSA Program (described in the following 
section), more active NCATS leadership will require that it take on sig-
nificant responsibilities in promoting collaborations, conducting evalua-
tions of progress, and ensuring that the program leverages the 
innovations provided by each of the individual CTSAs and their re-
searchers, leaders, staff, and partners. Striking the right balance between 
top-down and grass-roots leadership will not be easy, and a number of 
challenges and possible unintended consequences need to be carefully 
considered as changes are made to the governance and leadership of the 
program. For example, imposing a top-down generated research agenda 
or priorities that do not meet the needs of local researchers, health care 
providers, and communities would conflict with the original intent and 
spirit of the program. In addition, an overly directive approach to leader-
ship could dampen creativity, ingenuity, and collaboration among the on-
the-ground researchers. More active, but appropriately balanced, leader-
ship from NCATS, combined with the creative talents and leadership 
from the PIs, will be critical in moving the CTSA Program to a more sys-
tems- and network-based approach to clinical and translational research 
and ensuring that the program remains focused on the outcomes most 
relevant to its overarching mission.  
 Given the size of the CTSA Program, appropriate feedback loops and 
checks and balances should be incorporated into the program’s govern-
ance, particularly through the vice-chair and other PIs on the new steer-
ing committee that is recommended below. These bidirectional 
communication and governance strategies will help achieve balanced and 
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informed leadership and will ensure that the active engagement of the on-
the-ground perspectives and expertise is maintained and promoted.  
 
 
Defining the Mission and Goals of the CTSA Program 
 
When NCATS was created in December 2011, components of vari-
ous NIH programs were moved into the new center. These components 
include the CTSA Program, the Office of Rare Diseases Research, a va-
riety of programs and activities that are housed in the NCATS Office of 
the Director for re-engineering translational research,1 and the newly cre-
ated Cures Acceleration Network (IOM, 2012; NCATS, 2013c). All of 
these diverse activities must work together in order to fulfill the NCATS 
mission. Maximizing the benefits of bringing these various elements to-
gether within NCATS requires rethinking the missions and goals of the 
individual pieces. The need for greater alignment within and across HHS 
agencies and activities was a major theme of a 2009 IOM report, HHS in 
the 21st Century: Charting a New Course for a Healthier America, 
which concluded that better alignment and focus on performance were 
essential to meeting departmental and agency goals (IOM, 2009).  
 
Mission 
 
As the CTSA Program matures, it is important to revisit the missions 
of NCATS and the CTSA Program to ensure alignment and that the 
CTSA Program supports the mission of NCATS. This IOM committee 
was specifically asked for its assessment of the appropriateness of the 
CTSA Program’s mission and goals. Box 3-1 contains the current mis-
sion statements of NIH, NCATS, and the CTSA Program. In considering 
the appropriateness of the CTSA mission, the committee heard both sup-
port for preserving coverage of the full spectrum of clinical and transla-
tional research from T0–T4 and concern about the feasibility of doing so, 
given the limited available resources (IOM, 2013a). Tension about the 
scope of mission and uncertainty about the adequacy of resources is also 
reflected in the input that NIH received, in response to a request for in-
formation (RFI), regarding ways to improve the program (Mulligan, 
2012; NCATS, 2012c).  
                                                        
1For example, the tissue chip for drug screening initiative, activities related to rescuing 
and repurposing drugs, and activities related to identifying and validating drug targets.  
Copyright © National Academy of Sciences. All rights reserved.
The CTSA Program at NIH:  Opportunities for Advancing Clinical and Translational Research
LEADERSHIP 59 
 
PREPUBLICATION COPY: UNCORRECTED PROOFS 
The IOM committee noted that the current mission of NCATS could 
be interpreted as being more narrowly focused on the development of 
diagnostics and therapeutics than on the more global mission of the 
CTSA Program, which focuses on the full spectrum of clinical and trans-
lational research including preventive interventions and translation into 
front-line clinical and community practice. The committee concurs with 
NCATS’s recent decision to allow increased flexibility for individual 
CTSAs in meeting program requirements, while ensuring that the CTSA 
Program as a whole continues to support the full spectrum of clinical and 
translational research. 
The current CTSA Program mission statement conflates mission and 
goals. As indicated below, strategic goals should be separated from the 
mission, and both need to be clear and consistent. The most recent RFA 
refers to a slightly different mission than that shown in Box 3-1, stating 
that the program works toward “increased quality, efficiency, and de-
creased cost of all translational research within academic institutions and 
nationally” (NIH, 2012c).  
A revamping of the mission should strive for simplicity and should 
reflect the program’s overarching purpose. In working to update the mis-
sion of the CTSA Program, the committee suggests that NCATS also 
consider whether revisions to its own mission statement would help 
achieve better alignment between the two missions, highlighting support 
for the full spectrum of clinical and translational research. The commit-
tee’s suggested streamlined mission for the CTSA Program also is pro-
vided in Box 3-1. 
 
 
BOX 3-1 
Aligning the Missions 
 
Current Mission Statements 
 
NIH Mission: to seek fundamental knowledge about the nature and behavior of 
living systems and the application of that knowledge to enhance health, 
lengthen life, and reduce the burdens of illness and disability. 
 
NCATS Mission: to catalyze the generation of innovative methods and technolo-
gies that will enhance the development, testing, and implementation of diagnostics 
and therapeutics across a wide range of human diseases and conditions. 
 
CTSA Current Program Mission: seeks to strengthen the full spectrum of trans-
lational research. Institutional CTSA awards are the centerpiece of the pro-
gram, providing academic homes for translational sciences and supporting 
research resources needed by local and national research communities to 
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improve the quality and efficiency of all phases of translational research. Insti-
tutional CTSAs also support the training of clinical and translational scientists 
and the development of all disciplines needed for a robust workforce for trans-
lational research. 
 
Proposed CTSA Program Mission Statement 
 
A Suggested Streamlined Mission: to improve the quality and efficiency of the 
full spectrum of clinical and translational research and to speed the develop-
ment and use of new diagnostics, therapeutics, and preventive interventions.  
 
SOURCES: NCATS, 2013a,b; NIH, 2011. 
 
 
 
Goals 
 
Although the difference between mission and goals may seem large-
ly semantic, the lack of separately articulated, achievable goals—versus 
a broad mission—weakens the ability to measure overall progress and 
establish accountability. As the CTSA Program has grown and evolved, 
variations on the goals have been cited, which indicates the goals of the 
program have not been communicated consistently and may not be well 
understood. For example, a CTSA fact sheet notes that “its goals are to 
accelerate the translation of laboratory discoveries into treatments for 
patients, to engage communities in clinical research efforts, and to train a 
new generation of clinical and translational researchers” (NCATS, 
2012a), and the recent RFA said that “the goal of the CTSA Program 
remains focused on integrated academic homes for the clinical and trans-
lational sciences that increase the quality, safety, efficiency and speed of 
clinical and translational research, particularly for NIH supported re-
search” (NIH, 2012c). Most recently, the program’s website describes 
goals for the “next phase” of the CTSA Program: 
 
 “Building a better bridge between pre-clinical and clinical science; 
 Providing a foundation of shared resources that could reduce 
costs, delays and difficulties experienced in clinical research, in-
cluding trials;  
 Developing partnerships for research to be better integrated 
across sites and into ongoing patient care; and 
 Strengthening strategies for engaging patient communities into 
the research process” (NCATS, 2013b). 
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The issue of CTSA goals is further complicated by the CTSA Con-
sortium’s separate set of five strategic goals: 
 
1. National clinical and translational research capability; 
2. Training and career development of clinical and translational 
scientists; 
3. Consortiumwide collaborations; 
4. The health of our communities and the nation; and 
5. T1 translational research (CTSA Central, 2013a). 
 
As noted in Chapter 1, these consortium-generated goals were devel-
oped through a strategic planning process conducted by the PIs in 2008, 
with the fifth goal added in 2009 (Disis, 2012; Reis et al., 2010). The 
IOM committee believes that these goals are overly broad and cannot be 
easily measured. In addition, because innumerable confounding factors 
in the clinical and translational ecosystem influence progress in these 
areas (Chapter 2), the direct impact of the CTSA Program cannot be as-
sessed. As the various lists of goals have grown apart, it is not clear 
which set, if any, accurately reflects the current and most pressing chal-
lenges facing the clinical and translational research ecosystem or the 
goals that NCATS has for CTSA 2.0. 
Clearly defined, measurable goals directly tied to the mission and 
work of the CTSA Program will help better align the 61 awardees to 
achieve the vision for a more integrated network and will provide a basis 
for evaluation, reporting, and accountability. Clearer communication re-
garding the goals, as distinct from the mission, also would facilitate pro-
gram management and increase understanding of the program among its 
stakeholders.  
 
Reshaping and Reconciling Mission and Goals for the Future 
 
NCATS needs to take a leadership role in shaping the CTSA Pro-
gram’s future by engaging in a strategic planning process in collabora-
tion with the CTSAs to revise the program’s mission and establish 
measurable goals. As noted, the work of the CTSA Program has numer-
ous important audiences and touches people in many domains—
researchers, educators, clinicians, health care providers, payers, policy 
makers, staff in other government departments and agencies (e.g., De-
partment of Veterans Affairs, Agency for Healthcare Research and Qual-
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ity [AHRQ], Center for Medicare & Medicaid Services, Patient-Centered 
Outcomes Research Institute, and the other NIH institutes and centers), 
private industry, nonprofit funding agencies, and, ultimately most im-
portant, communities, patients, and families. All these groups have a vital 
interest in achieving a more efficient and rapid clinical and translational 
research enterprise (see, for example, IOM, 2011), and they should be 
asked for input during the strategic planning process.  
 In the transition of the CTSA Program from NCRR to NCATS, the 
NIH sought internal and external advice through an 11-member NIH 
working group. This group was asked to “enumerate the roles and capa-
bilities of the CTSAs that could support and enhance the mission of 
NCATS; identify CTSA needs and priorities; and propose processes for 
ensuring a smooth transition from the NCRR to NCATS” (Katz et al., 
2011). The working group consulted widely with individuals involved in 
the program in developing its recommendations for a smooth integration. 
In addition, NIH issued an RFI for input from public stakeholders, NIH 
personnel, and CTSA PIs that generated 139 responses, mostly from 
CTSA institutions (Mulligan, 2012; NCATS, 2012c). Conducting such 
broad-based outreach (as well as using the input already collected as a 
departure point) might be a useful strategy in assuring that relevant 
viewpoints about the program’s mission and goals are considered. 
 A particular benefit of the collaborative approach to developing 
plans for integrating the CTSA program into NCATS was the positive 
response from the individual CTSAs, which demonstrated their “deep 
commitment to the NCATS mission”, willingness to move forward rap-
idly, and recognition of new opportunities that NCATS would create, 
including greater visibility and closer more transparent working relation-
ships with NIH institutes and centers (CTSA PIs, 2012). 
Whatever process is adopted should result in a compelling mission 
statement and a single set of strategic goals that 
 
 are clearly defined and measurable; 
 reflect the full range of clinical and translational research; 
 are targeted at overcoming specific, current research challenges 
and barriers;  
 encourage clear decision points (go/no-go decisions) that pro-
mote a flexible and dynamically responsive program; 
 build on program successes and reinforce areas of progress (e.g., 
training and education, community engagement, child health);  
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 are fully supported and consistently communicated by all those 
involved; and  
 can serve as the basis for developing a set of common metrics for 
evaluating the individual CTSAs and the program as a whole. 
 
All components of the CTSA Program—NCATS, CTSA consortium 
committees, the CTSA Coordinating Center, individual CTSAs, and the 
researchers whose work is supported through the program—should be 
focused on achieving these unified goals. This is essential in order to es-
tablish accountability and assess progress, as outlined in HHS in the 21st 
Century (IOM, 2009). As the CTSA Program moves forward, these goals 
should be reviewed and updated periodically as progress is made, as the 
research ecosystem continues to evolve, and as population health needs 
change.  
 
 
STRUCTURE OF THE CTSA PROGRAM 
 
The CTSA Program has grown rapidly, from 12 sites in 2006 to 61 
in 2012. From the program’s outset, the NIH and the individual CTSAs 
have recognized the value of collaboration and the need for a cross-
institutional structure to advance the program’s efforts; this recognition 
was the beginning of the vision for a CTSA network. In the early stages 
of the program, the NIH charged CTSAs with developing a national con-
sortium to promote and implement best practices, policies, and proce-
dures (NIH, 2005). The first funding announcement stated that a National 
CTSA Consortium Steering Committee should be organized for PIs. In 
addition, as discussed in Chapter 1, it directed that subcommittees be 
formed to foster advances in the NIH-identified common themes (e.g., 
education, informatics, regulation) and that these committees meet annu-
ally and have representation from each CTSA (NIH, 2005).  
In subsequent years, the CTSA Consortium developed largely as an 
unfunded grass-roots effort through the commitment and energy of PIs 
and researchers. It now has three leadership committees (Executive 
Committee, Steering Committee, and Child Health Oversight Commit-
tee); committees charged with making progress on each of the five 
CTSA Consortium strategic goals; 14 key function committees, 10 the-
matic special interest groups, and numerous working groups and task 
forces under each of those committees. In total, these committees involve 
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more than 2,000 people (CTSA Central, 2013d; Reis et al., 2010) (Chap-
ter 1).  
A 2011 addition is the CTSA Consortium Coordinating Center, 
which was awarded to Vanderbilt University through a competitive pro-
cess (Vanderbilt University, 2011). A variety of collaborative informatics 
tools have been developed and are being disseminated through the Con-
sortium Coordinating Center. One of the most widely adopted is RED-
Cap (Research Electronic Data Capture), a Web-based tool for creating 
online surveys and databases used in clinical research. Currently, 602 
institutional partners in 54 countries actively participate in REDCap 
(Vanderbilt University, 2013b). Other examples of research tools that are 
available through the CTSA Program are provided in Table 3-1. The full 
range of collaborative tools developed through the CTSA Program 
should be assessed, and those deemed successful can be deployed further 
in NIH-funded projects, with data being shared as openly and freely as 
possible. 
 
TABLE 3-1 Examples of Collaborative Tools
ROCKET 
(Research Organization, 
Collaboration, and 
Knowledge Exchange 
Toolkit) 
 
A Web-based tool that provides a common plat-
form for CTSA institutions to share documents and 
build web pages. ROCKET is designed to be easy 
for users to edit and maintain their private work-
spaces but allows specific pages to be made public 
in order to share information with a larger audience 
(CTSA Central, 2013g).  
 
IRBshare 
 
 
This shared IRB review model for multisite studies 
provides an established set of review documents 
and review processes as well as an IRBshare Mas-
ter Agreement. Twenty-three sites currently use the 
model, and it is open to new NIH-funded studies 
(Vanderbilt University, 2013a). 
 
ResearchMatch 
 
An online registry aimed at bringing researchers 
and volunteers together for health-related research. 
Volunteers willing to participate in studies com-
plete a questionnaire with their contact information 
and health history. Registered researchers search 
the database for individuals who qualify for a par-
ticular study. Individuals decide whether to allow 
ResearchMatch to release their contact information 
to the researcher. Currently, the service is limited 
to institutions affiliated with the CTSA Program,
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and in order to gain access to recruit volunteers, 
researchers must have IRB approval of their pro-
posal. More than 35,000 research volunteers are 
currently registered, and more than 1,600 research-
ers conducting more than 350 studies at 78 institu-
tions are using this resource (Vanderbilt University, 
2012). 
 
eagle-i Network 
 
An openly available online network that anyone 
can use to search for more than 50,000 biomedical 
resources at 25 member institutions. Resources 
available vary from biological specimens and rea-
gents to software and physical laboratory space 
(Harvard College, 2012). 
 
VIVO 
 
An open-source Web application that allows
researchers at seven participating institutions to 
describe their interests, activities, and accom-
plishments in order to create groups or networks of 
people with similar research goals within and 
across institutions (VIVO, 2013). 
 
CTSA-IP A website that compiles and publicly shares infor-
mation on technology, intellectual property, and 
licensing opportunities available through more 
than 24 CTSA institutions. The goal is to promote 
research activity and collaboration opportunities 
among CTSAs (University of Rochester, 2012).  
 
 
 
Opportunities and Next Steps 
 
Moving toward systems- and network-based approaches to resolving 
the challenges in clinical and translational research will require more 
hands-on leadership from NCATS than in the past; more focused, 
streamlined, and efficient centralized leadership of the program; and 
changes in its structure.  
The IOM committee believes that CTSA Program governance should 
be markedly simplified from the current structure, which involves an ex-
ecutive committee and a steering committee, more than 200 committee 
members total, and separate monthly conference calls. The IOM commit-
tee envisions that the primary governance of the program would reside 
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within a new NCATS-CTSA Steering Committee that would be respon-
sible for 
 
 program oversight and direction;  
 trans-CTSA activities; 
 collaborative efforts with external partners; 
 promotion of collaborative opportunities within and outside the 
NIH; 
 identification, dissemination, and implementation of best prac-
tices; and  
 implementation of a proposed new innovations fund to promote 
collaboration with other NIH institutes and centers and external 
partners.  
 
The steering committee should represent a cooperative program 
leadership effort between NCATS and the CTSAs that provides strategic 
direction and guides progress to ensure that individual CTSAs and the 
program as a whole are fulfilling their revised mission and strategic 
goals. The committee should be chaired by an NCATS lead staff mem-
ber, with a CTSA PI as vice-chair, and should have a rotating member-
ship representing diverse CTSA and stakeholder interests to ensure 
responsive and effective governance. The number of steering committee 
members should be small enough to enable the committee to be nimble 
and efficient. This steering committee should oversee the Coordinating 
Center and a streamlined structure of consortium committees (see Figure 
3-1). Development of the specific details of committee membership, re-
sponsibilities, and operations should be a joint effort between NCATS 
and the CTSA PIs and should be part of the strategic planning process. 
This new governance model centralizes accountability for the program 
and provides a more active leadership role for NCATS, while enabling 
focused, stakeholder-based leadership that should fully leverage the ex-
perience, creativity, and commitment of the CTSA PIs and other stake-
holders. As discussed previously, possible disadvantages to a more active 
leadership role for NCATS should be considered as the governance and 
structure of the program evolve. 
Streamlining the current consortium committee structure is an urgent 
need. However, the structure and governance should evolve over the next 
year or two as a component of the recommended strategic planning pro-
cess. Only those consortium committees that are most relevant to the 
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program’s revised goals and priorities should be retained. The current 
unwieldy committee setup was perhaps a natural result of the rapid 
increase in the number of CTSAs, with each wanting to ensure it had a 
voice in the program’s leadership. However, according to testimony 
received by the IOM committee and from interviews conducted as part 
of the Westat site visit evaluation, the current number and size of 
committees—some having more than 150 members—makes too many 
burdensome demands on researchers’ time (Westat, 2011). 
While the IOM committee recognizes the dedication and commit-
ment many people have given to the program’s work, now is the time to 
build on what has been accomplished and rechannel that commitment 
through a leaner structure. The result should be greater management effi-
ciency as well as increased productivity. Larger numbers of stakeholders 
and CTSA leaders can be convened periodically to communicate pro-
gress, solicit input, and plan next steps. With this streamlined structure, 
care should be taken to ensure that ample opportunities exist for commu-
nication; collaboration; and sharing best practices, available resources, 
and expertise within and across the CTSAs.  
Opportunities abound for the CTSA Program to reengineer its struc-
ture and governance. A new NCATS-CTSA Steering Committee, along 
with the Coordinating Center and a simpler consortium committee struc-
ture, will position the program to better coordinate the advancement of 
clinical and translational research. 
 
 
COLLABORATIONS AND PARTNERSHIPS 
 
The CTSA Program is a facilitator of clinical and translational re-
search. Its inherent function is to initiate and foster collaborations—
including developing innovative tools, policies, and processes; removing 
barriers to research; training teams of investigators; engaging communi-
ties in the research process; and other efforts—that bring together re-
searchers, research networks, NIH institutes and centers, community 
stakeholders, health care providers, industry partners, government re-
search agencies, and others to advance clinical and translational science. 
NCATS, the CTSA Coordinating Center, and the individual CTSA sites 
need to ensure that the full range of potential collaborators understands 
the value that the CTSA Program brings to clinical and translational re-
search and that the CTSA Program is responsive to their needs. Incentives  
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FIGURE 3-1 A revised structure for the CTSA Program in the Division of Clin-
ical Innovation at NCATS. The components of a reorganized CTSA Program 
would include the staff and CTSA Program oversight activities at NCATS; indi-
vidual CTSAs; a set of streamlined consortium committees; the CTSA Coordi-
nating Center; and the new NCATS-CTSA Steering Committee, which would 
provide oversight and direction to the Coordinating Center, the consortium 
committees, and, to a lesser extent, the individual CTSAs. Leadership, collabo-
ration, and communication among all these entities will be essential for the effi-
ciency and effectiveness of the program overall. 
 
 
for building these partnerships are also needed. The IOM committee urg-
es the establishment of an innovations fund to promote further collabora-
tion and emphasizes that the success of CTSA 2.0 will depend on the 
extent and strength of the partnerships and collaborations formed. 
 
 
Collaborations with NIH Institutes and Centers 
 
Some of the most natural partnerships are occurring and need to oc-
cur more frequently between the CTSA Program and NIH institutes and 
centers. A number of NIH institutes and centers have their own research 
centers, networks, and clinical trials (e.g., Comprehensive Cancer Cen-
CTSA Program Oversight Within NCATS Division of Clinical Innovation
CTSA Coordinating
Center
The CTSA Program
Consortium
Committees
Individual
CTSAs
NCATS-CTSA Steering Committee
NCATS Division of Clinical Innovation
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ters, NeuroNext, Type 1 Diabetes TrialNet) already benefiting from the 
CTSA Program’s collaborative databases and tools. Nonetheless, indi-
viduals who provided testimony to the IOM committee reported that in-
tra-NIH collaborations with the CTSA Program need to be strengthened. 
Evidence of the potential for collaboration is shown in Figure 3-2, which 
reports the number of NIH grants using some form of CTSA support or 
resources, although the extent and depth of that interaction is not indicat-
ed. CTSA support or resources frequently come in the form of providing 
institute grantees with facilities, core resources, equfeipment, staff exper-
tise, or administrative services. They may also take the form of providing 
specific tools, such as those described earlier. Box 3-2 illustrates some of 
the general CTSA resources that NIH institutes are finding helpful. 
 
 
 
 
FIGURE 3-2 Top 10 NIH institutes and centers using CTSA resources. 
NOTE: NCI = National Cancer Institute, NHLBI = National Heart, Lung, and 
Blood Institute, NIA = National Institute on Aging, NIAID = National Institute 
of Allergy and Infectious Diseases, NIAMS = National Institute of Arthritis and 
Musculoskeletal and Skin Diseases, NICHD = National Institute of Child Health 
and Human Development, NIDA = National Institute on Drug Abuse, NIDDK = 
National Institute of Diabetes and Digestive and Kidney Diseases, NIMH = Na-
tional Institute of Mental Health, NINDS = National Institute of Neurological 
Disorders and Stroke.   
SOURCE: NIH, 2012b Reprinted with permission from the National Institutes 
of Health/U.S. Department of Health & Human Services. 
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BOX 3-2 
Selected Examples of NIH Institute Uses 
of CTSA Skills and Capacities 
 
National Cancer Institute (NCI) 
 Cancer centers have benefited from CTSAs’ experience in educat-
ing and mentoring investigators, community outreach, clinical facili-
ties, and pilot project programs (Weiss, 2012). 
 NCI projects and CTSAs invest in a range of shared resources, 
such as biostatistics and laboratory management tools and 
biorepositories and genomics resources. They also jointly support 
pilot projects, faculty and staff recruitment and training programs, 
clinical research infrastructure, and community-based research 
through 
practice-based research networks, mobile clinical research units, 
and e-health programs (Weiss, 2012).  
 
National Institute of Allergy and Infectious Diseases (NIAID) 
 NIAID Clinical Research Centers use CTSA support for research 
volunteer recruitment (e.g., 34 allergy and infectious disease–related 
studies used ResearchMatch, and 110 NIAID-related pilot projects 
were funded) (CTSA Central, 2011b). 
 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
 CTSAs provide support for many NIDDK-funded large clinical trials 
and networks. For example, most of NIDDK’s liver disease consortia 
and the Drug-Induced Liver Injury Network have used CTSA infra-
structure for follow-up activities (Germino, 2012). 
 
 
 
The way that skills and resources available through the CTSA Pro-
gram can be translated into tangible support for institute and center 
grants and projects is further illustrated by these more detailed examples: 
 
 NeuroNEXT, a National Institute of Neurological Disorders and 
Stroke network to conduct Phase 2 clinical trials in neurological 
disorders of children and adults, has 25 clinical sites, 23 of 
which also have CTSA awards. The network is in its early phas-
es and is collaborating with the CTSA Program whenever possi-
ble in order to connect researchers with CTSA resources; the 
NeuroNEXT RFA specifically asked applicants to identify how 
they would interact with CTSAs. A number of overlapping goals 
between the network and the CTSAs include the use of central 
Institutional Review Board (IRB) processes and standing trial 
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agreements across sites and early involvement of patient advocacy 
groups (Kaufmann, 2013). 
 The University of Iowa’s CTSA provides support to meet the in-
formatics needs of a multidisciplinary team that was awarded a 
5-year, $3 million grant from the National Cancer Institute to 
develop image analysis tools that will be used in future clinical 
trials to better assess patient responses to cancer treatments 
(NIH, 2012b). 
 Three California CTSAs are collaborating with the Stanford 
Synchrotron Radiation Lightsource2 to develop an automated and 
customizable drug discovery pipeline called “Auto-Drug,” which 
can screen samples that could be used to develop new pharmaco-
logical treatments for a variety of diseases (NIH, 2012b; 
Stanford University, 2012; Tsai et al., 2012).  
 The National Heart, Lung, and Blood Institute’s ongoing multi-
site trial, the International Study of Comparative Health Effec-
tiveness with Medical and Invasive Approaches (ISCHEMIA), 
used the CTSA resource IRBShare to help participating institu-
tions share review documents and review processes on a secure 
web portal (Shurin, 2012). 
 The National Institute on Drug Abuse used set-aside funds for 
three studies at CTSA sites: an examination of models to reduce 
disparities in clinical trials, including recruitment and retention 
of drug users and underrepresented populations; an experimental 
trial of a drug to reduce opioid overdose; and a study on how 
best to prevent drug abuse among Hispanic adolescents 
(Volkow, 2012).  
 
The IOM committee believes that many of the challenges in clinical 
and translational research must be solved using systemwide approaches 
and that the CTSA Program is well positioned, perhaps uniquely so, to 
facilitate and implement those approaches. The combination of local, 
disease-specific resources and the more general collaborative approaches 
and tools developed under the CTSA Program strengthen the potential 
contribution CTSAs can make when partnered with projects funded by 
NIH institutes and centers. In addition, these types of partnerships and 
                                                        
2Stanford Synchrotron Radiation Lightsource is a research tool that uses extremely 
bright X-rays to study compounds and other samples at atomic and molecular levels 
(Stanford University, 2013). 
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collaborations provide opportunities to optimize available resources and 
to increase efficiency and cost-effectiveness. Collaborative efforts would 
go a long way toward “dissolving the artificial barriers that inevitably 
spring up in any large organization,” a benefit envisioned at the time of 
the program’s launch (Zerhouni, 2005, p. 1622). In a sense, this repre-
sents a scaling up of the program sites’ success at building academic 
homes for clinical and translational research, reducing intradepartmental 
boundaries to collaboration, and developing regional collaborations 
(Briggs and Austin, 2012).  
 
 
Partnerships with Health Care Providers, Health Care Systems, 
and Practice-Based Research Networks 
 
Beginning in 2007, the IOM, through its Roundtable on Evidence-
Based Medicine (now the Roundtable on Value Science-Driven Health 
Care), has examined a broad range of topics related to reengineering clin-
ical research and health care delivery so as to support a continuously 
learning health care system (Chapter 2) (IOM, 2007, 2013b). Built on the 
foundation of a strong digital infrastructure, innovative health care mod-
els, research on practice, and aligned incentives, the learning health care 
system offers the promise of more efficient and effective clinical care.  
The work of CTSAs can bear directly on the nation’s ability to 
achieve a learning health care system through collaborations that 
strengthen ties between the realms of practice and research. Among the 
strongest candidates for these types of CTSA collaborations are practice-
based research networks (PBRNs) and the HMO Research Network 
(HMORN).  
PBRNs are “groups of primary care clinicians and practices working 
together to answer community-based health care questions and translate 
research findings into practice” (AHRQ, 2012). As of 2011, almost 
13,000 primary care practices (providing care to approximately 47.5 mil-
lion people) were involved in PBRNs, and just over half of them (52 per-
cent) were affiliated with CTSAs (Peterson et al., 2012). Several surveys 
of the relationship between CTSAs and PBRNs have found disappoint-
ingly low levels of community engagement and collaboration. In a 2008 
survey, PBRN directors noted that the value of CTSAs to PBRNs includ-
ed funding, aid with IRB processes, biostatistics, training, and consulta-
tion. In return, PBRNs were in a position to help CTSAs move their 
research into community settings and improve connections between 
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CTSA home institutions and the community (Fagnan et al., 2010). Nev-
ertheless, these relationships were not without challenges. For example, 
“CTSA leaders often sought PBRNs as study recruiting sites . . . but they 
seemed less aware of the need for cultivating ongoing relationships and 
the importance of engaging practitioners in the support and development 
of study protocols” (Fagnan et al., 2010, p. 482).  
In 2011, PBRNs registering with the AHRQ’s National PBRN Re-
source Center noted that having a relationship with a CTSA made no 
significant difference in PBRN research opportunities or capacity 
(Peterson et al., 2012). The researchers reported that “although 63 regis-
tered PBRNs (52 percent) reported a formal affiliation with a CTSA, in 
2011 these PBRNs conducted the same number of studies as PBRNs not 
affiliated with a CTSA” (Peterson et al., 2012, p. 568). Calmbach and 
colleagues (2012) characterized the relationship between CTSAs and 
PBRNs as “a process that still is developing” (p. 572). While partner-
ships with CTSAs may be helpful in increasing support for PBRNs and 
raising their visibility, these partnerships also “could be detrimental if the 
university tries to impose a top-down research agenda onto already busy 
primary care physicians” (Calmbach et al., 2012, p. 572). Further, the 
institutions may not fully appreciate the costs to the physicians’ practices 
of participation in CTSA projects.  
As noted in these articles, support for the concept of collaboration 
between the academic researchers and clinicians working in the commu-
nity remains strong despite the time and effort involved in forging strong 
relationships and the difficulties noted. The development of electronic 
health records and their use as part of a learning health care system, as 
well as the work of the Patient-Centered Outcomes Research Institute, 
may enable and motivate closer working relationships between research-
ers and clinicians in the future. The CTSA Program offers a venue and 
mechanisms for these types of partnerships, which are critical to the fu-
ture of translational sciences. 
Another potential source of clinician partnerships is offered by the 
HMORN, a network of 18 U.S. health care delivery organizations with 
recognized research departments or institutes that also have a defined 
patient population (HMO Research Network, 2013). Input to the IOM com-
mittee from the HMORN Governing Board indicated that 14 HMORN sites 
have established relationships with local CTSAs, and 1 HMORN site has 
two such relationships. One site has discontinued its CTSA relationship 
(Steiner, 2013). Suggestions from HMORN board members for improved 
collaborations included the following: 
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 development of partnerships that are aligned by purpose and values; 
 expanded pilot funding for community-based investigators; 
 expanded bidirectional training opportunities; and 
 ongoing education for members of academic leadership about the 
importance of research related to defined populations and then 
translating findings into community-based delivery systems 
(Steiner, 2013). 
 
HMORN board members made several suggestions for ways in 
which the CTSA Program could become a more effective incubator for 
innovation. These suggestions included more coordinated outreach by 
CTSA-HMORN partners to underserved populations; broader use of 
supplemental funds to support HMORN dissemination of “translatable” 
research findings; strategic application of pilot funds to codevelop inno-
vations; and increased incentives for community-based clinical trials 
(Steiner, 2013). HMORN board members suggested that the NIH-
initiated Health Care Systems Research Collaboratory may be an example 
of how collaborative work between CTSAs and HMORN could work in 
the future.3 
 
 
Partnerships with Industry 
 
As with community-based clinician involvement, partnerships with 
industry have been viewed as essential components of the CTSA Pro-
gram from the beginning. In a 2010 meeting organized by the NIH, sen-
ior industry executives formally met with CTSA awardee scientists for 
the first time to discuss ways to advance both groups’ goals. Although 
general consensus exists about the desirability of moving useful innova-
tions quickly and safely into clinical care, how to achieve this goal is 
much less obvious (Fine, 2012; Wadman, 2010).  
 Among the obstacles to greater CTSA-industry partnerships are in-
tellectual property constraints and concerns about conflicts of interest. 
“We are not able to work effectively together because of the perception 
and reality of conflict of interest,” one industry participant said 
                                                        
3The Health Care Systems Research Collaboratory, housed at Duke University, is a co-
ordinating center for a set of pragmatic randomized trials involving HMORN sites. The 
center is currently developing and disseminating collaborative research tools to the inves-
tigator community, including the NIH Distributed Research Network (Steiner, 2013).  
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(Wadman, 2010, p. 256), although some instances were cited in which 
these concerns have been overcome. One initiative described at the con-
ference is Eli Lilly and Company’s not-for-profit tuberculosis drug con-
sortium,4 which links academic investigators to expertise and tools 
donated by Eli Lilly, Merck, private foundations, the National Institute of 
Allergy and Infectious Diseases, and the nonprofit Infectious Disease 
Research Institute (NIAID, 2012). Another is Merck’s new Calibr (Cali-
fornia Institute for Biomedical Research) initiative, a nonprofit organiza-
tion intended to speed the development of innovative new medicines 
(Fine, 2012). Similarly, the Indiana Clinical and Translational Science 
Institute formed a partnership with Veeda Clinical Research and Eli Lilly 
to develop a shared research facility for first-in-human studies and other 
early phase studies (NIH, 2012b). 
 At the IOM committee’s December 2012 meeting, Jacqueline Fine of 
Merck Research Laboratories spoke specifically about collaborative op-
portunities in early phases of translational research (Fine, 2012). She 
pointed out that, from industry’s point of view, successful translation is 
not achieved until an innovation becomes part of the standard of care. 
The activities that will facilitate this process, including regulatory ap-
proval and other favorable policy actions, should be thought about at the 
front end of a project. It is not clear to industry leaders that academic 
researchers, accustomed to nondirected discovery, are sufficiently fo-
cused on those end-of-the-process considerations (Fine, 2012). Success-
ful partnerships in this arena will require identification of shared goals 
and an understanding of the roles and value that each of the partners 
brings to the table.  
 The CTSA Program provides a unique venue to build strategic 
partnerships and collaborations between academia and private-sector 
partners, including pharmaceutical and biotech companies and companies 
involved in the development of medical devices, technologies, and diag-
nostics. These partnerships and collaborations will be imperative to 
realizing the program’s streamlined mission. Characteristics that may 
facilitate effective industry-CTSA relationships include a simple and 
transparent interface for partnering including shared strategies and priori-
ties, a clear mission for CTSAs and their multisite collaboratives, the 
willingness of individual CTSAs or CTSA groups to align their focus 
with that of an industry partner, and an ethical and transparent relation-
ship.  
                                                        
4See http://www.tbdrugdiscovery.org.  
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 The CTSA Program needs to explore and implement new approaches 
for collaboration with industry that foster the translation of research into 
products while remaining within legal and regulatory boundaries. In ad-
dition, the CTSA Program can serve as a leader in promoting innovation, 
entrepreneurship, and cultural changes; developing and testing new ap-
proaches for managing conflict of interest and intellectual property; and 
engaging the Food and Drug Administration and other regulators in col-
laborations. As these partnerships are established and grow, it will be 
important for NCATS and the CTSAs to share and implement best prac-
tices. 
 
 
Opportunities and Next Steps 
 
Collaborations across and among researchers and research networks 
are core to building an integrated network that supports the work of clin-
ical and translational science. Because the CTSA Program is a facilitator 
and accelerator of this research, NCATS, the CTSA Program, and indi-
vidual CTSA sites need to ensure that they are working to initiate, nur-
ture, and strengthen collaborations across CTSA institutions, with NIH 
institutes and centers, with private and public sector research institutions 
and networks, and with community stakeholders. With their core focus 
on strengthening the infrastructure of clinical and translational research, 
CTSAs are ideal partners for all these entities.  
Mutually beneficial collaborations take time, energy, and initiative to 
build and sustain. All sides need to find value in the partnership, and all 
need to work to maintain and further shared goals. Sufficient incentives 
for collaboration may be inherent in the partnering organizations’ ongo-
ing priorities, but in many cases, external incentives may be needed in 
order to provide the impetus to collaborate.  
The IOM committee urges NCATS to establish a CTSA innovations 
fund that would provide incentives for creating new collaborations and 
supporting collaborative pilot studies or resource-sharing initiatives. For 
example, such projects might require the collaboration of multiple 
CTSAs, might jointly involve CTSAs and PBRNs or other research net-
works, or might engage groups of CTSAs and NIH institutes or centers. 
These collaborative projects might also involve new industry or commu-
nity partners, other government agencies (e.g., the FDA, AHRQ, VA), or 
public and private research entities. The fund could be used to support 
collaborative initiatives to develop novel strategies for implementation 
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research that would be tested in multiple locations. This fund could be 
created through a set-aside mechanism within the CTSA Program that 
provides flexible funding to foster collaborative efforts that are pioneer-
ing and have great potential to accelerate clinical and translational re-
search. Projects associated with this fund should include clear metrics 
and evaluation measures. 
 
 
INDIVIDUAL CTSAs 
 
The NIH developed the CTSA Program in order to increase the 
speed and efficiency with which new ideas and technologies would move 
from the research laboratory into clinical and community practice. Ac-
complishing this objective has required strengthening many research ac-
tivities in academic health centers (and other institutions), such as 
biomedical informatics and training for researchers, as well as a focused 
effort to find efficient and effective ways to share resources and develop 
common tools, databases, and research processes, all with the ultimate 
goal of improving human health. Building an active and productive 
CTSA at an academic health center or other institution often involves not 
only the funds from the CTSA cooperative agreement but also substantial 
financial and staff commitments from the institution; although institu-
tional cost sharing is not required. The committee could not identify any 
data to quantify these institutional contributions but heard testimony 
from many individuals about the depth of efforts and the commitment to 
the CTSA Program from top leaders at health research institutions across 
the nation.  
In its first seven years, the CTSA Program has done much to develop 
and nurture the CTSA sites as academic homes for clinical and transla-
tional research with an emphasis on training researchers, providing 
shared resources, streamlining and improving clinical research manage-
ment, and developing community and research partnerships. Zerhouni 
(2005) defined an academic home as a place that provides intellectual 
and physical resources for original clinical and translational science. He 
envisioned CTSAs as creating “environments that over time provide the 
theoretical underpinnings of the discipline, provide much needed educa-
tion programs, contribute to the growth of well structured and well rec-
ognized career pathways, and provide a research environment more 
nimble, conducive to and responsive to the demands of modern transla-
tional and clinical research” (Zerhouni, 2005, p. 1622). Progress has been 
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made in creating these academic homes. The challenges ahead will be to 
capitalize on these efforts and refocus the program so that it becomes a 
network that is responsive, nimble, and innovative in accelerating clini-
cal and translational research.  
The early funding announcements for the CTSA Program identified a 
set of key functions that evolved over time, some of which became a re-
quired part of the program. Some of the key functions were as follows: 
 
 Development of novel clinical and translational methodologies 
 Research education, training, and career development 
 Pilot and collaborative translational and clinical studies 
 Biomedical informatics 
 Design, biostatistics, and clinical research ethics 
 Regulatory knowledge and support 
 Clinical research resources and facilities 
 Community engagement 
 Evaluation 
 Translational technologies and resources (NIH, 2005, 2009).  
 
In its most recent CTSA funding announcement, the NIH changed 
the criteria so that applicants were given greater flexibility to build on the 
strengths of their home institutions in specific phases of clinical and 
translational research (T0–T4) or in a specific area of research (e.g., child 
health research) (NCATS, 2012b; NIH, 2012c).  
The 61 CTSA sites provide a wide array of training and research re-
sources to help researchers identify promising therapeutics and interven-
tions and move them forward as rapidly as feasible, as discussed in 
Chapter 1. These resources often require large institutional investments 
in purchasing equipment and instruments, renovating space, and provid-
ing at least partial support for staff. Despite the availability of these re-
sources, researchers in some institutions have reported that they were 
unaware of the core resources or found them too expensive or cumber-
some to use (Curley, 2013; Raue et al., 2011). A central database cata-
loging CTSA resources has been developed (CTSA Central, 2013b), but 
questions regarding the cost of using the resources and visibility contin-
ue, according to testimony received by the IOM committee from a num-
ber of involved individuals.  
CTSAs have worked to facilitate and simplify clinical research man-
agement through the use of project managers or navigators and other 
mechanisms and tools. For example, CTSA sites are attempting to ensure 
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efficient protocol development processes and limit required review steps 
to those that actually add value to the final research protocol. In a partial 
inventory of the process improvements that had been achieved, as of 
2010, 15 sites reported they had developed process maps, and at least 20 
reported improvements that, in some cases, reduced processing times by 
more than 30 percent. Some of these improvements resulted from 
streamlining IRB approvals (Rosenblum and Alving, 2011). 
Variation in the activities of individual CTSAs has grown up across 
the program due in part to the range of CTSA site funding (from $4 mil-
lion to $23 million in fiscal year [FY] 2012) (Briggs and Austin, 2012) 
and in part to differences in home institution governance structures, 
management styles, and the areas of focus and depth in research portfoli-
os (Rosenblum and Alving, 2011). Although the CTSA Program is dis-
ease agnostic in its overall resources and approach, the individual CTSA 
sites may facilitate research on specific conditions, and their home insti-
tutions may be research leaders in those areas. Thus the individual 
CTSAs and the program as a whole provide great potential to augment 
and facilitate the disease-specific work of NIH institutes and centers, as 
well as that of their home institutions (see Box 3-3). The CTSA Program 
supports disease-specific research in a variety of ways, which may in-
clude funding, research tools and facilities, expert consultation, research 
participant recruitment, and other research resources and support mecha-
nisms described in Chapter 1. In its assessment of the CTSA Program, 
the committee identified numerous examples of disease-specific research 
connected to the Program. The types of CTSA resources that were used 
to support the research were rarely identified or described, however.  
 
 
BOX 3-3 
Examples of Disease-Specific Research Aided by CTSA Resources 
 
 
Cancer: An international team of researchers led by Weill Cornell Medical Col-
lege investigators identified two inherited gene deletions that more than triple 
the risk of aggressive prostate cancer (Demichelisa et al., 2012; Woods, 
2012). 
 
Heart Disease: Using financial support and an information network provided 
by Harvard’s CTSA, investigators at Beth Israel Deaconess Medical Center 
used a mouse model to develop molecular evidence that helps explain why 
preeclampsia and multiple gestation are risk factors for peripartum cardiomyo-
pathy, a sometimes fatal condition that develops in one in 3,000 pregnant 
women with no known heart disease history (Patten et al., 2012; Prescott, 
2012). 
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Lung Disease: Leading a 175-person research team in 13 sites in Japan, 
Canada, and the United States, with partial CTSA funding, University of Cin-
cinnati researchers identified a treatment for a rare, severe lung disease 
(lymphangioleiomyomatosis) that affects women in their childbearing years 
(McCormack et al., 2011; Pence, 2012) 
 
Muscular Dystrophy: Using a national database developed by the University of 
Rochester Medical Center, researchers explored the impact of symptoms on 
the lives of patients with muscular dystrophy and found that those symptoms 
affecting daily life (e.g., fatigue, limited mobility) are more important to patients 
than those most commonly associated with muscular dystrophy (e.g., 
myotonia). Study results are being used to improve patient outcome measures 
and could be used to target future treatment (Heatwole et al., 2012; Michaud, 
2012). 
 
Stroke: Physicians at Barnes-Jewish Hospital used partial funding through 
Washington University in St. Louis’s CTSA to reduce the average time be-
tween a stroke patient’s arrival and treatment from 58 to 37 minutes by elimi-
nating inefficient steps in the care process. Rapid administration of anticlotting 
medication is key to preventing brain damage from stroke (Purdy, 2012). 
 
 
 
 
Opportunities and Next Steps 
 
Individual CTSAs have made progress in establishing academic 
homes for clinical and translational research. The challenge for CTSA 
2.0 will be to create a national network of institutions that are engaged in 
accelerating clinical and translational science. In its assessment of the 
program, the IOM committee heard many questions from stakeholders 
about the optimal number of individual CTSAs. The committee did not 
choose to specify an ideal number, but rather believes that over time the 
number could change as strategic goals and priorities are set and as de-
terminations are made about future program directions. The focus should 
not be on the absolute number of CTSAs but on whether the CTSAs are 
achieving progress as measured by defined goals and priorities. 
As described in Chapter 1, individual CTSAs, the CTSA Program, 
and NCATS need to continually push to identify effective therapeutics 
and interventions and move them to the individuals and populations that 
could benefit from them. The IOM committee realizes that this major 
undertaking will move forward in incremental steps as well as major 
leaps. For individual CTSAs, the challenge will be to keep their home 
institutions engaged and active while reaching out to develop the collab-
orations with other CTSAs, research networks, industry, and community 
stakeholders. Effective clinical and translational research requires crea-
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tivity and innovation that could be ignited by collaboration across disci-
plines and beyond the biomedical and health sciences. In order to tackle 
the most complex and pressing health challenges, CTSAs should attempt 
to create partnerships with schools of business, law, engineering, nurs-
ing, public health, and communications, as well as with relevant academ-
ic departments, such as anthropology and psychology.  
The IOM committee supports the recent change to the CTSA RFA 
that allows greater flexibility for individual CTSA sites to focus on the 
strengths of their institutions. Recognizing that some CTSAs may excel 
in early discovery science, others in later development research, and oth-
ers in implementation of findings in the community, it will still be criti-
cally important for NCATS to ensure that the CTSA Program, as a 
whole, covers the full spectrum of clinical and translational research. 
Further, sites should retain their emphasis on community engagement in 
order to ensure participation and breadth of input by community practi-
tioners, patients, and other stakeholders (Chapter 4). 
The IOM committee urges NCATS and CTSAs to continue to foster 
integrated research communities of CTSAs with common interests and 
expertise, to share infrastructure further, to work on common projects, 
and to strengthen collaborations. Individual CTSAs are encouraged to 
identify and implement efficient and cost-effective ways to provide ac-
cess to core facilities and resources. Further efforts are needed to pro-
mote awareness of their many resources, training, and services and to 
reduce their costs. 
 
 
EVALUATION 
 
Stakeholders, including research funders, the public, and Congress, 
increasingly demand evidence of returns on investments in the health 
research enterprise, such as advances in clinical practice and increases in 
the availability of new therapeutics and interventions (Austin, 2013; 
Reed et al., 2012; Shuster, 2012). Evaluation can be an incentive or cata-
lyst for positive change and improved outcomes and is necessary for ac-
countability, transparency, informed decision making, and communication 
about outcomes and the value of an investment.5 In a multifaceted and 
                                                        
5The definition of “evaluation” used for this report is from Patton’s work on utiliza-
tion-focused evaluation: “Program evaluation is the systemic collection of information 
about the activities, characteristics, and results of programs to make judgments about the 
program, improve or further develop program effectiveness, inform decisions about 
future programming, and/or increase understanding” (Patton, 2008).  
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complex effort such as the CTSA Program, evaluation is a formidable 
undertaking, but one that is vital to ensuring accountability and planning 
for future directions. Over the life of the CTSA Program, the NIH has 
recognized the importance of evaluation by building it into the require-
ments for the first set of CTSA awards, maintaining the requirement for 
each of the subsequent CTSA awards, and initiating an external evalua-
tion process that assessed the program as a whole, as described below. 
 
 
Evaluating Individual CTSAs 
 
As part of the application process for a CTSA award, applicants are 
required to have a plan in place to 
 
 monitor the use, quality, and costs associated with the programs, 
resources, and services that are provided;  
 assess data and modify programs, resources, and services as nec-
essary in order to better meet the needs of researchers, increase 
quality and efficiency, and reduce costs; and  
 track and assess innovative methods and practices related to the 
structure, aggregation, and provision of services, programs, and 
resources (NIH, 2012c). 
 
The recent RFA also requests “a full description of tracking processes, 
metrics, and milestones proposed to ensure ongoing assessment and 
timely adjustment of activities of the CTSA” (NIH, 2012c). Individual 
CTSA evaluation plans correspond to the varying needs and capacities of 
an individual CTSA’s structure, available funding, and programs and 
activities supported. This diversity makes cross-CTSA evaluation a chal-
lenge that may become even more difficult as individual CTSAs are giv-
en more latitude to specialize. However, some salient summative 
measures are necessary in order to establish program accountability and 
to demonstrate its progress and value as a whole. Cross-CTSA evaluation 
will require high-level common metrics and measures that can be applied 
consistently at all sites. 
 
Self-Evaluations of the Individual CTSAs 
 
Each CTSA site conducts internal assessments of its own activities, 
processes, and performance. Individual CTSAs report a median of three 
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members on their evaluation teams representing 1.3 full-time equivalents 
(FTEs) on average. Approximately three-quarters of evaluation teams, 
however, report significant assistance from other staff in evaluation ef-
forts, which may not be captured in the FTEs reported (Alexander et al., 
2013). Sites often use mixed-methods approaches that may include quan-
titative data collection, satisfaction surveys, social network analysis, fo-
cus groups, interviews, and case studies. Many use a systems approach 
that assesses programmatic components individually and collectively 
(Alexander et al., 2013; Rubio et al., 2012).  
The 2012 National CTSA Evaluators Survey6 recognized robust 
evaluation efforts across the program cumulatively, but also identified 
significant heterogeneity in strategies and methods being employed at 
individual CTSAs. The authors concluded that the heterogeneity repre-
sents both a strength, in terms of diversity and flexibility, and a challenge 
with regard to obtaining standardized information (Alexander et al., 
2013). The IOM committee noted variability in publicly available infor-
mation on the individual CTSAs’ evaluation efforts and overall accom-
plishments—for example, some CTSAs post information about their 
broad evaluation plans on their websites,7 and some include impact in-
formation.8 However, descriptions of these evaluation processes, metrics, 
and outcomes are not consistently available for public information. 
Although flexibility in the evaluation approaches and processes of 
the individual CTSAs is appropriate given their variation in size, struc-
ture, and focus, some level of standardization is also needed. The Na-
tional CTSA Evaluators Survey highlighted challenges related to a lack 
of common metrics, clear definitions, and guidance from funders 
(Alexander et al., 2013). Overcoming these obstacles needs to be a pri-
ority in order to implement effective evaluation strategies that will ensure 
sufficient consistency and establish accountability. 
 
                                                        
6For the last 3 years, the Shared Resources Working Group of the Evaluation Key 
Function Committee (described below) has used the National CTSA Evaluators Survey to 
assess the evaluation management and methods being applied across the individual 
CTSAs and to identify emerging challenges and new evaluation tools in use, such as 
dashboard technologies (Alexander et al., 2013; Rubio et al., 2012). 
7See, for example, http://casemed.case.edu/ctsc/cores/evaluation.cfm; http://dccweb2.bumc. 
bu.edu/wordpress/index.php/programs/program-tracking-and-evaluation. 
8See, for example, http://ctsi.ucsf.edu/impact. 
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Fostering Best Practices 
 
In the early phases of the CTSA Program, the Evaluation Key Func-
tion Committee was established to provide “a forum for institutions to 
exchange information about their evaluation approaches, challenges, and 
progress” (CTSA Central, 2013f). This key function committee and its 
working groups are making strides to foster best practices and improve 
evaluations being conducted at the individual CTSA level. Every other 
month the committee produces a newsletter and hosts a cohort call dur-
ing which two CTSAs present evaluation strategies and challenges. 
Members of the key function committee have found these presentations 
valuable for sharing best practices and identifying common challenges 
(and possible solutions) encountered in the sites’ self-evaluation processes 
(personal communication, D. Rubio, University of Pittsburgh, March 15, 
2013).  
The Evaluation Key Function Committee is attempting to develop 
common metrics in specific areas that could be used as benchmarks for 
individual CTSAs and the CTSA Program as a whole. It is currently 
working across the consortium committees to develop, test, and imple-
ment common metrics related to clinical research processes and out-
comes. While in the early stages of development, this effort is focusing 
on 15 metrics in areas such as clinical research processes, careers, ser-
vices, economic return, collaboration, and products (Rubio, 2013).  
The committee has advised other key function committees on the de-
velopment of common metrics also. For example, it worked with the 
Biostatistics, Epidemiology, and Research Design Key Function Com-
mittee to develop consensus on 56 performance items related to collabo-
ration, use of existing methods, and discovery of new methods (Rubio et 
al., 2011a); it consulted with the Community Engagement Key Function 
Committee in developing the evaluation section of Principles of Com-
munity Engagement and with the Education and Career Development 
Key Function Committee to develop common metrics for measuring ca-
reer success (Lee et al., 2012; Rubio et al., 2011b, 2012; Task Force on 
the Principles of Community Engagement, 2011).  
Finally, the evaluation committee’s National Evaluation Liaison 
Working Group consulted with the American Evaluation Association to 
propose an evaluation framework for the CTSA Program (Rubio et al., 
2012). The framework was developed to provide recommendations to 
NCATS and other program stakeholders on how the program could be 
evaluated effectively, given its complexity. The recommendations focus 
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on a range of areas that include scope of evaluation, structure and organ-
ization, funding, methodology, utilization, policy, and capacity (CTSA 
Evaluation Key Function Committee, 2012). This framework has the po-
tential to serve as a valuable resource for NCATS as it considers its next 
steps in implementing the CTSA Program and in identifying approaches 
to evaluating individual CTSAs and the program as a whole. 
 
NCATS’s Role in Evaluating Individual CTSAs 
 
As part of their award obligations, CTSA sites must submit annual 
progress reports to NCATS, describing their accomplishments, mile-
stones, challenges, and the barriers affecting their work. The Office of 
Management and Budget is requiring that the progress report format be 
updated and standardized across agencies; the new format will capture 
information on accomplishments, products, participants, impact, chang-
es, special reporting requirements, and budget (NIH, 2012a). The IOM 
committee understands, however, that the new format will reduce flexi-
bility in the types of specific information that NCATS can request as part 
of the reporting process (personal communication, E. Collier, NCATS, 
March 20, 2013).  
Despite a statement in the recent RFA that “the NIH is committed to 
transparency in the CTSA Program to ensure the program is delivering 
on its mission” (NIH, 2012c), no parts of the sites’ annual progress re-
ports are publicly available (nor were they available to the committee). In 
addition, the progress reports are not currently used for evaluation pur-
poses, according to NCATS staff (Parsons, 2013). The IOM committee 
cannot say whether these required progress reports are the most appro-
priate way to evaluate the individual CTSAs or the program or to com-
municate annual progress, not having inspected them. Nevertheless, the 
committee strongly believes that, given the size of this investment, there 
must be a mechanism in place that requires all of the individual CTSAs 
to regularly and publicly report on defined metrics, milestones, and ac-
complishments. From the IOM committee’s perspective, this lack of public 
information thwarts the need to ensure transparency and accountability. 
During the December 2012 IOM committee workshop, NCATS staff 
reported that the NIH’s current primary evaluation mechanism for CTSA 
sites is the peer-review process associated with renewal applications for 
the cooperative agreements (Briggs, 2012). The recent RFA provided an 
extensive list of review criteria that will be used to assess these applica-
tions; however, it is unclear how NCATS evaluates the CTSAs during 
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the 5-year award cycle and what mechanisms are in place for midterm 
assessments or any necessary corrective actions. The committee urges 
NCATS to assert leadership in improving transparency in reporting of 
metrics, milestones, and accomplishments at the individual CTSA level 
and to ensure that sufficient accountability monitoring is in place through 
a set of common metrics that reflect the program’s mission and strategic 
goals. 
 
 
Evaluating the CTSA Program 
 
Various aspects of the CTSA Program have been evaluated. External 
evaluations by Westat provided quantitative and qualitative baseline 
measures for the program. That 3-year evaluation used site visits to as-
sess training and education, resource utilization, publications, and the 
overall progress of individual CTSAs (see Box 3-4). Westat’s final 
 
BOX 3-4 
Evaluations of the CTSA Program 
 
Report on Field Visits to the CTSAs (Westat, 2011): Westat conducted site 
visits at 9 CTSA institutions with interviews of 369 individuals in various posi-
tions. Despite variation across the sites, Westat concluded that the CTSAs are 
making progress on meeting program goals related to building infrastructure, 
training and education, and translation of research findings into practice. Par-
ticipating interviewees across the sites indicated that CTSA support had ena-
bled progress in clinical and translational research that would not have been 
made otherwise. The report points out that at the time of these interviews, the 
program was still in its early stages and notes that many aspects of the program 
were still evolving, especially those related to building collaborations.  
 
Findings from the CTSA National Evaluation Education and Training Study 
(Miyaoka et al., 2011): Westat surveyed 553 CTSA-supported scholars and 
trainees and 665 mentors and found that both groups were very positive in 
their review of the education and training components of the CTSA program. 
Areas identified for improvement included increasing the ethnic diversity of 
mentors, scholars, and trainees; expanding training in team science and tech-
nology transfer; and dedicating more resources to the online learning and ca-
reer planning components of the program. 
 
 
Findings from the CTSA National Evaluation Utilization Study (Raue et al., 
2011): Westat conducted a survey of 302 users of CTSA resources and 537 
nonusers, all of whom worked for one of the initial 46 CTSA sites that were 
established between 2006 and 2009. A large majority of nonusers (80 percent) 
conducted nonclinical research, and 48 percent indicated they did not need 
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additional resources. The evaluators highlighted the wide range of research 
resources available and found that 79 percent of the users were satisfied with 
those resources. However, the report cited a lack of awareness and confusion 
about the program and its resources and noted a need for increased visibility 
and communication.  
 
Final Report on CTSA-Supported Publications: 2006 to 2011 (Steketee et al., 
2012): Westat analyzed the CTSA sites’ annual progress reports and online 
journal databases and found 17,038 publications identified as supported by CTSA 
resources. Evaluators indicated that publications per CTSA institution increased 
every year it had CTSA funding and found a growing number of publications 
that involved collaboration between more than one CTSA. The report identified 
a need for improvements in standardization in reporting CTSA-supported pub-
lications; more than 2,800 publications that cited CTSA support were not in-
cluded in awardee annual progress reports, and 85 percent of publications 
listed in the annual reports did not cite CTSA funding. 
 
The CTSA National Evaluation Phase 1 Final Report (Frechtling et al., 2012): 
This report concluded that the CTSA Program is enabling a new research in-
frastructure and encouraging the adoption of new practices that have the 
potential to streamline the clinical and translational research process. Westat 
recommended that, going forward, the program should support institutional 
pilot programs, increase awareness of the program and available resources, 
expand education and training opportunities, streamline the CTSA Consorti-
um, increase incentives for collaboration and partnership, and conduct long-
term evaluations.  
 
 
summary report concluded that “the CTSA program is making important 
strides toward encouraging and enhancing a new kind of medical re-
search infrastructure and re-engineering the scientific research process” 
(Frechtling et al., 2012, p. vii). In addition, the OIG evaluated the admin-
istration of the CTSA Program under the NCRR (discussed earlier in the 
chapter) (OIG, 2011).  
Despite these previous efforts and the obvious commitment to evalu-
ation at the CTSA site level, the committee is not aware of future plans 
to evaluate the overall program. The IOM committee believes that a for-
mal, programwide evaluation process should be undertaken to measure 
progress toward NCATS’s vision for CTSA 2.0. Elements that could be 
considered in developing metrics have been identified by NCATS staff 
(Briggs and Austin, 2012) and by the IOM committee and include the 
extent to which program awardees are facilitating clinical studies, with 
an emphasis on multisite studies; advancing the translation of research 
findings into therapeutics, diagnostics, and preventive interventions; de-
veloping innovative research methods; promoting community engage-
ment; training and educating the next generation of clinical and 
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translational researchers; protecting human subjects and reducing delays 
in clinical trials; developing informatics standards; and promoting data 
resources and research tools.  
In addition to the evaluations described, additional reporting mecha-
nisms document and communicate the accomplishments of CTSA sites 
and the CTSA Consortium. For example, the CTSA Consortium commit-
tees produce an annual report recounting the activities and achievements 
of each committee, working group, and task force. These reports detail a 
range of activities, from small-scale accomplishments, such as establish-
ing committee-specific e-mail addresses, to larger efforts, such as devel-
oping a catalog of unique T1 resources available through the program 
(CTSA Central, 2011a). The CTSA Consortium compiled an extensive 
list of activities that demonstrates the breadth and capabilities of the pro-
gram for the NIH CTSA/NCATS Integration Working Group (Katz et 
al., 2011; Pulley, 2013).  
In addition, the NIH has produced two progress reports that cover 
accomplishments of individual CTSAs and the CTSA Consortium from 
2006 to 2008 and 2009 to 2011 (NCRR, 2009; NIH, 2012b). The most 
recent report highlights specific examples of program accomplishments 
in six key areas: accelerating discoveries, improving clinical research 
efficiency, training the next generation of investigators, fostering collab-
oration and partnerships, enhancing the health of communities and the 
nation, and developing resources and networking for sharing data. Just as 
some individual CTSAs feature information on achievements on their 
websites, the NCATS website has a page that includes stories about suc-
cesses attributed to the CTSA Program and other NCATS-supported 
programs (NCATS, 2013d).  
These mechanisms, although not part of a formal evaluation process, 
are important for communicating the value of the program. They could 
be modified to include specific detail on how CTSAs contributed to par-
ticular accomplishments or which program resources were used to 
achieve them. They also could be used to report results of a more formal-
ized evaluation process. The NIH and NCATS should report on any 
programwide evaluation findings in pursuit of transparency, and as men-
tioned previously, there should be a mechanism in place for individual 
CTSAs to report regularly on defined metrics, milestones, and 
accomplishments. 
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Opportunities and Next Steps 
 
 The IOM committee believes that a set of clearly defined, measura-
ble strategic goals is the starting point for shaping the CTSA Program’s 
future. These measurable goals should serve as a foundation for develop-
ing high-level common metrics and measures that could be applied and 
reported consistently to demonstrate progress. At this point, NCATS’s 
plans for evaluating individual CTSA sites and the CTSA Program as a 
whole are unclear. Progress is being made at the individual CTSA level 
in terms of self-evaluation, but the current lack of transparency in report-
ing and lack of high-level common metrics are barriers to overall pro-
gram accountability. 
 Developing common metrics that can be implemented across the 
CTSAs will be a formidable challenge that will require input and cooper-
ation from all the CTSAs. The complexity of the CTSA Program may 
also require the application of innovative metrics that go beyond standard 
academic benchmarks of publications and number of grants awarded.  
The ultimate goal of clinical and translational research, and therefore 
the ultimate goal of the CTSA Program, is to improve human health. 
Although it would be ideal to evaluate the CTSA Program’s impact on 
clinical care and public health, currently this is neither feasible nor realis-
tic given the numerous driving forces that shape the research enterprise 
(Chapter 2) and the multitude of factors that affect health outcomes. In 
addition, there are multiple direct and indirect ways in which the CTSA 
Program contributes to research infrastructure and resources, collabora-
tions, cultural changes, training, and community engagement that influ-
ence clinical and translational research but cannot be easily identified or 
measured. Despite these and other such challenges, the CTSA Program 
can be a leader in developing evaluation methodologies and metrics that 
could provide more real-time assessments of progress in advancing clini-
cal and translational research, overcoming research barriers, fulfilling the 
program’s mission and strategic goals, and, whenever possible, changing 
clinical care and improving public health.  
 
 
COMMUNICATIONS 
 
A common underlying theme to establishing leadership and account-
ability is effective communication. “The effective communication of sci-
entific results and viewpoints to the public is an important responsibility 
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of the scientific community. This is particularly so for science that has 
been publicly funded” (ICSU CFRS, 2010, p.1). In this report, the IOM 
committee takes a broad perspective on the role of communications. It 
does not mean only an occasional news release or printed report, but ra-
ther the full array of activities and methods of communication undertak-
en to attract partners, achieve transparency and accountability, promote 
public support and understanding of findings, and ensure that findings 
are acted on, whether they relate to advances affecting clinical care or 
ways to improve the working of the scientific enterprise. Communication 
in this global sense is fundamental to clinical and translational research. 
It is likewise fundamental to conveying and achieving the value added 
from the CTSA Program. 
In part, the need for a robust and diverse communications effort has 
been anticipated through the creation of two entities: the Communica-
tions Key Function Committee and the CTSA Consortium Coordinating 
Center. The key function committee provides the opportunity for CTSA 
and NIH information officers and staff “to share local and national 
CTSA communications best practices, activities and experiences; and to 
identify and generate ideas to address CTSA communications opportuni-
ties and challenges” (CTSA Central, 2013e). The committee’s Year in 
Review report highlights best practices from individual CTSAs in their 
use of a range of media, including social media, to highlight their work 
and attempt to educate the public generally about clinical and transla-
tional research (CTSA Central, 2013c).  
When the CTSA Consortium Coordinating Center was established in 
November 2011, its role explicitly included enhancing communications 
through organizing networking resources and enabling outreach and dis-
semination of tools. Although some overlap may exist in mission be-
tween the Coordinating Center and the key function committee, the 
latter’s efforts appear more heavily focused on media dissemination, 
whereas the Coordinating Center’s role is more directed to providing 
technical assistance and facilitating communication within the program. 
To the extent that the Communications Key Function Committee and 
Coordinating Center, as they evolve, cannot take on all of the communica-
tions roles that might be desired, this structure might need reassessment by 
NCATS. Further, a CTSA Program strategic communications plan is 
needed to fully implement this role. 
Around the world, scientific communication efforts are slowly mov-
ing away from a strictly dissemination-based approach to a more partici-
patory and collaborative one, as “the [Public Understanding of Science] 
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‘paradigm of science dissemination’ has been partially translated into 
what could be termed a ‘paradigm of dialogue and participation’ or Pub-
lic Engagement with Science” (Felt et al., 2007, p. 55). This paradigm 
shift will require ongoing commitment and leadership from within the 
research enterprise. Signs of progress are evident at the NIH and, specifi-
cally, with the CTSA Program, wherein community engagement has 
been a strong part of the program from its inception. Community en-
gagement provides a platform for collaborative dialogue and participa-
tion and encourages development of new strategies for scientific 
communication. Although scientists in general have resisted a more ac-
tive role in communications, in part because they have not been trained 
for it and most likely see it as time-consuming with unclear benefit, “the 
lack of [professional] reward is a bigger issue” (Palmer and Schibeci, 
2012, p. 12). NCATS is in a position to ameliorate this problem by, for 
example, including strength of communications and of community part-
nerships among its criteria to assess the quality of CTSA research efforts.  
Both general oversight and various high-level communications activ-
ities—for example, with federal policy makers—are most appropriate for 
NCATS to carry out. Other, more program-specific communications ac-
tivities and technical assistance might be appropriate at an intermediate 
level, such as by the Coordinating Center or through the communications 
committee. Finally, some communication activities are most effectively 
carried out by individual CTSA sites and projects. Box 3-5 provides ex-
amples of the opportunities at each of these levels. 
 
BOX 3-5 
Communications Opportunities Within the CTSA Program 
 
 
 At the broad NCATS level, 
 communicate the CTSA Program’s mission and goals clearly and 
consistently. 
 ensure that NIH institute and center leadership know about the CTSA 
Program, the opportunities it offers to add value to their research ef-
forts, and how to connect with and use it. 
 ensure that CTSA PIs and researchers appreciate the importance 
that NCATS places on their ability to clearly articulate the goals of 
their research and findings for various audiences, including communi-
ty partners, and reward teams that do so effectively.  
 coordinate efforts where NCATS leverage may be needed to achieve 
institutional, governmental, or legislative policy changes, particularly 
with respect to the barriers to multi-institutional research projects 
(e.g., uncoordinated reviews, multiple IRB filings, and so on).  
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 use what is learned from the individual CTSAs to distill best research 
practices that might be deployed across the nation’s biomedical re-
search enterprise and disseminate the best practices in ways that en-
courage their adoption.  
 maintain essential transparency and accountability through a system 
of reporting on both program implementation and results (IOM, 2009). 
 provide funding for professional communications staff within the Co-
ordinating Center. 
 
At an intermediate level (e.g., the CTSA Coordinating Center or communi-
cations-focused committee), 
 provide consultation and support for individual CTSAs and projects in 
their website development, media outreach, and social media strate-
gies. 
 coordinate with other key committees as well as CTSA leadership 
and NCATS on media-related topics and opportunities.  
 train site representatives on effective communication with the media 
and public. 
 identify and share communications best practices from the sites, as 
with the 2011–2012 Year in Review report (CTSA Central, 2013c) and 
develop tools to simplify site adoption of these best practices.  
 provide technical assistance to sites in identifying potential audiences 
and communications partners (e.g., community and industry). 
 continue promotion of the specific tools and databases that sites have 
developed and encourage their wider adoption (at present, the Coor-
dinating Center’s website includes a listing of shareable informatics 
tools, and it conducts monthly webinars on how to use these tools).  
 work with sites to develop novel dissemination strategies aimed at 
achieving impact and sharing their findings (examples of impact 
would be a policy change, a clinical practice change, or an improve-
ment in public understanding). 
 continue efforts to collect “success stories” from site efforts and de-
veloping strategies to deploy them effectively. 
 provide researchers, especially new researchers, training on appro-
priate communication strategies and preparing journal articles for 
publication. 
 
 
At the individual CTSA level, 
 promote and disseminate intra-institutional communications about 
specific projects to maximize sharing of technical, information, and 
human resources within the CTSA institution and its collaborators. 
 ensure broad communication of available tools and resources across 
researchers within the home institution. 
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 include in their teams a person with appropriate skills and defined re-
sponsibility for communications, including community outreach, col-
lection of information on best practices, dissemination planning, and 
so on.  
 brief media, communications, and development offices at home insti-
tutions about projects, major milestones, and findings. 
 keep community and industry partners in the communications loop. 
 work with the Coordinating Center and NCATS on a plan for dissemi-
nating findings through the media and beyond.  
 consistently share success stories and research findings on the indi-
vidual CTSA websites.  
 ensure that at least one member of the research team from each 
CTSA participant has had training on effective communication of sci-
entific information. 
 
 
 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
 The CTSA Program has made progress in fulfilling its task of 
strengthening the nation’s infrastructure for clinical and translational sci-
ence. In implementing the CTSA Program and moving it toward CTSA 
2.0, NCATS has an obligation to ensure that the significant public in-
vestment that has been made thus far is effectively contributing to the 
research enterprise. The IOM’s 2009 report HHS in the 21st Century out-
lined a systematic approach to accountability that could be useful in lead-
ing the CTSA Program toward greater accountability and efficiency. This 
approach requires 
 
 a small number of critical, measurable goals; 
 clearly delineated lines of responsibility; 
 quantifiable targets and time-specific milestones; 
 identification of barriers and strategies to overcome them; 
 a process of regular reporting and assessment; 
 rewards and recognition for achieving goals; 
 a clear understanding of whether progress is being made; and  
 corrective action as needed (IOM, 2009). 
 
The current clinical and translational science ecosystem presents 
many challenges in identifying and testing therapeutic and preventive 
interventions for safety and efficacy and moving them into clinical and 
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community settings. The IOM committee believes that the CTSA Pro-
gram has a major role to play in overcoming those challenges and facili-
tating and accelerating clinical and translational research. Meeting these 
tasks will necessitate a CTSA Program that meets the accountability 
standards outline above, is nimble enough to be action oriented, has the 
ability to focus the disparate energies and talents of many institutions and 
individuals, and is able forge the partnerships and collaborations needed 
to move forward in a complex research ecosystem. 
The committee urges NCATS to take a more active role in the direc-
tion of the CTSA Program and to build on its current strengths by setting 
clear and measurable goals, streamlining the program structure, estab-
lishing accountability and transparency, communicating its value, and 
instilling strong evaluation expectations.  
 
Recommendation 1: Strengthen NCATS Leadership of the CTSA 
Program 
 
NCATS should strengthen its leadership of the CTSA Pro-
gram to advance innovative and transformative efforts in 
clinical and translational research. As it implements CTSA 
2.0, NCATS should 
 
 increase active involvement in the CTSA cooperative 
agreements and the CTSA Consortium;  
 conduct a strategic planning process to set measurable 
goals and objectives for the program that address the full 
spectrum of clinical and translational research;  
 ensure that the CTSA Program as a whole actively sup-
ports the full spectrum of clinical and translational re-
search while encouraging flexibility for each institution 
to build on its unique strengths;  
 form strategic partnerships with NIH institutes and cen-
ters and with other research networks and industry;  
 establish an innovations fund through a set-aside mecha-
nism that would be used for collaborative pilot studies 
and other initiatives involving CTSA institutions, other 
NIH institutes, and/or other public and private entities 
(e.g., industry, other government agencies, private foun-
dations, community advocates and organizations); 
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 evaluate the program as a whole to identify gaps, weak-
nesses, and opportunities and create mechanisms to ad-
dress them; and 
 distill and widely disseminate best practices and lessons 
learned by the CTSA Program and work to communicate 
its value and accomplishments and seek opportunities for 
further efforts and collaborations.  
 
Recommendation 2: Reconfigure and Streamline the CTSA 
Consortium 
 
NCATS should reconfigure and streamline the structure of 
the CTSA Program by establishing a new multi-stakeholder 
NCATS-CTSA Steering Committee that would 
 be chaired by a member of NCATS leadership team and 
have a CTSA principal investigator as vice-chair, and 
 provide direction to the CTSA Coordinating Center in 
developing and promoting the use of available shared re-
sources. 
 
Recommendation 3: Build on the Strengths of Individual CTSAs 
Across the Spectrum of Clinical and Translational Research  
 
Individual CTSAs, with the leadership of NCATS, should 
emphasize their particular strengths in advancing the pro-
gram’s broad mission and goals. In doing so, CTSAs should 
 
 drive innovation and collaboration in methodologies, 
processes, tools, and resources across the spectrum of 
clinical and translational research;  
 emphasize interdisciplinary team-based approaches in 
training, education, and research; 
 involve patients, family members, health care providers, 
and other community partners in all phases of the work 
of the CTSA;  
 strengthen collaborations across the schools and disci-
plines in their home institutions;  
 build partnerships with industry, other research net-
works, community groups, and other stakeholders; and 
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 communicate the resources available through the CTSA 
Program. 
 
Recommendation 4: Formalize and Standardize Evaluation Pro-
cesses for Individual CTSAs and the CTSA Program 
 
NCATS should formalize and standardize its evaluation pro-
cesses for individual CTSAs and the CTSA Program. The 
evaluations should use clear, consistent, and innovative met-
rics that align with the program’s mission and goals and that 
go beyond standard academic benchmarks of publications 
and number of grant awards to assess the CTSA Program 
and the individual CTSAs.  
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Crosscutting Topics 
 
 
 
 
 
 
 
 
 
 
The Clinical and Translational Science Awards (CTSA) Program has 
demonstrated progress in three crosscutting domains that the Institute of 
Medicine (IOM) committee believes are integral to effectively advancing 
clinical and translational science: training and education, community en-
gagement, and child health research. These efforts, along with the pro-
gram’s contributions in building infrastructure and providing a range of 
research resources, make the CTSA Program a unique national resource 
within the clinical and translational research landscape. As with all such 
activities, each of these functions can be strengthened in a variety of 
ways. The committee provides a brief overview of each of these areas, 
followed by its recommendations for next steps. 
 
 
TRAINING AND EDUCATION 
 
The health needs of the nation call for a generation of scientists 
trained in “interdisciplinary, transformative translational research” 
(Meyers et al., 2012, p. 132; Van Hartesveldt et al., 2008) and in the 
leadership and team skills to engage in effective collaborative partner-
ships. A major challenge in rapidly translating research findings into 
health care practice is the concomitant need for support of clinician sci-
entists in order to overcome the growing divide between clinical (M.D.) 
and research (Ph.D.) careers (Roberts et al., 2012). Further, emerging and 
growing areas of research (including comparative effectiveness and 
community engaged research) are emphasizing skills and collaborations 
integral to both clinical and translational research. 
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Background and Context 
 
Sustaining a vibrant clinical and translational research enterprise in 
the future depends on building and retaining a diverse research work-
force. Education and training in clinical and translational research are 
priorities for the CTSA Program. All CTSA institutions are expected to 
provide robust postgraduate training (NIH, 2012c), and many have ex-
tensive training programs that often include undergraduate and 
predoctoral student training as well as training for research staff and 
community collaborators. In addition, the CTSA Consortium has identi-
fied “training and career development of clinical and translational scien-
tists” as a consortium strategic goal and has devoted considerable 
resources to enhancing the effectiveness of training and education pro-
grams across institutions (CTSA Central, 2013a,e).  
 
CTSA Training Awards and Programs 
 
Since the inception of the CTSA Program, the training of new clini-
cal and translational science investigators has been an integral part of the 
program. The KL2 Mentored Clinical Research Scholar Program is a 
required part of all individual CTSAs (NIH, 2012c). This career devel-
opment program provides awardees who have a doctoral degree (M.D., 
Ph.D., or equivalent) with formal research training experience and fund-
ing support to help them become independent investigators (NCATS, 
2013). The TL1 Clinical Research Training Program provides an intro-
duction to clinical and translational research to pre- and postdoctoral 
candidates or others who want to learn more about these types of re-
search. For example, the TL1 program can provide medical students with 
a structured year-long research opportunity. In fiscal year (FY) 2011, 501 
scholars participated in the KL2 program, and 469 trainees participated 
in the TL1 program through the CTSA Program (Collier, 2013a). Many 
CTSAs offer a master’s level degree in clinical and translational re-
search.  
In 2011, Westat provided its findings from an online survey of 
CTSA-supported scholars, trainees, and mentors from CTSAs funded 
between 2006 and 2010 (Miyaoka et al., 2011). A total of 665 mentors 
(56 percent response rate) and 553 scholars and trainees (43 percent re-
sponse rate) completed the surveys. Overall, the results were positive. 
Mentors reported providing a range of support in key areas for career 
development, and they reported benefits to their own professional devel-
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opment. Scholars and trainees reported developing more skills and hav-
ing enhanced opportunities for career development. Areas for improve-
ment included the need for greater diversity among mentors, scholars, 
and trainees; increased emphasis on team science; and additional focus 
on the development of skills related to technology transfer, commerciali-
zation, and communicating with policy makers. Box 4-1 presents a few 
highlights from this evaluation. 
 
CTSA Consortium Efforts on Training and Education 
 
At the consortium level, the Strategic Goal Committee on Training 
and Career Development has developed and disseminated core compe-
tencies in clinical and translational science for master’s degree students 
(CTSA Central, 2011), as well as core competencies in specific areas, 
including child health translational research, T1 research, academia-
industry drug development, and medical device innovation and technolo-
gy transfer (CTSA Central, 2011).  
 
BOX 4-1 
Selected Highlights from the CTSA National Evaluation 
Education and Training Study 
 
 CTSAs are engaging scholars and trainees across the spectrum of 
translational research (21 percent basic biomedical research; 52 percent 
clinical research; 26 percent postclinical research) 
 Trainees report positive experiences in educational activities. For exam-
ple, 92 percent responded that building relationships with mentors was 
useful; 96 percent were positive about working as a member of a re-
search team. 
 Evidence of success was found in obtaining R01 funding (47 percent of 
R01 applications were funded). The rate of submission was low, howev-
er (16 percent of scholars or trainees reported submitting an R01 appli-
cation). 
 Clear benefits were noted by mentors (97 percent of mentors rated their 
experience as positive) and trainees or scholars (83 percent assessed 
their levels of training and expertise in clinical research as moderate or 
high after participating in the CTSA Program, compared with a baseline 
33 percent).  
 Most scholars and trainees reported serving as the PI on their first (79 
percent) and second (72 percent) grant/award applications.  
 
SOURCE: Miyaoka et al., 2011. 
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The additional goals of the strategic goal committee are to provide 
CTSA-wide access to training resources, develop a core curriculum, im-
plement a mentoring training program that shares best practices, and de-
velop metrics and criteria for recognizing success and achieving career 
promotion in clinical and translational research (CTSA Central, 2013e). 
 
 
Opportunities and Next Steps 
 
CTSA 2.0 should build on the successes of the training and educa-
tion components of individual CTSAs and the consortium-level work. 
This calls for new and innovative training and education approaches and 
methodologies. Training and education efforts are a prime area for col-
laboration with NIH institutes and centers to monitor, track, and adopt 
best practices and successful models in education, mentoring, and career 
development.  
Presentations to the IOM committee and peer-reviewed publications 
highlighted a range of innovative training opportunities that could be 
brought to scale for greater impact. These include training and education 
across the educational spectrum (i.e., from undergraduate to postgraduate 
levels) and learning opportunities for community partners, faculty, and 
research administrators. Academic training options also exist across lev-
els of intensity, from individual courses to certificate programs to ad-
vanced degrees.  
 
Innovative Curricula and Team-Based Education and Training  
 
The excitement and the challenge of clinical and translational science 
is that it requires approaches to training and education that are outside of 
traditional scientific fields. The focus on a truly team-based and interdis-
ciplinary approach to science requires collaborations that go far beyond 
lip service and necessitates relationship building between and among 
professional schools (e.g., medicine, nursing, business, law, engineering, 
public health), as well as with a range of community partners (from pa-
tients and families to health care providers). Learning in this field is of-
ten through and by experience. Further, the topics to be covered stretch 
beyond traditional ones to include, for example, entrepreneurship, intel-
lectual property, regulatory science, health equity, unconscious bias, and 
community engagement.  
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In a number of CTSAs, innovative efforts to develop new courses 
and curricula are already under way. For example, the CTSA partnership 
in which the University of Washington is involved implements a team-
based translational educational program with a clinical and translational 
research boot camp workshop and several active seminar series, includ-
ing a monthly clinical research education series focused on conveying 
practical information and tools (ITHS, 2013). The goal is for translation-
al scientists to have competencies related to key questions at each phase 
of the translational research cycle, including 
 
 Which problems will we tackle? (discovery phase);  
 How will the handoff happen to move discoveries into human 
studies? (development phase);  
 Can we scale up into clinics or communities? (delivery phase); 
and  
 How will we know we are making a real impact? (outcomes 
phase) (Edwards, 2013; Kelley et al., 2012).  
 
In another innovative training model, the University of Pennsylvania 
offers a variety of training options for undergraduates; predoctoral, grad-
uate, and postdoctoral students; fellows; clinical residents; and faculty 
with several types of certificates or advanced degrees offered. In addition 
to general training in clinical and translational science, this program of-
fers a concentration in translational therapeutics that includes public-
private partnerships for industry internships and training in intellectual 
property and commercialization (Meagher, 2011; University of 
Pennsylvania ITMAT, 2013). 
CTSA 2.0 should build on these and other innovative training and 
education programs that are bridging the gap between the basic and clin-
ical sciences. Emphasis on experiential and team-based learning and in-
corporating topics outside the traditional realm will provide the solid 
foundation needed to spur clinical and translational research. CTSAs 
have the potential both to create learning cultures that embrace innova-
tive teaching methods and content (e.g., gaming, flipped classrooms,1 
mini-institutes) and to disseminate those innovations rapidly and effectively.  
                                                      
1Flipped classrooms typically offer instruction online and doing homework in the 
classroom. 
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Effective Mentoring and Coaching 
 
An emphasis on effective mentoring has also been a strength and in-
tegral component of CTSA training programs. In 2008, the CTSA Educa-
tion and Career Development Key Function Committee established a 
Mentor Working Group that has identified several key elements of suc-
cessful mentoring programs: mentor selection and support, alignment of 
mentor and mentee expectations, mentor training, evaluation, and feed-
back (Fleming et al., 2012).  
Recent surveys and interviews found that the active mentoring pro-
grams that are in place at CTSAs for the KL2 awards differ widely re-
garding policies on selecting mentors, criteria to qualify as a mentor, and 
processes to evaluate the mentoring relationships (Huskins et al., 2011; 
Silet et al., 2010; Tillman et al., 2013). Programs also varied on the for-
mality of the mentoring program, with 30 percent reporting the use of 
mentoring contracts (Huskins et al., 2011). Two-thirds of the mentoring 
programs reported requiring or encouraging mentees to have multidisci-
plinary mentors, with mentors or the program taking the lead to coordi-
nate this effort to varying degrees (Silet et al., 2010). The same survey 
found that CTSA institutions infrequently provide tangible support for 
mentors, such as salary support, institutional recognition, and research 
support.  
Successful mentoring practices should be disseminated across 
the CTSA Program. While avoiding the pitfalls of just checking boxes, the 
CSTA Program should consider developing metrics for how mentoring is 
evaluated. Mentoring is not an inherent skill for many people, but it can 
be developed by training and alignment of incentives. Positive mentoring 
experiences appear to be linked to strong relationships with individual 
mentors. The time commitment made to mentoring should be recognized 
in decisions on the mentor’s career advancement.  
A new initiative being announced by the NIH Common Fund and the 
National Research Mentoring Network offers opportunities for focused 
efforts on mentoring and will aim to provide mentoring standards, train-
ing for mentors, and opportunities to increase the diversity of participants 
involved in being a mentor or mentee (NIH, 2013b). CTSA Program par-
ticipation in this network could be a benefit to furthering CTSA mentor-
ing opportunities. Consideration could be given to trans-CTSA 
mentorships where predoctoral students in one institution would have 
mentors in multiple CTSA institutions, thereby sharing specific exper-
tise, creating venues for innovative partnerships, and opening up a poten-
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tial pipeline for recruitment across institutions when their predoctoral 
training is completed. 
 
Flexibility and Focus 
 
Consistency in key components of training and education, such as 
core competencies and standards, can be balanced with flexibility in the 
elements and focus of the training experiences. Input received by the 
IOM committee from those who had participated in the CTSA training 
programs identified many positive aspects of the training experience, 
including protected time to develop a programmatic research agenda and 
grant proposals; exposure to multidisciplinary perspectives; committed 
mentoring relationships; high-quality courses, seminars, and workshops; 
support for participation in national conferences; and access to pilot grant 
funding and core resources (Ceglia, 2013; IOM, 2013; Shackelford, 
2013). Areas of concern included the lack of awareness of the range of 
core resources available through the CTSA and the extensive time com-
mitment for completing an advanced degree in the CTSA institutions that 
require this as part of the training program.2  
In moving to CTSA 2.0, the IOM committee urges increased flexibil-
ity in training and education programs. The extensive list of competen-
cies identified by the strategic goal committee (CTSA Central, 2011) 
offers many potential areas for program development. The objective 
should be to personalize training experiences to meet the needs and goals 
of individuals and focus on competency rather than on the absolute re-
quirement of obtaining a master’s or other advanced degree. This flexi-
bility will be valuable in attracting and retaining KL2 scholars and TL1 
trainees and may be particularly pertinent to clinician-scientists, who can 
play a major role in the clinical and translational research enterprise. 
 
Disseminating Education and Training Materials 
 
The transformation of training and education is possible only through 
the dissemination of successful approaches and practices. Several efforts 
are under way to provide online repositories of CTSA training and edu-
cation modules and materials. The Virtual University through the Uni-
                                                      
2CTSA institutions have the flexibility to decide how to structure their career develop-
ment programs. In some CTSAs the KL2 participants are required to obtain a master’s 
degree as part of the KL2 program, and the degree is optional at other CTSA sites 
(Collier, 2013b). 
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versity of Iowa offers access to online courses relevant to clinical and 
translational sciences (University of Iowa ICTS, 2013). The National 
CTSA Educational Resource Program, developed by the University of 
Rochester’s Clinical and Translational Science Institute, provides links to 
educational modules from a number of CTSAs (University of Rochester 
CTSI, 2013). Online access to course materials on mentoring is available 
through the Mentor Development Program at the University of Califor-
nia, San Francisco (University of California San Francisco CTSI, 2013). 
Notable in the information obtained by the IOM committee regarding 
training and education is frequent sharing of courses, seminars, work-
shops, and other resources among the CTSA sites and other training and 
education programs within institutions. This sharing enhances cross-
disciplinary training within individual institutions and across the CTSA 
institutions. The IOM committee notes that similarities in core curricula 
highlight opportunities for improving efficiencies in training as well as 
for exposing scholars and trainees to expertise in areas of particular 
strength from one CTSA institution to another.  
 
Increasing Diversity and Growth of the Clinical and Translational 
Research Workforce 
 
To date, scholars, trainees, and mentors in CTSA programs lack di-
versity. The Westat evaluation showed that most mentors are white 
males, and most scholars and trainees are white females (Miyaoka et al., 
2011). Bringing the brightest minds to research, which is critical for new 
discoveries to improve health, depends on creating a training and educa-
tion environment that attracts and retains a diverse pool of scientists. In-
novative education programs such as Harvard University’s Summer 
Clinical and Translational Research Program for undergraduate scholars 
have the potential to create a pipeline of diverse clinical and translational 
scientists (Harvard Medical School DCP, 2013), particularly if partner-
ships are formed with colleges and universities that traditionally serve 
racial and ethnic minority students.  
Opportunities may also be available for CTSAs to connect with 
STEM (science, technology, engineering, and mathematics) initiatives 
within and across institutions. CTSAs need to take full advantage of ef-
forts sponsored by the NIH and others to build diversity, and, moreover, 
they should lead in the implementation of these initiatives. An example is 
the BUILD Program (Building Infrastructure Leading to Diversity) and 
the National Research Mentoring Network (NIH, 2013a). The National 
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Institute on Minority Health and Health Disparities sponsors Research 
Centers in Minority Institutions (RCMI), which provide additional op-
portunities for ongoing collaborations with the CTSA Program, particu-
larly with the RCMI Translational Research Network (NIMHD, 2013). 
 
Metrics and Incentives for Careers in Clinical and Translational Research 
 
Traditional metrics have been used for the most part to measure the 
success of CTSA training and education programs. These metrics include 
 
 number of scholars and trainees; 
 conversion rate from K (training) to R (independent investigator) 
grants; 
 number of publications; and 
 number and types of degrees completed (Miyaoka et al., 2011).  
 
These metrics do not measure or provide incentives for the team-
based and interdisciplinary approaches needed to accomplish clinical and 
translational research. If the CTSAs are to be centers for innovations in 
clinical and translational research, they should also lead in innovations in 
mentoring and its evaluation, including assessment of the professional 
career trajectory of those who have participated in the training programs, 
creation of networking opportunities, active participation in national pro-
fessional organizations, and commitment or intention of the scholars and 
trainees to engage in clinical and translational research.  
Two groups within the CTSA Program have begun related efforts to 
examine the components of career success for clinical and translation 
scientists and the metrics needed to assess individual and organizational 
progress. The Research on Careers Workgroup at the University of Pitts-
burgh identified personal factors (e.g., demographic and psychosocial 
factors, research experience) and organizational factors (e.g., training 
opportunities, financial resources, balance of research and clinical re-
sponsibilities) contributing to career success for physician-scientists 
(Rubio et al., 2011). This information can provide training programs with 
insights on critical areas for working with scholars, trainees, and men-
tors. The CTSA Education Evaluation Working Group identified validat-
ed metrics and measures for assessing personal and organizational 
determinants of career success for clinical and translational scientists 
(Lee et al., 2012).  
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NCATS and individual CTSAs have the opportunity to lead changes 
in how training and education programs are assessed and in instituting 
incentives for the recognition and promotion of those involved. The tra-
ditional benchmarks for academic promotion and advancement are fo-
cused on individuals and products (e.g., publications, new grants). New 
benchmarks that value team-based efforts and collaborative approaches 
are needed to complement these traditional metrics. Changing those 
measures will be challenging because it is difficult to assess the depth or 
substance of collaborations. Identifying the right measures and incentives 
is a major challenge for CTSA 2.0. Examples of relevant measures might 
include the following:  
 
 evidence of interdisciplinary collaborations and of teams that 
cross disciplines and include community partners; 
 increases in the number of training and educational opportunities 
outside of KL2 and TL1; 
 increases in the number and level of involvement of community-
based health care providers and other community stakeholders in 
the CTSA’s activities; 
 higher satisfaction with mentoring relationships and increases in 
trained mentors; and 
 the extent of public communication and knowledge transfer.  
 
Expanding Training Opportunities 
 
To date, CTSAs have made substantial progress in developing grad-
uate and postdoctoral training in clinical and translational research. In 
addition to sustaining and building on those efforts, further work is need-
ed to expand those opportunities, including training and continuing edu-
cation for faculty, professional staff, and community partners. For 
example, substantive involvement of community partners in clinical and 
translational science provides the opportunity for education in research 
methodologies and design, policy and regulatory aspects of clinical trials, 
and dissemination of clinical innovations.  
Community partner training generally appears rather informal across 
CTSA institutions. One example of a formal program is the Community 
Engaged Scholars Program developed and implemented by the South 
Carolina Clinical and Translational Research Center for Community 
Health Partnerships. This 18-month program focuses on developing 
competencies in community-based participatory research among teams 
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that must include at least one academic and one community partner. Pro-
gram components include monthly sessions focused on problem-based 
learning, mentorship, and funding for pilot projects. An early evaluation 
found the program successfully recruited and retained teams that identi-
fied and implemented community-based translational research pilot stud-
ies (Andrews et al., 2012). 
As CTSAs continue to develop as strong networks of diverse stake-
holders, there will be important opportunities to provide all participants 
with training and education on clinical and translational science. Mean-
ingful involvement and collaboration among diverse groups require some 
common starting points, and CTSAs are the prime location for the train-
ing needed. 
 
 
Conclusions and Recommendation 
 
Training and education in clinical and translational research is a core 
element of all CTSAs. To date, significant progress has been made in 
identifying core competencies and in developing curricula in clinical and 
translational research. CTSA 2.0 will require further efforts to develop 
and implement innovative education and training approaches that empha-
size the unique aspects of clinical and translational science. The full 
range of stakeholders needs to have expertise so they can contribute fully 
to the accelerated development and implementation of new therapies, 
preventive measures, and devices to improve health.  
 
Recommendation 5: Advance Innovation in Education and 
Training Programs 
 
The CTSA Program should provide training, mentoring, and 
education as essential core elements. To better prepare the next 
generation of a diverse clinical and translational science work-
force, the CTSA Program should 
 
 emphasize innovative education and training models and 
methodologies, which include a focus on team science, lead-
ership, community engagement, and entrepreneurship;  
 disseminate high-quality online offerings for essential core 
courses for use in CTSA and other institutions; 
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 champion the reshaping of career development pathways for 
researchers involved in the conduct of clinical and transla-
tional science; and  
 ensure flexible and personalized training experiences that of-
fer optional advanced degrees.  
 
 
COMMUNITY ENGAGEMENT 
 
Effective translational research requires effective community en-
gagement across the full spectrum of research from basic science and 
first-in-human studies (T0–T1) to community and population health re-
search (T4). For the purposes of this report, the IOM committee has 
adopted a widely cited CDC definition of community engagement: “the 
process of working collaboratively with and through groups of people 
affiliated by geographic proximity, special interest, or similar situations 
to address issues affecting the well-being of those people” (CDC and 
ASTDR, 1997). The committee considers that the term “community” can 
include all stakeholders connected to clinical and translational research. 
This broad definition encompasses the people who are served by the in-
dividual CTSAs, including patients and families, community organiza-
tions, and disease advocates, as well as clinicians and health 
professionals, including physicians, nurses, dentists, nutritionists, social 
workers, and many others. The committee also recognizes the “research 
community,” which includes the full range of researchers—basic, clini-
cal, and locally based researchers who work both inside and outside of 
academic settings. In this section of the chapter, however, when the word 
“community” is used, it denotes the people who seek and provide health 
care in community, academic, and private settings, as well as individuals 
and organizations working in communities to improve the health and 
well-being of local populations. 
Community engagement in clinical and translational research varies 
in terms of both level of engagement and the stage(s) of research in 
which public participants are involved. The type of research in which 
community members are most deeply involved is community-based par-
ticipatory research (CBPR), which engages local participants as partners 
and involves them in shared leadership roles throughout the entire re-
search process, from concept development to protocol design to dissemi-
nation of the research findings. The least involvement includes outreach 
mechanisms that are primarily unidirectional and may entail a researcher 
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providing information about research results or ongoing research in the 
region (Hood et al., 2010; Task Force on the Principles of Community 
Engagement, 2011). 
Communities can contribute to the full range of clinical and transla-
tional research in important ways that are not always recognized (Box 4-2). 
For example, partnerships with community representatives can identify 
community health needs and priorities, provide critical input and data on 
clinically relevant questions, develop culturally appropriate clinical re-
search protocols, promote successful enrollment and retention of re-
search participants, and, ultimately, disseminate and implement research 
results more effectively. In addition, community engagement at early 
stages of research helps to ensure that ethical considerations are taken 
into account and facilitates early establishment of trust (Horowitz et al., 
2009; Martinez et al., 2012; Woolf, 2008).  
The benefits of community engagement therefore are numerous and 
can lead to a more robust research enterprise, stronger community sup-
port for research and research funding, and attract more, and more di-
verse, young people to careers in research (Freeman and Seifer, 2013; 
Staley, 2009; Task Force on the Principles of Community Engagement, 
2011; Yarborough et al., 2012).  
 
BOX 4-2 
Examples of Community Engagement in Clinical and 
Translational Research 
 
 
For basic research (T0–T1), communities and patient advocacy organiza-
tions can play a vital role in identifying research areas, providing resources 
and specimens to support research, and putting a human face on the dis-
eases and disorders being studied. For example, the Hermansky-Pudlak 
Syndrome (HPS) Network is a nonprofit advocacy organization that supports 
patients and families with HPS, a genetic disorder associated with albinism, 
bleeding, visual impairment, inflammatory bowel disease, and pulmonary 
fibrosis (HPS Network, 2013). The HPS Network has worked to identify re-
search questions, recruit researchers, build partnerships, and fund research 
studies that have used animal models to investigate cell lines in the lungs of 
mice with HPS that are most susceptible to pulmonary fibrosis (Young et al., 
2007). Likewise, PXE International, Inc., a nonprofit advocacy organization, 
provides support for research and for individuals and families affected by 
pseudoxanthoma elasticum (PXE), a genetic disorder that can lead to 
changes in vision, skin elasticity, and the cardiovascular and gastrointestinal 
systems. To expand research in this area, PXE International worked with pa-
tients and families to establish a biobank of blood and tissue samples made 
available to researchers conducting genetic research (PXE International, 
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2012). Both of these organizations work to bridge the gap between patients 
and basic science researchers studying these rare disorders. 
In the clinical trial phases of clinical and translational research (T2–T3), 
community organizations can play a significant role in developing appropri-
ate research protocols, helping researchers understand the needs and cul-
ture of the patient population, and recruiting prospective research 
participants. The HIV/AIDS community has played an active role in research 
since the beginning of the HIV/AIDS epidemic. To facilitate these interac-
tions, the National Institute of Allergy and Infectious Diseases (NIAID) made 
Community Advisory Boards (CABs) a requirement for all HIV/AIDS clinical 
trial networks and sites it funds (Community Partners, 2009). The CABs have 
provided a venue for dialog between the community and clinical researchers 
and provided an opportunity for community representatives to participate in 
trial design and recruitment. NIAID continues to make community engage-
ment a priority in HIV/AIDS research by supporting a number of other mech-
anisms to foster community participation in clinical trials. For example, the 
Legacy Project and Community Partners work to build trust, cultivate part-
nerships, and ensure effective community representation in clinical trials with 
an emphasis on engaging underrepresented communities (Dieffenbach, 
2011; HANC, 2013a,b; Kagan et al., 2012). 
Community engagement is an inherent part of community health and 
population health research (T4). The Healing Canoe Project is an example of 
a multiphase collaborative project that applies the community-based partici-
patory research model. The project is a partnership between the Suquamish 
Tribe, the Port Gamble S’Klallam Tribe, and the Alcohol and Drug Abuse In-
stitute (ADAI) at the University of Washington and is funded by the National 
Center on Minority Health and Health Disparities (Healing of the Canoe, 
2013; Thomas et al., 2010). The first phase of the project (2005–2008) fo-
cused on the partnership between ADAI and the Suquamish Tribe. During 
that phase, researchers conducted a community assessment that involved 
interviews and focus groups to identify needs related to substance abuse 
prevention and cultural identity among youth. They used a team-based ap-
proach to develop a curriculum that blended elder community members’ ex-
periences, the community’s traditions and culture, cognitive-behavioral skills, 
and information about alcohol and drugs. The second phase of the project 
(2008–2013) is continuing this work and using the same methods to adapt 
the project for the Port Gamble S’Klallam Tribe (Healing of the Canoe, 2013; 
Thomas et al., 2010). 
 
An array of information has been developed on the principles, best 
practices, and need and potential for community engagement in all as-
pects of the research process, and studies have delineated the best meth-
ods to achieve authentic engagement, including defining community, 
identifying partners, learning the etiquette of community engagement, 
building sustainable networks of community engagement researchers, 
developing new engagements, and refining translation and dissemination 
plans (Hatcher and Nicola, 2008; IOM, 2012a; Michener et al., 2012). 
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Nevertheless, as noted by Hood and colleagues (2010), “to date, there is 
a paucity of research about the prevalence of community engagement in 
research, especially among clinical and translational research studies tra-
ditionally funded by NIH” (p. 19). This report will not review the litera-
ture on best practices and principles of community engagement. The 
committee recognizes the many valuable contributions to the field made 
by such reports as Principles of Community Engagement (Task Force on 
the Principles of Community Engagement, 2011), Communities as Part-
ners in Cancer Clinical Trials: Changing Research, Practice and Policy 
(ENACCT and CCPH, 2008), and Recommendations for Community In-
volvement in National Institute of Allergy and Infectious Diseases 
HIV/AIDS Clinical Trials Research (Community Partners, 2009), along 
with the work conducted, for example, through the CTSA Program, the 
Community-Campus Partnerships for Health (CCPH), the Centers for 
Disease Control and Prevention, the Patient-Centered Outcomes Re-
search Institute, and various NIH institutes and centers.  
 
 
The CTSA Program and Community Engagement 
 
Community engagement was identified as a priority area from the 
earliest stages of the CTSA Program and became a required key function 
for CTSA sites as administered by the National Center for Research Re-
sources (NIH, 2009a,b, 2012b). Shifts in the requirements of the most 
recent RFA, which were made to provide increased flexibility for the 
individual CTSAs, have caused concern among some community organi-
zations and advocacy groups that community engagement is being 
downplayed (CCPH, 2012b; Seifer, 2013; Thomas, 2013). Although the 
key functions that were previously required are no longer explicit re-
quirements, the recent RFA does indicate that all CTSAs must have core 
resources across the full spectrum of translational research. It also en-
courages individual CTSAs to build a program to “meet the needs of 
their own investigative and public communities and to develop and build 
upon unique institutional and community strengths,” which implies some 
level of necessary community engagement (NIH, 2012c).  
The CTSA Consortium has adopted a set of competencies for clinical 
and translational research that includes community engagement as a core 
competency (CTSA Central, 2011). The “Frequently Asked Questions” 
section of the recent RFA refers to future solicitations in 2014 and high-
lights community engagement as an area of interest for NCATS 
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(NCATS, 2012a). NCATS staff confirmed that “the NCATS Advisory 
Council approved concept clearance for [a new initiative titled] 
‘Strengthening Community-Engaged Research in the CTSA Program’ at 
its September 2012 meeting” but indicated that “no decision has been 
made on what form this initiative will take” (Parsons, 2013). Initial in-
formation regarding future partnerships with NIH institutes and centers 
for demonstration projects also highlights community engagement as an 
area of focus (NCATS, 2012a).  
On October 15, 2012, NCATS released an RFI focused on how 
community engagement research could be enhanced through the CTSA 
Program with the end goal being “the development of a research agenda 
that would leverage the community engagement capability of the CTSA 
institutions to solve critical roadblocks in the translational research pro-
cess” and that would build “on the CTSA community engagement pro-
jects, collaborations, and infrastructure to facilitate the conduct of 
translational research” (NIH, 2012b). The RFI asked for stakeholder in-
put on possible research questions and opportunities to advance research, 
tools, and techniques for community engagement and on the role of 
community engagement and community-based participatory research in 
clinical and translational research. The responses to the RFI were still 
being reviewed by NCATS just prior to the IOM committee’s final meet-
ing in March 2013, but the authors of a few of the responses shared their 
comments with the committee and emphasized a commitment to com-
munity engagement and a continued need for it within the CTSA Pro-
gram (CCPH, 2012a; Emmons, 2012; Parsons, 2013). 
The initial commitment to community engagement within the CTSA 
Program should be commended. However, NCATS’s vision for how 
community engagement will be a part of the CTSA Program moving 
forward remains unclear. Although indications point to community en-
gagement remaining an important feature of the program, there are seri-
ous concerns that if it is not an explicit requirement for all CTSAs, it 
may fade in importance. These concerns were expressed clearly by the 
CCPH in its response to the RFI on community engagement, highlighted 
at the IOM committee’s January 2013 meeting. The CCPH sees “trou-
bling signs that CTSAs are already responding to a perceived lack of 
NCATS support for community engagement” by reducing resources sup-
porting community engagement and putting a hold on community en-
gagement activities (CCPH, 2012a). In developing its plans for 
implementing the CTSA Program and how community engagement will 
fit within it, NCATS must carefully consider unintended consequences of 
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its decisions in terms of developing and sustaining fragile partnerships 
that have been and continue to be built.  
 
 
Progress in Community Engagement 
 
Because community engagement has been a required part of the 
CTSA Program, individual CTSAs and the CTSA Consortium have ded-
icated time and resources to building partnerships with community or-
ganizations and representatives, developing and sharing tools and 
resources to facilitate community engagement, educating researchers and 
communities, building trust, and engaging communities in the research 
process. The CTSA Consortium has two main committees focused on 
community engagement—Strategic Goal Committee 4, which focuses on 
“enhancing the health of our communities and the nation,” and the 
Community Engagement Key Function Committee, which has eight 
working groups devoted to a range of related areas, including practice-
based research network collaborations, health policy, resource develop-
ment, and community partner integration (CTSA Central, 2013c). These 
two committees work “to identify and develop effective partnerships 
among researchers and community stakeholders” and “to implement a 
successful broad plan of community and practice engagement among the 
CTSA sites by sharing knowledge, expertise and resources” (CTSA 
Central, 2013c,f). These committees and working groups have facilitated 
the development of a range of tools and resources for CTSAs and re-
searchers that promote effective community engagement (see Box 4-3) 
(Brady, 2012). 
In addition to activities facilitated through the CTSA Consortium, 
individual CTSAs are making progress in community engagement ef-
forts. A recent survey of involvement of community representatives in 
CTSA activities found that, of the 47 CTSAs responding (out of 60 sur-
veyed), almost 90 percent have established a community advisory board 
(Spofford et al., 2012). However, these boards are used primarily to ad-
vise the community engagement cores at the CTSAs and are involved to 
a lesser extent in advising CTSA leadership. The survey also revealed 
few opportunities for community representatives to participate in leader-
ship roles beyond those within the community engagement core or on 
CTSA leadership committees.  
To fully engage community representatives throughout the CTSA 
Program, strategies should be developed and implemented that integrate 
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community representatives beyond community engagement projects. 
This effort should include having community representatives actively 
participate in leadership and governance committees of the CTSA Pro-
gram and individual CTSAs and obtaining substantive input from them 
on how to improve community engagement. 
 
BOX 4-3 
Examples of Community Engagement Tools 
 
 Sentinel Network for Community-Based Participatory Research: a col-
laborative project with five CTSAs and several partner organizations that 
works to identify strategies to increase community participation in clinical 
research through education and referrals. Since the start of the program, 
more than 5,000 individuals have been surveyed on topics related to bar-
riers to participating in research, local health concerns and needs, and 
the types of research in which they would be willing to participate (NIH, 
2012a). 
 
 Community Engagement Consultative Service (CECS): a two-phase 
program that provides consultations and referrals to help individual 
CTSAs and researchers “develop the knowledge, skills, and attitudes to 
successfully engage with internal and external groups and communities” 
(Carter-Edwards et al., 2013, p. 34). Phase I of the program tested the 
feasibility and utilization of the service, and Phase II paired individual 
CTSAs with consultants to promote improvements in community en-
gagement (Carter-Edwards et al., 2013; Duke Center for Community 
Research, 2013).  
 
 Community Research Utilities and Support (CORUS): an online data-
base designed for sharing resources and tools related to community-
engaged research. Resources include evaluation tools and strategies, 
education modules, stakeholder registries, communications tools, and 
ethics resources (Indiana University CTSI, 2012). 
 
 The Research Toolkit (formerly known as PRIMER or Partnership-driven 
Resources to IMprove and Enhance Research): an online library of 
available resources and tools meant to facilitate multisite research in-
volving community organizations and PBRNs. The toolkit is organized by 
phase of research to provide investigators with a complete guide. A col-
laborative team of researchers that included members from three 
CTSAs, PBRNs, and the HMO Research Network developed the toolkit 
(Dolor et al., 2011; Research Toolkit, 2012). 
 
 Principles of Community Engagement: an almost 200-page primer de-
veloped by a task force of the Community Engagement Key Function 
Committee. This resource compiles definitions, principles, examples, and 
best practices, along with challenges and mechanisms for evaluating 
community engagement (Task Force on the Principles of Community 
Engagement, 2011). 
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As noted by the NIH CTSA/NCATS Integration Working Group, 
“The CTSA requirement for community outreach has led many institu-
tions to develop or strengthen community‐based research, though this is 
one of the most highly variable aspects of the CTSAs” (Katz et al., 
2011). Examples of community engagement efforts at individual CTSAs 
are provided in Box 4-4. 
 
BOX 4-4 
Examples of Community Engagement Projects at CTSAs 
 
 Chicago Consortium for Community Engagement: a partnership be-
tween Northwestern University, the University of Chicago, and the Uni-
versity of Illinois at Chicago designed to facilitate coordination and 
synergy in order to enhance the capacity of each of the institutions for 
community engagement through a range of activities, including having 
regular meetings for the Chicago community-based participatory re-
search network, providing education and training for researchers and 
community organizations, developing a map of research opportunities 
across the city, and hosting a citywide summit to discuss challenges 
and opportunities for improving the health of Chicagoans (C3, 2013; 
CTSA Central, 2013b). 
 
 Clinical and Translational Science Collaborative of Cleveland at Case 
Western Reserve University: a collaboration of support of local PBRNs 
with stabilizing funding and micropilot grants that have supported more 
than 115 projects. One PBRN encompasses 50 practices and is sup-
ported by the Robert Wood Johnson Foundation. In three years the 
work of this PBRN has lowered hemoglobin A1c levels by one percent-
age point—enough to reduce risks of complications—in a population of 
27,000 patients with type II diabetes (Case Western Reserve University 
CTSC, 2012; Pulley, 2013a). 
 
 University of Cincinnati’s Community Leaders Institute: a 6-week train-
ing program for community leaders designed to “assist agencies that 
engage and empower communities to reduce health, social and educa-
tional disparities in leveraging funding and learning how to use data to 
improve services and programs.” Since the program started in 2010, 41 
community leaders have completed it. The first cohort of the program, 
which had 9 people, has secured more than $1.3 million in grants for 
their community organizations. Previous participants included individu-
als from such diverse local organizations as the YMCA of Greater Cin-
cinnati, the Cincinnati Health Department, Lincoln Heights Missionary 
Baptist Church, and Sickle Cell Affected Families of Greater Cincinnati 
(Pulley, 2013a; University of Cincinnati CCTST, 2013). 
 
 Scripps Translational Science Institute Community Engagement Pro-
gram: a partnership with the Scripps Whittier Diabetes Institute devel-
oped to improve prevention and treatment strategies for diabetes in a 
high-risk population—individuals in the San Diego area with Mexican 
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ancestry. To achieve these goals, the program leverages genomic sci-
ences, wireless technologies, established community partnerships, and 
culturally appropriate approaches to community education and health 
care. The program also includes a diabetes gene bank and a study on 
gestational diabetes (NIH, 2012a; STSI, 2013). 
 
 
Although many compelling examples of community engagement ex-
ist, assessing how widespread community engagement really is and at 
what level it is occurring is difficult. Hood and colleagues (2010) con-
ducted a survey to establish a baseline of community engagement across 
research being funded by the NIH at one midwestern university with a 
CTSA. Of the 194 NIH-funded studies (out of 480) for which responses 
were received, fewer than half (43 percent) included community en-
gagement activities at any level. Of the studies that included a communi-
ty engagement component, only 17 percent reported meaningful 
community engagement that involved significant collaborative actions. 
These results prompted the investigators to recommend that CTSAs clar-
ify the goals of community engagement and determine “whether com-
munity engagement programs should strive to increase the number of 
authentic CBPR studies, increase less intensive community engagement 
activities in all NIH-funded research, or both” (Hood et al., 2010, p. 22).  
 
Metrics and Evaluation 
 
Community engagement should be evaluated, just as any other as-
pect of the CTSA program, using clear and innovative metrics that can 
be applied uniformly and consistently at individual CTSAs and across 
the program. To date, a formal evaluation of the community engagement 
aspects of the CTSA Program as a whole has not been conducted. In re-
cent stakeholder input provided by the Center for Community Health 
Education Research and Service and the CCPH, one respondent wrote 
that the lack of common metrics “hurts [the] CSTA [community en-
gagement] programs’ ability to measure, document, [and] communicate 
their value in a way that’s understood by CTSA leadership locally and 
nationally” (Freeman and Seifer, 2013).  
The CTSA Community Engagement Key Function Committee has a 
working group to develop a uniform set of outcomes and measurements. 
This working group identified examples of community-engaged research 
and developed a logic model to guide development of community en-
gagement metrics (Eder et al., 2013) (see Figure 4-1). Additional possible 
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FIGURE 4-1 A logic model to guide community engagement metrics. 
NOTE: CBOs = community-based organizations; CBRNs = community-based 
research networks; CE = community engagement; CEnR = community engage-
ment research; IRB = institutional review board; IT = information technology; 
PBRNs = practice-based research networks. 
SOURCE: Adapted with permission from Eder et al., 2013.  
 
 
measures that have been suggested by researchers and community leaders 
include the following: extent of community partner integration into the 
research teams, documented research outcomes (e.g., community health 
improvements and outcomes, policy changes, successful translation), 
allocation of funds to community partners, and number of new and sus-
tained community partnerships (Freeman and Seifer, 2013).  
 
 
Opportunities and Next Steps 
 
Because involving the community in the continuum of research is a 
new experience for many researchers, the CTSA Program and NCATS 
must provide clear guidance and leadership that effectively defines and 
communicates their goals and expectations. A number of barriers need to 
be overcome in order to establish effective community partnerships, in-
cluding issues related to trust and respect, understanding the benefits and 
value of community engagement, challenges within academic cultures, a 
lack of clear expectations and protocols for engagement, and a lack of 
funding to compensate and provide training and education for community 
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partners (Freeman and Seifer, 2013; Spofford et al., 2012). Models from 
individual CTSAs that have effectively incorporated members of the 
community throughout the research and translation process should be 
actively disseminated.  
Although there is still much work to be done to integrate communi-
ties fully into all aspects of the CTSA Program, opportunities to embrace 
community engagement fully are increasing and are showing great prom-
ise. Electronic health records, social networking, and an increasingly ac-
tive and sophisticated disease and health advocacy community can and 
should accelerate progress toward improvements in health status and re-
ductions in health disparities. Partnerships with community engagement 
efforts sponsored by other NIH institutes and centers (e.g., the Research 
Centers in Minority Institutions program) offer potential for increasing 
the reach of CTSA’s investments and strengthening the program’s com-
munity engagement initiatives.  
Throughout the study, the IOM committee heard overwhelming sup-
port for community engagement as an integral part of the CTSA pro-
gram. An NIH working group on CTSA/NCATS integration, leaders of 
the CTSA Consortium, CTSA PIs, Congress, and a range of diverse 
stakeholders have all voiced support for the broad focus of the program, 
which encompasses the full spectrum of translational research including 
community engagement (CTSA PIs, 2012; Katz et al., 2011; NCATS, 
2012b; Pulley, 2013b; U.S. Congress, 2011). The IOM committee fully 
supports community engagement and involvement throughout the entire 
research process and believes that this program component is essential 
and needs to be preserved, nurtured, and expanded. 
Community engagement should not be a stand-alone program re-
quirement; it must be crosscutting and embedded in leadership, imple-
mentation, research, and communication strategies across all levels of the 
CTSA Program. Each CTSA site has unique strengths to build on, in ad-
dition to the opportunities afforded by the special interests, characteris-
tics, and needs of the surrounding population or specific patient 
populations served. Inevitably, geographic and program diversity will 
lead to variations in the nature of community engagement from one site 
to another. But without clear incentives, metrics, and evaluation internal-
ly and from NCATS, the potential value in engaging community partici-
pants in the full range of activities—from basic discovery through patient 
outcomes—will not be realized. 
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Recommendation 6: Ensure Community Engagement in All 
Phases of Research 
 
NCATS and the CTSA Program should ensure that patients, 
family members, health care providers, clinical researchers, and 
other community stakeholders are involved across the continu-
um of clinical and translational research. NCATS and the CTSA 
Program should 
 
 define community engagement broadly and use this defini-
tion consistently in RFAs and communications about the 
CTSA Program; 
 ensure active and substantive community stakeholder partic-
ipation in priority setting and decision making across all 
phases of clinical and translational research and in the lead-
ership and governance of the CTSA Program;  
 define and clearly communicate goals and expectations for 
community engagement at the individual CTSA level and 
across the program and ensure the broad dissemination of 
best practices in community engagement; and 
 explore opportunities and incentives to engage a more di-
verse community.  
 
 
CHILD HEALTH RESEARCH 
 
For too long, research examining the safety and efficacy of medica-
tions and other health interventions has focused on adults, and too little 
has been known about health- and development-related impacts of medi-
cations, devices, and preventive measures on children3 (IOM, 2012b). 
Because of the paucity of pediatric-specific research, health care provid-
ers caring for children often use their own personal experiences in clini-
cal practice, rather than published evidence, as the basis for treatment 
                                                      
3In 1998 the NIH released policy guidelines for the inclusion of children in research 
(NIH, 1998). In the past two decades legislation aimed at increasing clinical trials involv-
ing children has included the Best Pharmaceuticals for Children Act (Public Law 107-
109), the Pediatric Research Equity Act of 2003 (Public Law 108-155), and the Food and 
Drug Administration Safety and Innovation Act (Public Law 112-144). These initiatives 
support progress in pediatric clinical studies; however, empirical studies still need to be 
done in many areas.  
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decisions (Kon, 2008). Thus, clinical and translational research is urgently 
needed in the area of child health. The IOM committee was specifically 
asked to look at child health research efforts in the CTSA Program and 
concluded that the program has placed an appropriate emphasis on accel-
erating clinical and translational research to improve child health.  
The lack of pediatric studies results from a number of factors. Safety 
and ethical considerations for children participating in clinical trials are 
of primary concern, including the potential risks of exposing healthy 
volunteers to medications or other treatments that may have health or 
developmental side effects. Moreover, although some rare childhood dis-
eases can be catastrophic, most children are healthy, which makes case 
finding for trials difficult. Additional challenges are the small market for 
pediatric drugs and devices, the smaller number of potential research par-
ticipants, and variability among children because of age and develop-
mental factors (IOM, 2012b). Further, because drugs and devices are 
often already approved for adults, they can be legally prescribed for chil-
dren and may be widely used off label, before pediatric studies can be 
completed or even started (Portman, 2012).  
 
 
Context and Background 
 
Child health has been a focus of the CTSA Program. The NIH Re-
form Act of 2006 (Public Law 109-482) stipulated that independent 
funding and infrastructure for pediatric clinical research centers (former-
ly in the GCRCs) can be maintained. Subsequent to that legislation, the 
funding announcements for CTSAs have noted that applications can in-
clude a second principal investigator with authority for child health re-
search and proposals for designating a separate budget for child health 
research (Huskins et al., 2012; NIH, 2009a). As of March 2013, 9 of the 
61 CTSAs have a pediatrician as the principal investigator, and many 
have a designated pediatric or child health lead (Collier, 2013a). In addi-
tion, 53 CTSAs have some degree of partnership with children’s hospi-
tals (Collier, 2013a). Most CTSAs have pediatric researchers 
participating on the CTSA Consortium Child Health Oversight Commit-
tee (CC-CHOC).  
The CC-CHOC was established in 2006 as one of the CTSA Consor-
tium’s leadership committees. Its mission and goals are to provide a na-
tional forum to identify collaborative opportunities for facilitating 
clinical and translational research on child health; to set priorities for the 
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development of collaborative efforts and standard approaches; and to 
coordinate CTSA-wide efforts on child health research (CTSA Central, 
2012a).  
Several recent projects suggest the breadth of efforts spearheaded by 
CC-CHOC with participation by individual CTSAs:  
 
 The Point Person Project works to overcome barriers that have 
hindered past efforts in pediatric research by ensuring that con-
nections are made to respond to collaborative opportunities 
among industry, research networks, and investigators with rele-
vant expertise for protocol and trial development and implemen-
tation (see Box 4-5).  
 CC-CHOC is working toward the harmonization of policy and 
regulatory aspects of child health research, including efforts to 
standardize relevant terminology, case definitions, diagnostic cri-
teria, and core outcome measures (CTSA Central, 2012a; Davis, 
2012).  
 CC-CHOC and participating CTSAs have developed a federated 
IRB model to provide a thorough and flexible IRB process to fa-
cilitate multisite pediatric clinical trials (CTSA Central, 2012a). 
For example, CC-CHOC has collaborated with the Rare Disease 
Clinical Research Network in the use of the centralized IRB 
model to test a treatment for infantile Pompe disease (CTSA 
Central, 2012a). 
 
Interdisciplinary and multisite collaborations are particularly im-
portant for child health research. Multicenter studies are often necessary 
because the small number of children who meet eligibility criteria for 
clinical trials. The developmental and physiological needs of children 
differ from those of adults and require the expertise of multiple disci-
plines in the design and conduct of clinical studies. One of CC-CHOC’s 
short-term goals is to enhance interactions with child health research 
partners in the United States and globally. Efforts are under way to coor-
dinate with NIH-related networks (e.g., Pediatric Trials Network), prac-
tice-based research and other research networks (e.g., the American 
Academy of Pediatrics’ Pediatric Research in Office Settings Network, 
the Global Alliance for Pediatrics Therapeutics); and international net-
works (e.g., European Network of Paediatric Research at the European 
Medicines Agency) (Davis, 2012; Portman, 2012).  
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BOX 4-5 
The Point Person Project 
 
In an effort to increase the efficiency and response rate in multisite pedi-
atric clinical trials, the CTSA Consortium Child Health Oversight Committee 
initiated the Point Person Project in 2012 (Davis, 2012). This program allows 
research sponsors, industry representatives, or individual developers to pro-
pose and explore interest in a range of child health research studies (CTSA 
Central, 2012b). A synopsis of the protocol is submitted to the CTSA Coor-
dinating Center and reviewed by the CC-CHOC Operations Group, and, if 
approved, it is sent to the point person at each of the 55 CTSA sites with a 
pediatric program (Davis, 2012). The point person gives the synopsis link to 
investigators in their CTSA with related interests, and these investigators 
indicate whether they are interested, not interested, or need more infor-
mation. The responses are entered into a central database, and those who 
are interested are invited to join a weekly conference call where the project 
is discussed with the sponsor (Children’s National Medical Center CTSI, 
2013). In the first 5 months of this program, 20 protocols were reviewed 
(Davis, 2012). In addition to facilitating collaborations and expediting the ini-
tiation of clinical trials, an additional benefit may be identifying and recruiting 
experts and collaborators for protocol development (Davis, 2012).  
 
Safety and ethical considerations are of primary concern in child 
health research. CC-CHOC’s Pediatric Research Ethics Workgroup has 
reviewed protocols submitted by CTSA pediatric investigators to deter-
mine trends in IRB decision making and is encouraging shared IRB ap-
proaches for multisite trials. The group also facilitates a pediatric 
research ethics consultation service to link research ethics consultants 
and pediatric investigators in order to strengthen requests for protocol 
approval (CTSA Central, 2013d). 
CC-CHOC has ongoing efforts to develop evaluation metrics for 
child health research (Huskins et al., 2012). Further, it is surveying 
CTSAs regarding steps needed to enhance career pathways for child 
health investigators (Davis, 2012). 
 
 
Opportunities and Next Steps 
 
Leadership, Collaboration, and Evaluation in Child Health Research  
 
The CTSA Program, through CC-CHOC, has made important steps 
in streamlining and accelerating clinical and translational research specif-
ic to the neglected area of child health. To strengthen these efforts, the 
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IOM committee believes that the NCATS-CTSA Steering Committee 
should identify a relatively small number of CTSAs with established ex-
pertise and outstanding efforts in child health research as the leaders in 
this arena. Those designated CTSAs, in collaboration with CC-CHOC, 
would be charged with creating focused initiatives to develop key part-
nerships and collaborations across other CTSAs, and with the NIH and a 
variety of public and private sector research networks, including industry 
partners. The goal would be to strengthen the resources and leadership 
provided for child health research. These CTSAs would spearhead efforts 
to improve and accelerate clinical and translational research in child 
health, encourage research participation, and promote career pathways 
for child health investigators.  
Identifying specific CTSAs to take the lead in child health research 
would not preclude other CTSAs from involvement in this area. Instead, 
the IOM committee hopes that such focused efforts would encourage and 
promote collaborations among CTSAs for multisite studies and other 
efforts. The committee also believes that the CTSAs should be engaged 
in a life-span approach that includes research on the transition from ado-
lescence into adulthood.  
As part of a learning health care system, child health researchers 
need to be sure that this area of investigation is well positioned to fully 
embrace the use of electronic health records for research purposes and to 
actively partner with PBRNs. Implementing these types of strategies will 
allow researchers to understand what is occurring in clinical practice and 
will allow pediatric health care providers, patients, and families to learn 
about new medications, therapeutics, and preventive measures.  
 
The Involvement of Children, Parents, Family Members, and Community 
Organizations  
 
Efforts to advance child health research need the active and direct 
involvement of patients, parents, family members, pediatric and family 
health care providers, and other community stakeholders in all phases of 
research. As a part of the team that guides clinical and translational re-
search and encourages participation in this vital area, informed family 
and community participants will bring practical insights and dedicated 
commitment to setting research priorities, reviewing protocols, modify-
ing trial designs, and ensuring adherence to research subjects’ protection 
policies for clinical research involving children. Further, these groups 
can promote research participation. Recent study findings suggest that 
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families know little about potential opportunities for participation in 
clinical research and often do not understand its potential benefits (Davis 
et al., 2013). 
 
 
Conclusions and Recommendation 
 
Research is needed on medications, devices, and preventive measures 
that specifically assesses their impact on children, whether they are tar-
geted to specific diseases of children or are adult treatments used for pe-
diatric patients. Primarily because of the much smaller population 
affected with pediatric diseases, many of these diseases are “orphan con-
ditions,” yet they can be life limiting or result in lifelong mental, physi-
cal, or developmental disabilities.  
Because of the burden of these conditions, clinical and translational 
research is of special importance, and the IOM committee believes that 
the CTSA Program has placed an appropriate emphasis on accelerating 
clinical and translational research to improve child health. As a strong 
and vital part of the CTSA Program, the individual CTSAs and CC-
CHOC have made important steps in this direction. The CTSA Program 
should continue its role in leading efforts to coordinate and advance child 
health research by building on the expertise of individual CTSAs and by 
ensuring that the CTSA Program continues to be a leader in developing 
and sustaining the collaborations necessary to move these efforts forward.  
 
Recommendation 7: Strengthen Clinical and Translational Research 
Relevant to Child Health  
 
NCATS should collaborate with CC-CHOC to strengthen clini-
cal and translational research relevant to child health through 
efforts to  
 
 identify and designate CTSAs with expertise in child health 
research as leaders in advancing clinical and translational 
research relevant to child health and as coordinators for 
CTSA programwide efforts and other collaborative efforts in 
this research; and  
 promote and increase community engagement specific to 
child health by 
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o raising awareness of the opportunities for children and 
families to participate in research efforts with clear in-
formation conveyed on the risks and potential benefits; 
and  
o involving parents, patients, and family members more 
fully at all stages of the research process, including iden-
tifying priorities and setting research agendas.  
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5 
 
Conclusion: Opportunities for Action 
 
 
 
 
 
 
 
 
 
 
In its first 7 years, the Clinical and Translational Science Awards 
(CTSA) Program has served as a foundation and catalyst for clinical and 
translational research at 61 academic health centers and other institutions 
across the United States. With the ultimate goal of improving human 
health, the CTSA Program now has the opportunity to propel clinical and 
translational research efforts forward rapidly. To move to CTSA 2.0, the 
CTSA Program can build on its foundation, draw on the creativity and 
dedication of CTSA principal investigators, researchers, and staff; use 
the ever-expanding capabilities of informatics and other technologies; 
share data and research support tools as openly and freely as possible; 
and fully engage new cadres of researchers focused on team-based sci-
ence. Looking forward, the committee has identified four key opportuni-
ties for action: 
 
 adopt and sustain active program leadership;  
 engage in substantive and productive collaborations; 
 develop and widely disseminate innovative research resources; 
and  
 build on initial successes in training and education, community 
engagement, and child health research 
 
The next steps can be accomplished at multiple levels: 
 
 The National Center for Advancing Translational Sciences 
(NCATS) has responsibilities to increase its leadership presence 
for the CTSA Program. This effort will require working with all 
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program components to set goals and provide incentives and di-
rection in order to move to a fully integrated network focused on 
accelerating clinical and translational research.  
 The multiple components of the CTSA Program should work to-
gether under the direction of the recommended NCATS-CTSA 
Steering Committee to streamline the consortium structure, en-
gage all individual CTSAs in meeting strategic goals and objec-
tives, and use the Coordinating Center to share and implement 
best practices. 
 Individual CTSAs can bring their creativity and institutional 
strengths and their local collaborations to bear on removing bar-
riers and solving the larger challenges of clinical and translation-
al research. By engaging their local communities and building on 
their expertise, individual CTSAs can be active hubs within the 
larger CTSA Program network. 
 Community organizations and individuals, practice-based re-
search networks, the HMO Research Network, industry partners, 
other NIH institutes and centers, and other potential collabora-
tors can explore the opportunities that the CTSA Program pro-
vides and can push NCATS and individual CTSAs to engage in 
truly collaborative ventures focused on facilitating and accelerat-
ing clinical and translational research.  
 
In conclusion, the Institute of Medicine (IOM) committee believes 
that the CTSA Program should be the national leader for advancing in-
novative and transformative clinical and translational research to im-
prove human health. To achieve this, the CTSA Program should reshape 
its goals to reflect its new location within NCATS; build on the work of 
individual CTSAs to provide institutional leadership; focus on team-
based education and training; and establish a national network that will 
accelerate the development of new diagnostics, therapeutics, and preven-
tive interventions and, at the same time, drive innovation in clinical and 
translational research methods, processes, tools, and resources.  
Because the CTSA Program is not disease specific in its orientation, 
strong collaborations must be forged across disciplinary units within in-
dividual CTSA institutions and with other NIH institutes and centers, as 
well as with other government funders, industry, philanthropies, and 
community organizations.  
The CTSA Program should continue to lead efforts in expanding and 
diversifying the research workforce and to coordinate and advance child 
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health by streamlining and building on the expertise of individual 
CTSAs. In all these efforts, community engagement is essential.  
The contributions of individual CTSAs and the CTSA Program are 
vital to the clinical and translational research enterprise, and the nation’s 
health can benefit greatly from strengthening their efforts. 
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A 
 
Data Sources and Methods 
 
 
 
 
 
 
 
 
 
 
The Institute of Medicine (IOM) Committee to Review the Clinical 
and Translational Science Awards (CTSA) Program at the National 
Center for Advancing Translational Sciences (NCATS) was tasked with 
providing an independent appraisal of the CTSA) Program. The specific 
goals of this congressionally requested review were to assess the CTSA 
Program’s mission and goals and to explore the contributions of the 
CTSA Program in accelerating the development of new therapeutics, in 
facilitating disease-specific research and children’s health research, and 
in enhancing the integration of programs funded by the National 
Institutes of Health (NIH) institutes and centers. In conducting its work 
and responding to the statement of task, the IOM committee reviewed 
information that was collected from a variety of sources, including 
scientific literature, previous evaluations and progress reports, open-
session meetings and conference calls, public testimony and input, and 
other publicly available resources.  
 
 
COMMITTEE EXPERTISE 
 
The study committee comprised 13 individuals with expertise in 
community outreach and engagement, public health and health policy, 
bioethics, education and training, pharmaceutical research and 
development, program evaluation, clinical and biomedical research, and 
child health research, along the full continuum of clinical and translation 
research. Appendix B provides biographical sketches of each of the 
committee members. The committee’s expertise was supplemented by 
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the knowledge and insights of a number of experts who presented 
research during open-session meetings and conference calls. 
 
 
OPEN-SESSION MEETINGS, CONFERENCE CALLS,  
AND PUBLIC INPUT 
 
Between October 2012 and February 2013, the committee convened 
three open-session meetings and four open-session conference calls 
(Boxes A-1 to A-7). The committee’s first meeting in October was held 
remotely via conference call because of weather conditions associated 
with Hurricane Sandy. Over the course of the study, the committee also 
held a number of closed-session conference calls and a closed-session 
meeting in March 2013 to conclude its deliberations. The open-session 
meetings and calls allowed the committee to hear from a wide range of 
stakeholders, including a number of CTSA principal investigators and 
researchers, members of the NCATS and NIH leadership, community 
and patient advocacy organizations, industry partners and 
representatives, and thought leaders and researchers in the clinical and 
translational sciences arena who were not connected to the CTSA 
Program.  
Each of the open-session meetings included a public comment period 
that allowed the committee to hear from other researchers, stakeholders, 
and members of the public. Because of budget constraints, all of the 
open-session meetings were held in Washington, DC. To provide 
additional opportunities for public input by individuals who were unable 
to travel to the meetings or participate by conference call, the committee 
used an online public input tool with questions to guide further testimony 
and input. A link to the public input tool was made available on the 
IOM’s website from December 2012 through March 2013. The NCATS 
and IOM study listservs were used to notify stakeholders and the public 
about the opportunity to provide additional input to the committee’s 
work and the availability of the online tool. The list of questions included 
in the public input tool can be found in Box A-8. During the 3 months 
that the tool was available, 27 individuals submitted responses to the 
questions. This input was catalogued in the study’s public access file and 
is available by request through the National Academies’ Public Access 
Records Office. The committee also reviewed input submitted through its 
e-mail address, CTSAReview@nas.edu, throughout the duration of the 
study. 
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INFORMATION GATHERING AND DOCUMENT REVIEW 
 
In addition to information that was gathered during the open-session 
meetings and conference calls, the committee conducted a review of the 
available scientific literature with a focus on areas related to the CTSA 
Program and its work in clinical and translational sciences, training and 
education, community engagement, and child health research. The 
committee also reviewed previous evaluations of the CTSA Program, 
including the reports from the 3-year Westat evaluation and the 
evaluation of the administration of the CTSA Program under the NIH’s 
National Center for Research Resources that was conducted by the 
Department of Health and Human Services’ Office of the Inspector 
General; progress reports developed by the CTSA Consortium 
committees and the NIH; responses to the NIH’s requests for information 
related to the CTSA Program; a wealth of information provided by 
NCATS, a range of CTSA Consortium committees, and stakeholder 
groups; and results and recommendations from other working groups and 
stakeholder meetings that have considered the future directions of the 
CTSA Program. Any information that was provided to the committee 
from outside sources was catalogued in the study’s public access file and 
is available by request through the National Academies’ Public Access 
Records Office. 
 
BOX A-1 
Committee to Review the Clinical and Translational Science 
Awards Program at the National Center for Advancing 
Translational Sciences 
 
Monday, October 29, 2012 
 
Agenda 
 
9:30 – 9:45 Welcome and Introductions 
 Alan Leshner, Committee Chair  
 Sharon Terry, Committee Vice-Chair 
 
9:45 – 11:30 Charge to the Committee and Discussion of 
  Statement of Task 
 Chris Austin, Director, NCATS, NIH 
 Josie Briggs, Acting Director, Division of Clinical  
  Innovation, NCATS, NIH 
 
11:30 – 12:30 Lunch Break 
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12:30 – 2:30 Overview of CTSA Committees and Strategic 
  Goals 
 CTSA Consortium Steering and Executive 
  Committees 
 Bradley Evanoff, Washington University 
 Goal 1: National Clinical and Translational 
  Research Capability  
 Clay Johnston, University of California, San Francisco 
 Goal 2: Training and Career Development of  
  Clinical/Translational Scientists 
 Robert Toto, University of Texas Southwestern 
 Medical Center 
 Goal 3: Consortium-Wide Collaborations 
 Anantha Shekhar, Indiana University 
 Goal 4: Health of Our Communities and the Nation 
 Kathleen Brady, Medical University of South Carolina 
 Goal 5: Advance T1 Translational Research 
 Nora Disis, University of Washington 
 
 Q&A with Panelists and Committee Discussion 
 
2:30 – 2:45 Break 
 
2:45 – 4:45 Enhancing Integration: CTSAs and NIH Institutes  
  and Centers 
 
  National Cancer Institute  
  Linda Weiss, Director, Office of Cancer Centers,  
  NCI, NIH 
  National Heart, Lung, and Blood Institute 
  Susan Shurin, Deputy Director, NHLBI, NIH 
  National Institute of Allergy and Infectious Diseases 
  Hugh Auchincloss, Deputy Director, NIAID, NIH 
  National Institute of Diabetes and Digestive and 
   Kidney Diseases 
  Gregory G. Germino, Deputy Director, NIDDK, NIH 
  National Institute of Neurological Disorders and 
   Stroke 
  Walter J. Koroshetz, Deputy Director, NINDS, NIH 
 
  Q&A with Panelists and Committee Discussion 
 
4:45  Public Comment Period 
 
5:00 Adjourn 
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BOX A-2 
Committee to Review the Clinical and Translational Science 
Awards Program at the National Center 
for Advancing Translational Sciences 
 
Conference Call – November 19, 2012   11 a.m. to Noon (Eastern) 
 
Agenda 
 
11:00 – 12:00 Open Session 
 Nora Volkow, NIDA 
 Steve Katz, NIAMS 
 
BOX A-3 
Committee to Review the Clinical and Translational Science Awards Program 
at the National Center 
for Advancing Translational Sciences 
 
Conference Call – November 30, 2012 
10:30 a.m. to Noon (Eastern) 
 
Agenda 
 
10:30 – 12:00 Open Session 
 Steve Hirschfield, NICHD 
 Dianne Murphy, FDA 
 Charles Thompson, Pfizer Inc. 
 Ron Portman, Bristol-Meyers Squibb 
 Phil Pizzo, Stanford University 
 
BOX A-4 
Committee to Review the Clinical and Translational 
Science Awards Program at the National Center 
for Advancing Translational Sciences 
 
National Academy of Sciences Building 
2101 Constitution Avenue, NW 
Washington, DC 
 
Wednesday, December 12, 2012 
Agenda 
 
8:00 – 8:05 Welcome and Opening Remarks 
 Alan Leshner, Chair  
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8:05 – 8:20 CTSA Overview – Goals of the Program 
 Tom Insel, National Institute of Mental Health, NIH 
 
8:20 – 9:50 Panel 1: Translation of Basic Science to Human 
   Studies: Advancing T1 and T2 Research  
 Facilitator: Cliff Rosen 
 
 8:20 – 8:25 Panel Introductions 
 8:25 – 8:35  CTSA Perspective  
   Garret FitzGerald, University of 
    Pennsylvania 
 8:35 – 8:45  CTSA Perspective  
    Sundeep Khosla, Mayo Clinic  
 8:45 – 8:55  Community Perspective 
   Bernard Ewigman, University of 
    Chicago 
 8:55 – 9:05  Industry Perspective 
   Jacqueline B. Fine, Merck Research 
    Laboratories 
 9:05 – 9:50   Discussion with the Committee  
 
9:50 – 10:00 Break 
 
10:00 – 11:30 Panel 2: Children’s Health Research: Role of the 
   CTSA Program 
 Facilitators: Meg McCabe and Phyllis Dennery 
 
10:00 – 10:05 Panel Introductions 
10:05 – 10:15 CTSA Consortium Child Health 
  Oversight Committee 
  Jonathan Davis, Tufts University 
 10:15 – 10:25 CTSA Perspective 
   Margaret Grey, Yale School of 
    Nursing  
 10:25 – 10:35 CTSA Perspective  
   Terence Flotte, University of 
    Massachusetts 
 10:35 – 10:45 Community Perspective  
   Susan Weiner, Children’s Cause for 
    Cancer Advocacy 
 10:45 – 11:30 Discussion with the Committee 
 
11:45 – 12:30 Lunch 
 
12:30 – 1:45  Panel 3: Collaborations across CTSAs – Current  
 Status and Future Plans 
 Facilitator: Sue Curry 
 
12:30 – 12:35 Panel Introductions  
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12:35 – 12:45 CTSA Coordinating Center (C4) 
 Overview 
  Gordon Bernard, Vanderbilt University  
12:45 – 12:55 Collaborations on Informatics  
 Paul Harris, Vanderbilt University  
12:55 – 1:05 CTSA Perspective 
 Marc Drezner, University of Wisconsin  
1:05 – 1:15 Community Perspective 
 Mickey Eder, Access Community 
 Health Network, Chicago  
1:15 – 1:45 Discussion with the Committee 
 
1:45 – 3:00 Panel 4: Evaluating the CTSA Program  
 Facilitator: Robin Kelley 
 
1:45 – 1:50 Panel Introductions 
1:50 – 2:00 Westat Evaluations 
 Joy Frechtling, Westat  
2:00 – 2:10 NCATS Request for Information  
 Josie Briggs, NCATS, NIH 
2:10 – 2:20 NCATS/CTSA Integration Working  
 Group  
 Steve Katz, NIAMS, NIH 
2:20 – 2:30 Evaluating Large Scale Programs – 
 Frameworks and Considerations 
 David Chavis, Community Science 
2:30 – 3:00 Discussion with the Committee 
 
3:00 – 3:15 Break 
 
3:15 – 4:45 Panel 5: Roundtable Discussion: Future Directions for 
 the Mission and Goals of the CTSA Program  
 
3:15 – 3:20 Roundtable Introductions 
 3:20 – 4:00 Opening Comments on the CTSA 
   Program 
   Tachi Yamada, Takeda 
     Pharmaceuticals (via conference 
    call) 
   Wylie Burke, University of Washington 
    (via conference call) 
   John Adams, University of California, 
    Los Angeles 
 4:00 – 4:45 Roundtable and Committee Discussion  
 
4:45 – 5:30 Public Comment Period 
 
5:30  Adjourn 
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BOX A-5 
Committee to Review the Clinical and Translational 
Science Awards Program at the National Center 
for Advancing Translational Sciences 
 
 
20F Conference Center 
20 F Street, NW 
Washington, DC 
 
Thursday, January 24, 2013 
Agenda 
 
8:00 – 8:05  Welcome and Opening Remarks 
 Alan Leshner, Chair  
 
8:05 – 8:45 Opening Speaker 
 Chris Austin, NCATS  
8:45 – 10:10 Panel 1: Training and Education  
 Facilitator: Cliff Rosen 
 
 8:45 – 8:50 Panel Introductions 
 8:50 – 9:30 Panel Presentations 
David Shackelford, University of 
California Los Angeles 
Lisa Ceglia, Tufts University  
Kelly Edwards, University of 
Washington 
Cynthia Morris, Oregon Health and 
Science University  
 9:30 – 10:10 Discussion with the Committee 
 
10:10 – 10:20 Break 
 
10:20 – 11:45 Panel 2: Engaging Community Organizations and 
 Patient Advocacy Groups 
 Facilitators: Sharon Terry and Susan Axelrod 
 
10:20 – 10:25 Panel Introductions 
10:25 – 11:05 Panel Presentations 
Donna Appell, Hermansky-Pudlak 
Syndrome Network Inc.  
Bray Patrick-Lake, Clinical Trials 
Transformation Initiative  
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Sarena Seifer, Community-Campus 
Partnerships for Health  
Joan Reede, Harvard University 
11:05 – 11:45 Discussion with the Committee 
 
11:45 – 12:30 Lunch Break 
 
12:30 – 2:00 Panel 3: Advancing Research on Clinical Practice and 
Population Health: T3 and T4 Research 
 Facilitator: Ann Bonham 
 
12:30 – 12:35 Panel Introductions  
12:35 – 1:15 Panel Presentations  
Lloyd Michener, Duke University 
Joe Selby, PCORI (Patient-Centered 
Outcomes Research Institute) 
Leonard Sacks, FDA 
John Steiner, Kaiser Permanente 
Colorado 
1:15 – 2:00 Discussion with the Committee 
 
2:00 – 3:15 Panel 4: Future Directions for Using CTSA Programs and 
Resources 
 Facilitator: Ralph Horwitz 
 
2:00 – 2:05 Panel Introductions 
2:05 – 2:35 Panel Presentations 
Robert Califf, Duke University  
Martha Curley, University of 
Pennsylvania  
Edith Parker, University of Iowa  
2:35 – 3:15 Discussion with the Committee 
 
3:15 – 3:30 Break 
 
3:30 – 5:00 Panel 5: Roundtable Discussion: Future Directions for the 
Mission and Goals of the CTSA Program  
Facilitator: Edith Perez 
 
3:30 – 3:35 Roundtable Introductions 
3:35 – 4:05 Opening Comments on the CTSA 
  Program 
Morrie Schambelan, University of 
California, San Francisco 
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Stephen Thomas, University of 
Maryland  
Gigi Hirsch, Massachusetts Institute of 
Technology 
4:05 – 5:00 Roundtable and Committee 
 Discussion 
 
5:00 – 5:30 Public Comment Period 
 
5:30 Adjourn 
 
BOX A-6 
Committee to Review the Clinical and Translational 
Science Awards Program at the National Center 
for Advancing Translational Sciences 
 
Conference Call – January 30, 2013 
12:30 to 2:00 p.m. (Eastern) 
 
Agenda 
 
12:30 – 2:00 Open Session 
12:35 – 12:40 Welcoming Remarks 
 Alan Leshner, Committee Chair 
12:40 – 12:50 Petra Kaufmann, NINDS, NIH 
12:50 – 1:00 Committee Q&A 
1:00 – 1:20 Discussion with Francis Collins,  NIH 
1:20 – 1:30 Eric Topol, Scripps Research Institute 
1:30 – 2:00 Committee Q&A 
 
 
 
BOX A-7 
Committee to Review the Clinical and Translational 
Science Awards Program at the National Center 
for Advancing Translational Sciences 
 
Conference Call – February 27, 2013 
3:30 to 4:30 p.m. (Eastern) 
 
Agenda 
 
3:30 – 4:30 Open Session 
 Discussion with Chris Austin, Director of NCATS 
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BOX A-8 
Public Input Questions 
Mission 
 Is the mission of the CTSA Program clear and appropriate for defining 
the success of the program and for supporting the mission of NCATS?  
 Is the scope of the mission realistic given the available resources, 
support, and infrastructure?  
 Is the mission being disseminated adequately? Are potential 
stakeholders aware of the resources available through the CTSA 
Program, and are there barriers to the use of those resources? 
 
Strategic Goals 
 Are the strategic goals of the CTSA Program clear and appropriate? Do 
they clarify the purpose and mission of the CTSA Program? 
 Are the strategic goals realistic given the available resources, support, 
and infrastructure? 
 Are the strategic goals being disseminated adequately? 
 Do you have suggestions for refocusing and revising the strategic goals 
of the CTSA Program? 
 
Role of the CTSA 
 Since the inception of the CTSA Program, have the CTSA institutions, 
individually and collectively, played an appropriate and adequate role in: 
(please check the boxes where you believe the CTSA Program has 
played an adequate and appropriate role) 
 
o accelerating the development of new therapeutics 
o facilitating disease-specific research 
o facilitating children’s health and pediatric research 
o enhancing the integration of research funded by the NIH institutes 
and centers  
o involving and interacting with community organizations and patient 
advocacy groups?  
 
 Could the mission and strategic goals be improved to address these 
issues? If so, how should they be improved? 
Continuum of Research 
 Please comment on the balance of CTSA Program efforts across the 
continuum of research from first-phase studies in humans to clinical 
trials to population-based research on health outcomes and 
comparative effectiveness 
 Does the balance need to shift? Why or why not? 
 
Successes, Challenges, and Future Directions 
 What do you see as successes, challenges, and future directions of the 
CTSA Program? 
 
Additional Comments 
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B 
 
Committee Biographical Sketches 
 
 
 
 
 
 
 
 
 
 
Alan I. Leshner, Ph.D. (Chair), is chief executive officer of the Ameri-
can Association for the Advancement of Science (AAAS) and executive 
publisher of its journal, Science. Previously, Dr. Leshner served as direc-
tor of the National Institute on Drug Abuse at the National Institutes of 
Health (NIH) and as deputy director and acting director of the National 
Institute of Mental Health. Before that, he held a variety of senior posi-
tions at the National Science Foundation. Dr. Leshner began his career at 
Bucknell University, where he was professor of psychology. Dr. Leshner 
is an elected member of the Institute of Medicine (IOM) of the National 
Academies of Science and a fellow of AAAS, the National Academy of 
Public Administration, and the American Academy of Arts and Sciences. 
He was appointed by President George W. Bush to the National Science 
Board and reappointed by President Obama. He received an A.B. in psy-
chology from Franklin and Marshall College and his M.S. and Ph.D. in 
physiological psychology from Rutgers University. Dr. Leshner has been 
awarded six honorary doctor of science degrees. 
 
Sharon F. Terry, M.A. (Vice-Chair), is president and chief executive 
officer of the Genetic Alliance, a network of more than 10,000 organiza-
tions, of which 1,200 are disease advocacy organizations. Genetic Alli-
ance aims to improve health through the authentic engagement of 
communities and individuals. It also works to develop innovative solu-
tions through novel partnerships, connecting consumers to smart ser-
vices. Ms. Terry is also the founding chief executive officer of PXE 
International, a research advocacy organization for the genetic condition 
pseudoxanthoma elasticum (PXE). As codiscoverer of the gene associat-
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ed with PXE, she holds the patent for ABCC6 and has assigned her rights 
to the foundation. She developed a diagnostic test and conducts clinical 
trials. Ms. Terry is also a cofounder of the Genetic Alliance Registry and 
Biobank. She is the author of more than 90 peer-reviewed articles. In her 
focus on consumer participation in genetics research, services, and poli-
cy, she serves in a leadership role on many of the major international and 
national organizations, including the IOM’s Board on Health Sciences 
Policy, the IOM Roundtable on Translating Genomic-Based Research for 
Health, the board of the National Coalition for Health Professional Edu-
cation in Genetics, the International Rare Disease Research Consortium 
Interim Executive Committee, and the newly formed Invoke Health! She 
is on the editorial boards of several journals and was instrumental in the 
passage of the Genetic Information Nondiscrimination Act. Among her 
awards are an honorary doctorate from Iona College in 2005 for her work 
in community engagement the first Patient Service Award from the Uni-
versity of North Carolina’s Institute for Pharmacogenomics and Individu-
alized Therapy in 2007 the Research!America Distinguished Organization 
Advocacy Award in 2009 and the Clinical Research Forum and Founda-
tion’s Annual Award for Leadership in Public Advocacy in 2011. She is 
currently an Ashoka Fellow. 
 
Susan Axelrod is chair and founder of Citizens United for Research in 
Epilepsy (CURE). In 1998 Ms. Axelrod and other mothers joined forces 
to raise funds to invest in the search for a cure for epilepsy. She has 
brought national and international media exposure to epilepsy, appearing 
on television news programs as well as special featured segments. Both 
Parade and Newsweek magazine articles have featured Ms. Axelrod and 
her family’s journey with epilepsy. Ms. Axelrod has received numerous 
awards and honors for her leadership from Research!America, the Child 
Neurology Foundation, and the American Epilepsy Society, among oth-
ers. She has spoken and served as a panelist at international conferences 
focused on medical philanthropy and advances and has served on the 
NIH’s National Advisory Neurological Disorders and Stroke Council and 
as a reviewer for the Medical Research Program within the Department 
of Defense. Ms. Axelrod received a master’s degree in business admin-
istration from the University of Chicago.  
 
Enriqueta C. Bond, Ph.D., served from 1994 to 2008 as the first full-
time president of the Burroughs Wellcome Fund (BWF), a private, inde-
pendent foundation dedicated to advancing the medical sciences by sup-
Copyright © National Academy of Sciences. All rights reserved.
The CTSA Program at NIH:  Opportunities for Advancing Clinical and Translational Research
APPENDIX B 161 
 
PREPUBLICATION COPY: UNCORRECTED PROOFS 
porting research and other scientific and educational activities. During 
her presidency Dr. Bond guided BWF in its transition from a corporate to 
a private foundation. Prior to joining the BWF, Dr. Bond served as the 
executive officer for the IOM. In 1997 she was elected as a member of 
the IOM. In 2004 she was elected as a fellow to the AAAS for her distin-
guished contributions to the study and analysis of policy for the ad-
vancement of the health sciences. Dr. Bond is chairman of the National 
Research Council’s Board on African Science Academy Development 
and a member of the Forum on Microbial Threats. She is a past member 
of the National Academies’ Report Review Committee as well as numer-
ous other study committees. Dr. Bond is the recipient of numerous hon-
ors, including the 2008 Order of the Long Leaf Pine award from the state 
of North Carolina. The highest honor the governor can bestow on a citi-
zen, this award was given to Dr. Bond for her efforts to improve science 
education for the children of North Carolina. She has also received the 
IOM Walsh McDermott Medal in recognition of distinguished service to 
the National Academies and received the National Academy of Sciences 
Professional Staff Award. She received her bachelor’s degree from 
Wellesley College, her M.A. from the University of Virginia, and her 
Ph.D. in molecular biology and biochemical genetics from Georgetown 
University. 
 
Ann C. Bonham, Ph.D., is chief scientific officer of the Association of 
American Medical Colleges and directs an array of programs supporting 
all aspects of research and research training. She serves on the IOM Fo-
rum on Drug Discovery, Development, and Translation and on the De-
partment of Veterans Affairs National Research Advisory Council. Dr. 
Bonham was awarded the 2012 Distinguished Alumni Award for 
Achievement from the University of Iowa Carver School of Medicine 
and was the 2010 recipient of the Society for Executive Leadership in 
Academic Medicine International Award for Excellence. Prior to joining 
the association, Dr. Bonham served as executive associate dean for aca-
demic affairs and professor of pharmacology and internal medicine at the 
University of California (UC) Davis School of Medicine. Dr. Bonham, a 
member of the UC Davis faculty for almost 20 years, played a major role 
in UC Davis’s expansion of translational sciences and the School of 
Medicine’s emphasis on combining research, education, and mentoring 
as interwoven and inseparable missions. As executive associate dean, Dr. 
Bonham oversaw the School of Medicine’s research, undergraduate med-
ical education, and faculty academic programs. She previously served as 
Copyright © National Academy of Sciences. All rights reserved.
The CTSA Program at NIH:  Opportunities for Advancing Clinical and Translational Research
162 THE CTSA PROGRAM AT NIH 
 
PREPUBLICATION COPY: UNCORRECTED PROOFS 
chair of the Department of Pharmacology. She also served as vice-chair 
of research for the Department of Internal Medicine and chief of the Di-
vision of Cardiovascular Medicine. She was twice awarded the UC Davis 
Kaiser Award for Excellence in Teaching Science Basic to Medicine and 
was honored with the American Medical Women’s Association Gender 
Equity Award for providing a gender-fair environment for the education 
and training of women physicians. She has been recognized for her role 
in initiating training opportunities, mentoring fellows and students who 
have accepted positions in academics and industry, bringing together 
investigators to work in teams toward common goals, and fostering col-
laborations with faculty and department chairs across disciplines. 
 
Susan J. Curry, Ph.D., is dean of the University of Iowa College of 
Public Health. She is recognized internationally for expertise in behav-
ioral science and translation of research findings into health policy. Her 
extensive research on tobacco includes studies of motivations to quit 
smoking, randomized trials of promising smoking cessation and preven-
tion interventions, evaluations of the use and cost-effectiveness of tobac-
co cessation treatments under different health insurance plans, and health 
care costs and utilization associated with tobacco cessation. Dr. Curry’s 
research also encompasses studies of dietary change, modification of 
risky drinking patterns, and methods of increasing compliance with rec-
ommended cancer screening. She has served as a principal investigator 
or coinvestigator on 30 grants funded by the NIH, the Centers for Dis-
ease Control and Prevention, and major foundations. Dr. Curry has 
served on numerous national advisory boards, including the National 
Cancer Policy Board of the IOM, the Tobacco Cessation Consortium of 
the American Academy of Pediatrics, and the Subcommittee on Cessa-
tion of the Interagency Committee on Smoking and Health. She currently 
serves on the board of directors for the American Legacy Foundation and 
is a member of the U.S. Preventive Services Task Force. She received 
her Ph.D. in psychology from the University of New Hampshire. In 2010 
Dr. Curry was elected a member of the IOM. 
 
Phyllis A. Dennery, M.D., FAAP, is professor of pediatrics at the Uni-
versity of Pennsylvania and the Werner and Gertrude Henle Chair in Pe-
diatrics at the Children’s Hospital of Philadelphia. She serves as the chief 
of the Division of Neonatology and Newborn Services at the Children’s 
Hospital of Philadelphia and the University of Pennsylvania Health Sys-
tem, where she oversees more than 280 intensive-care beds as well as 
more than 80 practitioners and 18 trainees. Dr. Dennery is the recipient 
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of many awards and honors, including the Andrew Mellon Fellowship, 
the Ross Young Investigator Award from the Western Society of Pediat-
rics, the Alfred Stengel Health System Champion Award from the Uni-
versity of Pennsylvania, an honorary doctorate of science from Ursinus 
College, and the Mentor of the Year Award from the Eastern Society for 
Pediatric Research, among others. She has been listed as a “Top Doctor” 
in U.S. News World Report and in Philadelphia Magazine. Dr. Dennery 
is also an active member of many professional and scientific societies. 
She served as the president of the Society for Pediatric Research and is 
currently the president of the International Pediatric Research Founda-
tion. In addition to being the author of more than 100 publications, Dr. 
Dennery is associate editor for Free Radicals in Biology and Medicine 
and Pediatrics and a grant reviewer for the NIH. Her area of basic 
science research is the regulation of lung gene expression in oxidative 
stress, in particular the role of heme oxygenase, the rate-limiting enzyme 
in bilirubin production. Her clinical interests are in neonatal jaundice, 
bronchopulmonary dysplasia, and the long-term consequences of prematuri-
ty.  
 
Ralph I. Horwitz, M.D., MACP, is senior vice-president for clinical 
evaluation sciences at GlaxoSmithKline (GSK) and Harold H. Hines Jr. 
Professor Emeritus of Medicine and Epidemiology at Yale University. 
Dr. Horwitz trained in internal medicine at institutions (Royal Victoria 
Hospital of McGill University and the Massachusetts General Hospital) 
where science and clinical medicine were strongly connected. These ex-
periences as a resident stimulated a deep interest in clinical research 
training, which Dr. Horwitz pursued as a fellow in the Robert Wood 
Johnson Clinical Scholars Program at Yale under the direction of Alvan 
R. Feinstein. He joined the Yale faculty in 1978 and remained there for 
25 years as codirector of the Clinical Scholars Program and later as chair 
of the Department of Medicine. Before joining GSK, Dr. Horwitz was 
chair of medicine at Stanford University and dean of Case Western Re-
serve Medical School. He is an elected member of the IOM of the Na-
tional Academy of Sciences; the American Society for Clinical 
Investigation; the American Epidemiological Society; and the Associa-
tion of American Physicians (he was president in 2010). He was a mem-
ber of the Advisory Committee to the NIH director, under both Elias 
Zerhouni and Francis Collins. Dr. Horwitz served on the American 
Board of Internal Medicine and was chairman in 2003. He is a master of 
the American College of Physicians. 
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Jeffrey P. Kahn, Ph.D., M.P.H., is the inaugural Robert Henry Levi and 
Ryda Hecht Levi Professor of Bioethics and Public Policy at the Johns 
Hopkins Berman Institute of Bioethics and is professor in the Depart-
ment of Health Policy and Management in the Johns Hopkins University 
Bloomberg School of Public Health. Prior to joining the faculty at Johns 
Hopkins in 2011, Dr. Kahn was director of the Center for Bioethics and 
the Maas Family Endowed Chair in Bioethics at the University of Min-
nesota, positions he held from 1996 to 2011. Earlier in his career, Dr. 
Kahn was director of the graduate program in bioethics and assistant pro-
fessor of bioethics at the Medical College of Wisconsin (1992–1996), 
and from April 1994 to October 1995 he was associate director of the 
White House Advisory Committee on Human Radiation Experiments. 
Dr. Kahn works in a variety of areas of bioethics, exploring the intersec-
tion of ethics and public health policy, including research ethics, ethics 
and genetics, and ethical issues in public health. He has served on nu-
merous state and federal advisory panels and speaks nationally and inter-
nationally on a range of bioethics topics. He has published more than 125 
articles in the bioethics and medical literature and is a coeditor of the 
widely used text Contemporary Issues in Bioethics, now in its eighth edi-
tion. From 1998 to 2002 he wrote the biweekly column “Ethics Matters” 
for CNN.com. Dr. Kahn earned his B.A. in microbiology from the Uni-
versity of California, Los Angeles, his M.P.H. from Johns Hopkins Uni-
versity, and his Ph.D. in philosophy/bioethics from Georgetown 
University. 
 
Robin T. Kelley, Ph.D., M.S.W., is evaluation manager at the National 
AIDS Minority Council. Dr. Kelley received a doctorate in public and 
community health from the University of Maryland and a master’s de-
gree in social work from Columbia University. She has recently received 
a Fulbright Senior Specialist Award to train faculty who teach front-line 
health care workers in Zanzibar. She has worked for more than 18 years 
as a program and evaluation consultant, behavioral scientist, program 
developer, program director, and evaluator for community-based health 
organizations focused on vulnerable populations in the United States and 
abroad. Dr. Kelley has taught women’s health and human rights at 
Georgetown University and women’s health at George Washington 
University and at the Washington Center for Internships and Academic 
Seminars. 
 
Margaret McCabe, R.N., Ph.D., PNP, is the director of nursing re-
search for medicine patient services at Boston Children’s Hospital. This 
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role involves supporting staff education and promoting evidence-based 
practice (EBP) and research by working with staff in groups and one-to-
one mentoring. The EBP projects generally involve quality improvement 
initiatives and lead to larger-scale clinical nursing research projects. At 
the same time Dr. McCabe maintains her own program of research focus-
ing on fatigue in children, specifically children with inflammation, in-
cluding those with inflammatory bowel disease and cancer. This work 
focuses on a biobehavioral approach to understanding fatigue. In addi-
tion, Dr. McCabe teaches graduate-level research design and methods to 
nursing students and students from other health professions at Massachu-
setts General Hospital’s Institute for Health Professions. She teaches 
basic elements of research design for clinical inquiry emphasizing the 
process of developing clinically relevant and feasible research questions, 
concepts of reliability and validity in measurement and design, and the 
application of a variety of research designs for answering questions of 
clinical interest. Throughout Dr. McCabe’s nursing career she has 
worked in roles providing direct care and managing care units for pa-
tients participating in research protocols as well as working as part of a 
study team and being the principal investigator on her own research pro-
tocols. Dr. McCabe has been involved in research activities taking place 
in a range of settings from the laboratory to the community. 
 
Edith A. Perez, M.D., is the deputy director-at-large for the Mayo Clinic 
Cancer Center in Florida, group vice-chair of the Alliance for Clinical 
Trials in Oncology, director of the Breast Program, and the Serene M. 
and Frances C. Durling Professor of Medicine at Mayo Medical School. 
She is a cancer specialist and an internationally known translational re-
searcher at the Mayo Clinic. Her roles extend nationally, including posi-
tions within Mayo Clinic, the American Association for Cancer 
Research, the American Society of Clinical Oncology, and the National 
Cancer Institute. Dr. Perez has developed, and is involved in, a wide 
range of clinical trials exploring the use of new therapeutic agents for the 
treatment and prevention of breast cancer. She leads and has helped de-
velop basic research studies to evaluate the role of genetic markers in the 
development and aggressiveness of breast cancer. She has written more 
than 550 research articles and abstracts in journals and books. Dr. Perez 
is frequently invited to lecture at national and international meetings and 
serves on the editorial boards of multiple academic journals. A select list 
of awards Dr. Perez has received includes the Breast Cancer Research 
Foundation Research Grant Award (1998–2013); Horizon Achievement 
Award in Cancer Research (2002); Mayo Clinic Outstanding Faculty 
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Award (2002 and 2004); North Florida Hispanic of the Year Award 
(2003); Mayo Clinic Distinguished Educator Award (2003); Honorary 
Doctorate of Letters, University of North Florida (2006); Mayo Clinic 
Distinguished Investigator (2007); Florida State Biomedical Research 
Advisory Council (BRAC) (2009–2012); Alpha Omega Alpha Honor 
Medical Society (2009); Mayo Clinic Outstanding Course Director 
(2009); EVE Award for Lifetime Achievement (2011); NFL Hispanic 
Heritage Leadership Award (2011); and 1 of the 75 Most Influential 
People in Jacksonville HealthCare from Jacksonville’s 904 Magazine 
(2012). 
 
Clifford J. Rosen, M.D., is senior scientist at Maine Medical Center’s 
Research Institute. He is the former director of the Maine Center for Os-
teoporosis Research and Education, an affiliate of St. Joseph Hospital 
and a center that he started more than 20 years ago. He previously con-
ducted more than 20 NIH- and pharmaceutical-sponsored clinical re-
search trials, as well as currently overseeing three investigator-initiated, 
NIH-funded translational projects and one program project. He is past 
president of the American Society of Bone and Mineral Research (2002–
2003) and served 5 years as the first editor-in-chief of the Journal of 
Clinical Densitometry as well as associate editor of the Journal of Bone 
and Mineral Research and the Journal of Clinical Endocrinology and 
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